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Summary.
Breast cancer is a major killler of adult women, yet effective therapies are 
few. Prostate disease (both benign prostate hypertophy-BPH and prostate 
cancer) afflicts a large proportion of adult males.
Both breast cancer, and prostatic disease, represent abnormal growth of 
reproductive cells. Epithelial cells of the male and female reproductive 
systems respond to a variety of stimuli, notably including the sex steroid 
hormones. These hormones exert their effect by binding to an intracellular 
receptor, or steroid receptor. Hormone sensitivity - the basis of successful 
endocrine therapy - is best defined, for breast cancer, as the presence of 
specific receptors for oestrogen and progesterone. Presence of functional 
steroid receptors may also reflect better prognoses.
Steroid receptors are proteins that represent one category in the 
superfamily of intracellular receptors. They are composed of two types of 
protein subunits: steroid-/DNA-binding subunits and seemingly inert 
nonsteroid-/nonDNA-binding subunits. It is proposed that the two sets of 
subunits form multimeric complexes which appear as “non-activated’ 
steroid receptors. This large complex is unable to bind DNA. Binding of 
the correct steroid to the steroid-binding site of the steroid-/DNA-binding 
subunit(s) is thought to induce the dissociation of the inert subunit(s) to 
reveal the hitherto “masked” DNA-binding sites. This process has been 
termed activation, and it is fundamental to productive hormone action.
In recent years the “inert” subunit has been the subject of much interest. 
This protein has been identified as the highly conserved 90 kiloDalton
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heat shock protein (hsp 90); a heat inducible protein that has also been 
found to associate with various components of the cytoskeleton. Since 
this protein was both a vital component of steroid receptors, and a 
member of the thermally-inducable heat shock protein family, the work 
reported in this thesis investigated whether the endocrine functions of hsp 
90 could be enhanced or compromised after heat shock.
HSP 90 and M CF-7 Breast Cancer Cell Oestrogen Receptor.
The effects of heat shock on steroid receptor action were studied in the 
MCF-7 human breast cancer cell line. This epithelioid cell contains 
receptors for oestrogen (ER), progesterone (PR), and androgen (AR) in 
amounts convenient for laboratory assay.
In order to investigate whether the expression of hsp 90 could modulate 
steroid receptor activity, initial experiments tested the effect of heat on hsp 
90 in MCF-7 cells. Growing MCF-7 cells were exposed to a range of 
temperatures in order to gauge the point at which temperature became 
lethal. A fixed exposure time of two hours was always used so as to allow 
direct comparison between different experiments. These titration 
experiments found that the lethal temperature for MCF-7 cells fell between 
42°C and 43°C.
Later experiments showed that a prior 2 hour exposure of the cells to 
41 °C enabled the cells to survive 2 hours exposure at 44°C. This 
conditioning process of double heat shock was recognised as the 
acquisition of cellular thermotolerance.
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When an anti-hsp 90 monoclonal antibody (AC 88) was used to immuno- 
precipitate hsp 90 from MCF-7 cells, the greatsest amount of hsp 90 was 
precipitated from the cells subjected to double heat shock. Since this 
treatment also promoted thermotolerance, hsp 90 may represent an 
integral part of the thermotolerance machinery.
To assess whether this increased expression of hsp 90 had any effect on 
the activity of steroid receptors, oestrogen receptor assays were carried 
out on control and thermotolerance-induced (double heat shocked) 
MCF-7 cells. Conventional ligand-binding assay showed that ER-binding 
capacity was almost totally abolished as a result of heat shock. When 
time-course studies were carried out, this abolition of “available” ER was 
shown to be a transient phenomenon which seemed to mirror the known 
kinetics of hsp 90 induction.
Interestingly when enzyme immunoassay (a method independent of the 
ligand-binding ability of the receptor) was used to measure the levels of 
ER the effect of heat shock was drastically different from the results of the 
ligand-binding assay. MCF-7 cells subjected to heat shock maintained 
67% of the levels of ER in cells maintained at 37°C. This result suggested 
that heat shock results in an abolition of ER-binding ability through a 
mechanism other than by merely a down regulation of ER protein.
Since ER is located within the nucleus of target cells, the subcellular 
distribution of hsp 90 under “normal” (37°C) and heat shocked conditions 
was investigated. Fluorescent immunocytochemical staining using the AC 
88 anti-hsp 90 antibody was used to visualise the effects of heat shock on
x
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hsp 90 expression. The absolute amount of hsp 90 present was only 
marginally higher in the heat shocked cells, the result predicted by the 
immunoprecipitation experiments. However, the effect of heat shock on 
the distribution of hsp 90 was very obvious: a very pronounced nuclear 
accumulation was seen in these cells. This phenomenon has never 
before been witnessed for hsp 90, although heat shock-induced nuclear 
accumulation of hsp 70 is well documented. Thus, the action of heat 
shock is to induce the over expression of nuclear hsp 90 and so create a 
population of ER unable to bind oestrogen.
These results indirectly substantiate the stabilisation role of hsp 90 in the 
mechanism of steroid receptor action. Furthermore, they illustrate the 
need for assays of receptor-functionality as well as receptor-positivity in 
tumour biopsies. In addition, these data suggest one possible explanation 
that may account for the discrepancies between tumour receptor status 
and disease responsiveness in some patients of breast cancer.
2. Hsp 90 and Prostate Cancer Cell Androaen Receptor.
With these results in mind, it was decided to investigate a clinical scenario 
where thermal and endocrine manipulations are used in conjunction. The 
treatment of BPH has recently involved microwave probes to supply local 
irradiations of heat to promote regression of prostate disease. Treatment 
is often used in conjunction with antiandrogen therapy to the combined 
benefit of the patient.
To investigate any possible interactions between thermal and endocrine
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manipulations of prostate cancer, it was decided to use prostate cancer 
cell lines as an in vitro model. The LNCaP and DU-145 cell lines were 
chosen as although they are both thought to contain AR,- only LNCaP cells 
are known to respond to exogenous androgen.
In order to confirm the AR-status of these two cell lines immuno­
cytochemical staining was carried out using an anti-AR antibody. This 
illustrated the presence of AR within the nuclei of both cell lines, although 
the LNCaP cells showed significantly more intense staining of nuclear AR. 
This methodology was also used in conjunction with the AC 88 antibody 
to visualise hsp 90 staining within these cells; interestingly, this staining 
was predominantly cytoplasmic.
When the prostate cell lines were tested for thermal tolerance and the 
induction of thermotolerance, it was found that the sub-lethal temperature 
(41 °C) for the MCF-7 breast cancer cell line was in fact a lethal dose for 
both the LNCaP and DU-145 cell lines. However, when a priming 
exposure to 39°C was administered, both cell lines could withstand 
exposure to 42°C. These results showed that both prostate cell lines 
exhibited the thermotolerance phenomenon, and revealed a means of 
hsp 90 induction open to exploitation.
Immunocytochemistry showed that double heat shock (thermotolerance- 
induction) increased the overall levels of intracellular hsp 90. This 
staining was more prominent in the LNCaP cells, with some nuclear 
staining being obvious; though not the dramatic nuclear accumulation of 
hsp 90 that was displayed by the MCF-7 cell line.
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DU-145 cells failed to respond to either androgen or antiandrogen in 
terms of growth stimulation, but LNCaP cells were stimulated by both
ligands. Positive growth stimulation by 5a-dihydrotestosterone (5aD H T) 
was predictable, and occurred at “physiological” concentrations of 10~10 
to 10-12M. Positive stimulation by 4-OH flutamide (OH-Flut.) was not 
expected, although there have been a few reports of this in vitro 
phenomenon.
The level of LNCaP cell AR was also shown to be under the influence of 
both androgen and antiandrogen, being down- and up-regulated by
5aDHT and OH-flut. respectively. DU-145 cell AR on the other hand failed 
to regulate the levels of intracellular AR in response to either ligand, again 
suggesting the nonfunctional nature of this receptor.
Heat shock of LNCaP cells did not result in loss of androgen-binding in 
stark contrast to the activity of the heat shocked MCF-7 cell ER. In order to 
assess whether this difference was due to the nature of the cells or of the 
receptors, AR assay was carried out on heat shocked MCF-7 cells. Once 
again, heat shock did result in a significant inhibition of steroid receptor 
binding ability, although this was only a partial diminution (40% reduction 
of AR as assayed by ligand-binding assay).
When antiandrogen (OH-Flut.) was administered in conjunction with heat 
shock no significant differences were seen in the DU-145 cells treated 
with antiandrogen (either prior or subsequent to heat shock) when 
compared to cells grown in the absences of any exogenous ligands. 
However, when LNCaP cells were exposed to both heat and anti-
S ummary
androgen an additive suppression of growth was observed. This result, in 
contrast to the observed stimulatory effect of antiandrogen alone, was 
demonstrated irrespectively of the sequence of the two manipulations; 
although heat shock preceded by antiandrogen exposure resulted in the 
most profound inhibition of growth.
These results reflect the observations recorded in vivo when benign 
prostate hypertrophy patients undergoing antiandrogen therapy are 
subjected to thermal therapy. It is possible that either the heat 
shock-induced excess hsp 90 is interfering with the androgen/ 
antiandrogen stimulatory pathway; or alternatively, the presence of 
antiandrogen may inhibit efficient function of hsp 90 in the intracellular 
machinery of cellular resistance to heat. In either case, these studies 
suggest that the combination of endocrine and thermal therapies are most 
appropriate when used to treat patients possessing androgen-responsive 
tumours.
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1.1. BREAST CANCER: A GLOBAL ISSUE.
Between 1948 and 1985 the most frequent cause of cancer death among 
American women was breast cancer. In 1990, only carcinoma of the lung 
and of the colorectum are bigger killers. A woman's lifetime risk of 
developing breast cancer was recently estimated at 1 in 10 (S pr a tt  et alt 
1988). Fear of the disease itself, and its treatment in particular, have an 
immense psychological effect.
A study comparing the annual breast cancer mortality rate among age- 
standardised women in the 42 most industrialised countries gives us 
some indication of the disease occurrence (S eidm an  & M u s h in s k i, 1983). 
The annual death rate was highest in Denmark, closely followed by 
England & Wales with 33.8 and 33.6 annual deaths per 100,000 females 
respectively. Scotland lay eighth in the table with a death rate of 32.8, the 
United States lay fourteenth with 28.3, Greece lay twenty-eighth with 15.6, 
Japan lay thirty-ninth with 5.8 and finally Nicaragua with 0.5 annual 
deaths per 100,000 females. Obviously the magnitude of these numbers 
illustrate that breast cancer is a disease of enormous international impact; 
however, the reasons for the disease epidemiology still remain unclear.
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1.2. A BRIEF HISTORY OF THE DISEASE.
The human impact of breast cancer as a disease is made obvious by the 
amount of records left to us from many older cultures. Breast tumours 
were first described by the Egyptians circa 3000 B.C. Later, Greek and 
Roman physicians preserved their records, but these were not advanced 
further by the barbarian societies of the Dark Ages. The surgical 
treatments endorsed by Roman medicine gave way in medieval times to 
various extremes of folk and quasi-religeous therapies: these varied from 
mass prayer and the laying on of hands, to topical application of various 
natural agents such as milk, goat dung, frogs and bisected chickens. The 
sixteenth century saw a resurgence of surgery; the practice and technique 
of mastectomy being refined from the original Graeco-Roman protocols. 
However, any advances in terms of survival and patient morbidity awaited 
the arrival of anesthesia and antiseptic.
In 1757, a French surgeon Henry Frangoise LeDran significantly 
advanced the hope of a surgical cure by proposing the theory that the 
cancer began as a local disease, spreading first to the lymphatics and 
then on to the general circulation. Over the next century, many surgical 
procedures involving different degrees of breast, muscle and lymphoid 
tissue were employed with varying results, culminating in the operations 
described by William H alted . The Halsted radical mastectomy was used 
almost exclusively for around fifty years until in 1933 Emile Grubbe 
demonstrated the use of X-rays in the treatment of breast cancer; and so 
radiotherapy was born. The last half century has seen modification of
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surgical procedures with a view to breast preservation. The development 
of investigative biopsy techniques now allows more selective decisions 
on possible beneficial adjuvant therapy; chemotherapy or endocrine 
therapy are now almost always used in conjunction with surgery for 
patients with node positive disease. However, more recently the body's 
own immune system has been identified as a possible weapon in the fight 
against the disease, and a positive relationship seems to exist between a 
patient's psychological state and the activity of her immune system. This is 
interesting in the light of the observation of the Greek physician Galen, 
who comments on the occurrence of breast cancer among Roman women 
as being more frequent among the “melancholic” than the “sanguine”.
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1.3. CAUSATION OF THE DISEASE.
1.3.1. EPIDEMIOLOGY
There are many epidemiological studies available to those studying the 
aetiological basis of human breast cancer. Drawing useful conclusions 
from these studies, however, is complicated by the interplay of various 
factors.
A known factor is the woman's age at menarche and the time elapsing 
between this event and her age at first parturition. Recently, the freedom 
of women to control their own fertility means that the variation of this time 
differential among cultures has increased; women of industrial and more 
affluent societies have fewer children and wait longer before having them. 
At first sight it seems possible to correlate earlier and more frequent 
motherhood with a lowered risk of breast cancer; a conclusion that is 
reflected geographically. However there are other possible risk factors 
which vary between societies: environmental, cultural and dietary, and 
these may all act to cloud our objective conclusions.
For example, a third-world low protein diet may mean a delay in the 
menarche; however the woman may become pregnant on her first 
ovulation, and may also become pregnant after her subsequent 
infrequent ovulations. A Northern European woman eating a diet rich in 
animal proteins and fats may reach the menarche in her early teens, but 
the dictates of her lifestyle may mean that her first pregnancy, if any at all, 
could be 20 or more years later. Is the correct conclusion, therefore, that it 
is infrequency of parity (excess of menstrual periods), contrasting diets or
5
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some other environmental factor that causes Northern European women 
to have an 8-10 fold greater chance of developing breast cancer than her 
third-world counterpart? Against such a background of confounding 
factors certain conclusions have been drawn.
1.3.2. GENETIC & FAMILIAL FACTORS.
There is certainly a genetic predisposition to breast cancer inherent in 
certain populations and individuals. Daughters and sisters of breast 
cancer patients have a significantly increased risk of the disease, even 
after other common familial factors are discounted (A n d e r s o n , 1974). In 
the most extreme case, that of monozygous twins, the number of breast 
cancers codeveloping in twins after the first diagnosis was found to 
increase by a factor of six (H olm  et al, 1980).
1.3.3. REPRODUCTIVITY.
Lactation and childbearing are also important factors, although it seems to 
be childbearing rather than breast feeding that is important (Kalache  et al, 
1980). Contrastingly, a preponderance of right-breast cancer is manifest 
among certain nomadic tribes who traditionally suckle from the left breast. 
High levels of breast cancer among nuns has been noted for almost 300 
years. What seems critical is the length of time between the menarche 
and the first pregnancy; it has even been suggested that the number of 
menstrual cycles before the first pregnancy may be the ultimate 
determinant. If we compare the rat model for breast cancer which
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assumes an early carcinogenic event; pregnancy in the rat protects 
against a mammary carcinogen if it precedes exposure but promotes 
cancer formation if it follows exposure (S p r a tt  et al, 1988). This model 
correlates well with human epidemiological data.
1.3.4. ORAL CONTRACEPTION & HORMONE REPLACEMENT 
THERAPY.
Genetic factors and frequency of parity are probably modulating etiology 
of the disease through the endocrine-paracrine environment. This begs 
the question as to whether exogenous hormones; either in the form of 
contraception or hormone replacement therapy (HRT), can increase the 
risk of breast cancer. Studies from the Royal College of General 
Practitioners (1981) suggest that no increased disease risk, or 
alternatively no protective effect, are associated with oral contraception. 
HRT may slightly increase the disease risk (H u n t  etal, 1987; H o o v er  etal, 
1976) but studies are so far unsatisfactory.
1.3.5. VIRAL, RADIATION & DIETARY CARCINOGENESIS.
Viruses are known effecters of carcinogenesis in animals. Of particular 
interest is the mouse mammary tumour virus (MMTV), the oncogenic 
potential of the virus being influenced by hormones. It seems possible 
(although as yet unproven) that MMTV, or a similar virus, is instrumental in 
the genesis of human breast cancer.
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Doses of ionising radiation during repetitive fluorographic examination of 
the chest for tuberculosis is associated with breast cancer (Lo w e ll  et al, 
1968). More importantly, repetitive, poorly measured mammography may 
increase a woman's lifetime risk of disease (U p t o n , 1976). Conclusions 
on cumulative low dose environmental exposure are uncertain; however 
data from Hiroshima suggest that there is no threshold dose for the breast, 
but that risk is much increased in the actively growing breast of puberty.
Dietary carcinogenesis can be split into three areas: 1) dietary 
contaminants, i.e. xenobiotic carcinogenesis; 2) dietary excess, i.e. 
obesity; and 3) the proportions of constituents within the diet.
Polycyclic hydrocarbons have been shown to be potent tumourogenic 
agents in rats, but the extent of their responsibility for carcinogenesis in 
the human breast is unknown. Obesity is associated with an increase in 
the synthesis of oestrone from the liver and the fatty tissues (D e w a a r d , 
1975). This hormone is the major circulatory oestrogenic agent in 
postmenopausal woman after the cessation of ovarian oestrogen; and it 
has been proposed that the increased oestrone levels result in an 
increased breast cancer risk (W y n d e r  ef a/, 1976). Most interesting, 
however, is the constituents of the diet; in particular, the amounts of 
dietary fat, and to a lesser extent sugar and also animal protein. One 
notable study found a significant positive association between breast 
cancer and fat and animal protein (K o l o n e l  et al, 1981). These  
conclusions confirm numerous other investigations (for a review see G ray
8
Introduction
e ta l, 1979).
Nicotine and alcohol fail to demonstrate strong correlations with an 
increased risk of breast disease; as any increased risk is comparable with 
that of other cancers (M eara et al, 1989).
1.4. BREAST CANCER AND OESTROGENS.
1.4.1. HISTORICAL OVERVIEW.
The earliest report suggesting that normal human female breast 
development is under the influence of the ovary was made by Pott in 
1775. He removed the normal ovaries of a twenty-three year old woman 
while repairing a bilateral groin hernia; subsequently, the woman ceased 
to menstruate and experienced significant loss in breast size, but 
remained otherwise healthy. A most important observation that a similar 
relationship existed between malignant growth of the breast and the ovary 
was made in Glasgow by Beatson at the end of the nineteenth century 
(B ea tso n  1896). He described the healing of locally recurrent cancer of 
the breast of a thirty-three year old woman after undergoing ovariectomy.
Thirty years later oestrone and oestradiol-17p were characterised and 
proposed as oestrogenic agents, but it was not until after the Second
World War that oestrogens were proven to have a stimulatory effect on
/
human breast cancer, reversing the benefits of ovariectomy (P e a r so n  et 
al. 1954). The next decade saw the utilisation of new biochemical 
techniques to identify and estimate steroids in blood and urine samples; 
but the synthesis and target sites of oestradiol remained unknown.
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The adrenal cortex was known to secrete oestrogens, or their precursors, 
because women with advanced breast cancer who initially responded to 
castration, would later further respond to adrenalectomy (W e s t  et al, 
1952). However, the adrenal cortex was eliminated as a primary source of 
oestrogen synthesis by Baird and colleagues (Baird  eta l, 1969); and the 
human ovary, known to secrete oestrogen (D o is y , 1941) was shown by 
Mikhail (1970) unable to secrete oestrogen after the menopause. Then in 
1975 it was demonstrated that human breast fat could synthesise 
oestradiol from testosterone (N im r o d  & R y a n , 1975). The enzyme 
responsible for the catalysis, aromatase, has since been shown to be of 
greater activity in the breasts of patients with the disease; and the activity 
was most enhanced in the quadrant of the breast harbouring the tumour 
(O ’neill  eta l, 1988). Thus, in post-menopausal women, oestrogens are 
known to be synthesised in the breast (and other peripheral tissues) from 
19-carbon precursors from the adrenals.
A critical step forward, so far undiscussed, was the discovery of an 
intracellular receptor for oestrogen by the groups of Gorski and Jensen 
(G o r sk i etal, 1968; J ensen  et al, 1968). They proposed the classical two 
step model where steroid enters the cell, binds to a “cytosolic” receptor, 
which then enters the nucleus and activates an oestrogen responsive 
gene. This subject will be discussed in much more detail elsewhere, but 
the importance of receptors in the history of breast cancer should be 
noted. Due largely to the results of McGuire and coworkers, it was found
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that receptors for oestrogen were present in about two thirds of human 
breast cancers; furthermore, their concentration was relative to the age 
and menstrual status of the patient, and to the degree of differentiation of 
the tumour (M c guire  et al, 1975). Oestrogen receptors have since been 
used in the diagnosis, prognosis and treatm ent of breast and 
gynaecological cancers. (For a review see S o u tter  & Le a k e , 1987).
1.4.2. GROWTH AND DEVELOPMENT OF THE NORMAL BREAST.
The development of the breast (thelarche) begins about two years prior to 
the menarche, which for 95% of women in the UK, is reached by the end 
of the 15th year. The pubertal release of luteinizing hormone causes the 
secretion of ovarian oestrogens, but it is not until pregnancy that any 
further development occurs. Early in pregnancy, breast alveoli form ducts 
under the influence of ovarian oestrogens. Later, pituitary prolactin and 
placental lactogen induce synthesis of the enzymes involved in milk 
production - lactogenesis. Milk secretion is prevented until parturition by 
high levels of progesterone; when upon delivery, the suckling child 
stimulates milk ejection. The milk ejection reflex comes about as a result 
of pituitary secreted oxytocin acting directly on duct vessels to release the 
milk. (For a thorough review see N eville , 1983).
1.4.3. OESTROGEN AND DEVELOPMENT OF THE CANCEROUS  
BREAST.
When discussing breast cancer it is useful to consider the two-stage,
11
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initiation-promotion model of carcinogenesis (B e r e n b l u m , 1954). This 
model assumes that the neoplastic event is triggered by some chemical, 
biological or physical initiator which acts by irreversibly altering the DNA. 
Promoters, then, are agents which result in the expression of initiated 
cells by either permitting or stimulating proliferation to detectable tumours. 
There is little evidence to suggest that oestradiol could itself be 
considered an initiator, even though covalent binding of oestrogen to 
DNA has been shown. However, it is possible that oestrogen may 
indirectly enhance initiation due to its proliferative effects resulting in an 
increase in the number of carcinogen target sites. This is reflected in the 
number women who were exposed to irradiation after the atomic bombing 
of Hiroshima. Women who were in their teens at the time of explosion 
show higher levels of invasive breast cancers when compared to older 
women who received comparable exposure (H rubec  et al, 1989).
Rat models suggest that oestrogen is a very efficient promoter of breast 
cancer (H o w e ll , 1989). Prospective studies carried out by Bullbrook and 
colleagues (1986) involved measuring the blood oestradiol levels in 5000  
women and then examining clinically for signs of breast cancer. The 
results obtained suggest that women having a higher amount of 
bioavailable oestrogen in their blood were at greater risk from breast 
disease. Curiously, theseTindings are reflected in earlier reports of breast 
cancer in male to female transsexuals who were found taking high doses 
of oestrogen illicitly over a number of years (Sy m m e r s , 1968). Unlikely to 
act as an initiator of breast cancer therefore, oestrogen seems to exert its
12
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neoplastic effect as a potentiator or promoter of transformed cells.
Oestrogenic induction of epithelial cell mitogens, or growth factors, is well 
documented (L e a k e , 1988), and will be discussed in due course. 
However, a more direct mitogenic action of oestrogen has been shown 
(Lo o s e -m itc h e ll  et al, 1988) and is demonstrated by the induction of the 
c-fos and c-myc proto-oncogenes in rat uterus. It has been suggested 
(W eisz  & B r e s c ia n i, 1988) that the oestrogenic mechanism of mitogenisis 
arises as a result of direct activation by the oestrogen receptor complex of 
c-fos  gene expression. These oncogenes are associated with 
proliferation and differentiation (T h o m p s o n  et al, 1986) possibly by 
encoding a trans-acting promoter (R a u sc h e r  et al, 1988) and so may be 
directly involved in transformation.
1.5. STEROID RECEPTOR RELEVANCE IN BREAST CANCER.
1.5.1. A BREAK-THROUGH.
As previously mentioned, the identification of an intracellular receptor for 
oestrogen by the groups of Gorski and Jensen (G o rski etal, 1968; J ensen  
e ta l ,  1968) was an important step forward in understanding the 
underlying endocrine mechanisms of steroid hormone action. Prior to 
then, endocrine ablative surgery was found to be successful in about one 
third of patients, but no preoperative estimation of the outcome could be 
offered to the individual. In the early 1970's it was hoped that a tumour 
could be “typed” according to its receptor status, and so the success of
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subsequent endocrine therapy predicted. It is now known that 50-60% of 
patients of advanced disease presenting ER-positive tumours will 
respond to endocrine therapy, correspondingly less than 10% of patients 
presenting ER-negative tumours respond (C lark & M cGu ir e , 1989).
1.5.2. STEROID RECEPTOR ASSESSMENT.
Analysis of fresh breast biopsies for the presence of steroid hormone 
receptors can be carried out using a variety of methods, although some of 
which are more suited to research purposes (W it t l if f , 1988). These 
include; firstly, and most frequently, titration using ligand binding assay, 
density gradient centrifugation, various classes of HPLC, isoelectric 
focussing, immunohistochemical staining and finally, enzyme-immuno 
assay (EIA).
Ligand binding assay is the method most frequently used to quantify 
steroid receptors on a regular clinical basis. This method satisfies the 
major criteria describing a receptor assay; being able to accurately 
quantify a specific receptor, and to determine a single binding affinity 
while eliminating non-biological binding (Lea k e , 1981). These assays are 
basically titrations of radioactively labelled hormone with a suitably 
prepared tissue homogenate (L ea k e  & H a b ib , 1987), the specificity of 
receptor detected is discriminated by the labelled ligand and the 
unlabelled competitors selected. (See M eth o d o lo g y  section 3.1.).
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1.5.3. STEROID RECEPTOR STATUS.
The initial poor correlation between the levels of cytosolic ER and the 
patient response rate to endocrine therapy meant that nuclear ER were 
also assayed in the hope that this would prove a better diagnostic test 
(L a in g  et al, 1977). This tactic resulted in an increased correlation 
between ER positivity and responsiveness to endocrine manipulations; 
and was later justified by the discovery that the nucleus was the 
intracellular location of these receptors in vivo (K ing  & G r e e n , 1984). 
Since one of the early effects of oestrogen receptor is the induction of 
progesterone receptor synthesis (F r e if e l d  e ta l,  1974), Horwitz and 
McGuire proposed that the additional assay of progesterone receptor 
would confirm the presence of active  oestrogen receptor and hence 
oestrogen dependence and anti-oestrogen sensitivity (H o r w it z  et al, 
1975a). The combination of assaying both oestrogen and progesterone 
receptors in both the cytoplasm and nuclear fractions of tumour 
homogenates led to an improved correlation of from 71% to 91% between 
receptor status and patient response to endocrine therapy (D eg en sh ein  et 
al, 1980). Prognostic decisions on breast and gynaecological cancer 
patients could now be made with greater confidence (For a review see 
S outter  & Leake , 1987).
/
1.5.4. STEROID RECEPTORS AS PROGNOSTIC INDICATORS.
The most important determinant of prognosis is the degree of 
invasiveness demonstrated by the tumour. The number of histologically-
15
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involved axillary nodes is the critical parameter; the likelihood of treatment 
failure rising directly with the number of such deposits. Steroid receptor 
status is independent of axillary node status and can aid discrimination 
among patients within either the positive or negative nodal groups (C lark 
& M c g u ir e , 1989).
Initial findings from McGuire and colleagues suggested that patients 
presenting with ER-positive primary breast tumours had a significantly 
increased disease free survival when compared to their ER-negative 
counterparts (K n ig h t  et al, 1977). This group (O s b o r n e  et al, 1980) and 
others (Leake et al, 1981) later confirmed that the quantitative amount of 
ER was not only indicative of the response to endocrine therapy; but also 
the length of disease free survival.
There remains a significant number of patients whose tumours are ER- 
positive yet fail to respond to endocrine manipulations (M aass etal, 1980). 
As cytoplasmic ER assays only indicate the levels of ER and not its 
functionality, it has been proposed that these patients may display 
non-functional ER. This underscores the requirements for either nucler ER 
assay or PR assay; found to be the critical determinant in the prognosis of 
human breast cancer (C lark etal, 1983; Leake etal, 1981).
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1.6. OESTROGEN INTERACTION WITH OTHER GROWTH FACTORS 
AND THE REGULATION OF BREAST GROWTH.
1.6.1. EPIDERMAL GROWTH FACTOR (EGF) & TRANSFORMING
GROWTH FACTOR a  (TGF-a).
Although oestrogenic hormones remain the most important endocrine 
influence for the development and mitogenic control of both the normal 
and neoplastic breast, much evidence supports the concept that they act 
by triggering production of locally acting hormones or growth factors
(L e a k e , 1988). EGF and TG F-a are small related polypeptides which are 
both known to bind to the EGF receptor (C a r p e n t e r  et al., 1983). Most
breast cancer cell lines derived from epithelial tumours produce TG F-a  
(L ippman  & D ic k so n , 1989). Oestrogen has been shown to regulate growth
factor expression by inducing production of T G F -a  messenger RNA
(B ates et al, 1988). Expression of TG F-a can be induced by up to 14-fold 
in the ER positive cell lines MCF-7 and ZR-75-1 after the addition of 
physiological levels of oestrogens (D ic k so n  e ta l, 1986). Work from our 
own laboratory (R inaldi & Lea k e , in press) and from others has shown EGF 
to be a potent mitogen of cultured breast cancer epithelial cells.
Consequently, a hypothesis has evolved suggesting that malignant
/
proliferation may arise as a result of the excessive local actions of growth 
factors; this paracrine mechanism is presumed to be oestrogen-induced,
although EGF or TG F-a  may then continue to act as growth promoting 
agents in an autocrine manner (S porn  & Ro b e r ts , 1985).
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It has also been shown that a blockade of the EGF-receptor using 
monoclonal antibodies results in only a transient suppression of growth 
stimulation (A rteaga  e ta l, 1988), and oestrogen is known to be mitogenic 
independent of paracrine mechanisms (W e is z & Br e s c ia n i, 1988). These 
data suggest that autocrine/paracrine systems are not solely responsible 
for oestrogenic proliferation of breast cancer cells.
As for the transformation of breast epithelia to neoplasia it has been 
suggested that some initiating lesion may result in the novel expression of 
a growth factor or its receptor (N ishim ura  & S e k iya , 1987). There exists an 
oncogenic gene product, v-erb B, which shows significant structural and 
functional homology to the EGF receptor (C a r p e n te r  & Z e n d e g u i, 1986). 
EGF is known to undergo tyrosine autophosphorylation as a result of EGF 
binding and activation (D o w nw a rd  etal, 1985) and it has been suggested
that the truncated v-erb B, which is devoid of the EG F/TG F-a binding 
domain, may achieve transformation by acting as a constitutively activated 
EGF receptor (S c hlessing er , 1988).
1.6.2. TRANSFORMING GROWTH FACTOR p (TGF-p).
After the discovery of transforming growth factor activity which permitted 
anchorage-independent growth of normal cells in soft agar (D e la r c o  & 
T o d a r o , 1978) it was discovered that there was in fact two peptides 
present, both being required for transformation (R o b e r t s  et al, 1982).
Structurally similar TG F-a or EGF are required together with the unrelated
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polypeptide TGF-p in order to induce phenotypic transformation. There
has since been found multiple forms of both TGF-p and its receptor. (For a 
review see H s u a n , 1989). There is much confusion as to the function of
TG F-p as it has been shown to be both mitogenic and inhibitory in the 
same cell line. Growth of subconfluent normal rat kidney (NRK) cells is
inhibited by TGF-p (R oberts  e ta l, 1985) while growth arrested NRK cells
can be stimulated to proliferate in response to rat TGF-p (M a s s a g u e ,
1984). It is thought then that TGF-p is a modulator of some other growth 
factor activity rather than being considered as a direct mitogen itself.
Recently, experiments from our group (K err  et al, 1989) have shown that
interferon-a can inhibit the growth of ZR-75-1 breast cancer cells by
increasing transcription and expression of the TG F-p gene. This is
interesting as low concentrations of interferon-a have been shown to 
increase oestrogen receptor expression in this cell line (van den B erg  et al, 
,1986) sensitising the cells to subsequent inhibition of proliferation using 
the antioestrogen tamoxifen, although this mechanism may not work at
the current clinical levels of interferon-a (K err  etal, 1989). Tamoxifen has
been shown to upregulate TGF-p expression in MCF-7 breast cancer cells 
by Lippman and colleagues (K n a b b e  et al, 1987) and so it has been 
suggested that there could be a dual action of this antioestrogen: a
19
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receptor-mediated anti-proliferative effect which can be enhanced using 
interferon-a; and possibly a receptor-independent mechanism acting 
through TGF-p (Leake , 1988).
1.6.3. PROLACTIN.
The precise role of prolactin in the continuous proliferation of breast 
disease is unclear. It is known that women categorised as having a high 
risk of breast cancer present elevated serum prolactin and that this may 
result in a stimulation of breast epithelial proliferation (W ang  et al, 1987). 
In addition, birth of first child (known to reduce the relative risk of breast 
cancer in women under 30) and of subsequent children causes a 
decrease in circulating prolactin. There are many different physiological 
effecters of prolactin secretion and it may be the case that the higher 
levels observed in these patients may be symptomatic rather than 
aetiological. However, work from our laboratory, (R in a ld i & Le a k e , in 
press) has shown that prolactin may act in synergy with oestrogens to 
increase EGF receptor expression in cultured ER positive breast cancer 
cells. Work is continuing to assess the implications of prolactin in breast 
cancer although this will depend on a fuller understanding of the 
neoplastic significance of the EGF receptor.
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1.7. ENDOCRINE MANAGEMENT OF BREAST CANCER.
Treatment of primary breast cancer usually involves surgery of varying 
degrees followed up with an appropriate adjuvant therapy such as 
radiotherapy or chemotherapy. A comprehensive description of these 
treatments is too involved to be included in this thesis, however one line 
of adjuvant therapy is directly concerned with this research: endocrine 
therapy.
The concept underlying endocrine therapy is that certain tumour cells 
retain their sensitivities to the hormones which regulate their normal 
progenitor cells. Oestrogen is a highly potent mitogenic agent in the 
normal mammary gland and is, directly or indirectly, the major stimulus for 
the growth of hormone-dependent breast cancer (S a n t e n , 1982). 
Endocrine therapy must then be able to negate or even reverse the 
proliferative effects of oestrogens. Two lines of treatment exist which 
achieve< this goal in a significant number of patients: ablative hormonal 
therapy and additive hormonal therapy.
1.7.1. ABLATIVE HORMONE THERAPY.
Ablative hormonal therapy is principally castration; as adrenalectomy or 
hypophysectomy are today seldom practised. Oophorectomy, by surgical 
or radiation methods, results in a response rate of 31% in non selected, 
pre-menopausal advanced breast cancer patients (K a r d in a l , 1988). This 
response rate can be increased to 55% by selecting ER positive patients 
and to 78% by selecting ER and PR positive patients. Ablative hormone
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therapy is therefore still a common method of treatment among pre­
menopausal women, with ER positive tumours (D a o  & N e m o to , 1980).
1.7.2. ADDITIVE HORMONE THERAPY.
Post-menopausal patients presenting with ER positive advanced breast 
cancers are now routinely treated using antioestrogen therapies with 
success rates similar to oophorectomy, although again depending on the 
receptor status of the tumour (B r o o k s  et al, 1980). Additive endocrine 
therapy probably inhibits neoplasmic growth principally via a receptor 
specific mechanism rather than a general cytotoxic effect. The original 
practices of using androgens as oestrogen antagonists have now been 
almost wholly superseded by the use of antioestrogenic agents; 
exemplified by the drug tamoxifen and progestins.
Tamoxifen (Nolvadex®) is a non-steroidal antioestrogen that binds to the 
oestrogen receptor forming an abortive complex (Ba u lie u , 1987a & b.; the 
significance of this binding will be discussed in In t r o d u c t io n  section 
2.5.5), but note that the tamoxifen-receptor complex can induce PR 
synthesis. In oestrogen receptor positive cell lines tamoxifen acts in a 
cytostatic manner (O sb o r n e  et al, 1983). Response to tamoxifen among 
post-menopausal women has been shown restricted to the oestrogen 
receptor positive patients (R o s e  et al, 1985); together with 5-10%  of 
oestrogen receptor negative tumours.
Synthetic progestins including Megestrol acetate (Megace®) act in an
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antioestrogenic manner by decreasing the amount c of
the oestrogen receptor (R o c h e fo r t , 1984). Patient response is predictably 
governed by the levels of progesterone receptor, however antioestrogen 
therapy remains preferable because of reduced side effects. (Muss et al, 
1988).
Adjuvant therapy is now very much geared to the meta-analysis study of 
breast cancer trials (P eto  et al, 1988). Node positive, pre-menopausal 
patients receive chemotherapy, while node positive post-menopausal 
patients receive tamoxifen. Node negative patients do not normally 
receive additive, adjuvant therapy until relapse.
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2. Steroid Receptors.
2.1. THE STEROID RECEPTOR SUPERFAMILY.
2.1.1 STEROID RECEPTORS.
The steroid receptor superfamily includes receptors for what are generally 
thought of as steroids in the traditional sense: the male and female sex 
steroids, the glucocorticoids and mineralocorticoids, and vitamin D3. More 
recently added are the receptors for thyroid hormone, retinoic acid and 
various aryl hydrocarbons as well as the receptor-like product of the 
oncogene erb A. These receptors are grouped together as a superfamily 
for a variety of structural and functional reasons:
•  All (identified) ligands for these receptors are hydrophobic in nature 
and as such are permeable in the cell membrane.
•  All these receptors are intracellular; none are membrane bound.
•  These receptors show a marked homology of general primary 
structure; there is broad continuity in the order of the various 
functional domains.
•  There is a very high degree of sequence homology shown among 
the different DNA binding domains; and a lesser, though still 
significant homology among the ligand binding domains.
•  There is some inherent cross-reactivity of agonists and antagonists 
among receptors. In addition, it is possible to “transplant” DNA and 
hormone binding domains to form hybrid “chimeric” receptors
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which maintain some degree of functionality.
•  Finally and most importantly, all these receptors represent ligand- 
responsive transcription activation factors. There exists a common 
mechanism of gene activation exploiting similar hormone responsive 
elements.
These phenomena will be discussed in the following pages of this thesis; 
extensive reviews of this area have been published by O m alley  (1990), 
Beato  (1989) and Evans (1988).
2.1.2. STEROID RECEPTOR COMPARATIVE ANATOMY.
In recent years the primary sequences of the steroid receptor superfamily 
have been elucidated using complementary deoxyribonucleic acid 
(cDNA) cloning technology. Receptors for oestrogen (ER; G re e n  et al, 
1986; G re e n e  et al, 1986), progesterone (PR; C o n n e e ly  et al, 1986), 
glucocorticoid (GR; H o lle n b e rg  eta l, 1985), androgen (AR; Lubahn et al, 
1988), mineralocorticoid (MR) and vitamin D3 (V D 3R; M c D o n n e ll e ta l,
1987) have been cloned and the primary sequences obtained. F ig u r e  1. 
is a schematic summary of these receptdrs showing their comparative
lengths and the regions of most significant homology. It is obvious that
✓
these receptors have evolved from one primitive receptoroid and it has 
been suggested that the ancestral receptor may resemble the erb-A  
protooncogene product (W einberger  et al, 1985).
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F igure 1. The Steroid Receptor Superfamily.
The human steroid receptors are shown in terms of 
primary amino acid structure to compare the significant 
sequence homologies. The figures within the boxes 
show the similarity of both the DNA- and steroid-binding 
domains, defined as % homology to human GR.
(Adapted from O ’M alley , 1990)
The Steroid Receptor Superfamily.
Relative Sequence Homologies of the Human Steroid Binding Subunits.
DNA Steroid (a.a.)
H H m  1 777 GR
OD------QHEH 984 MR
9 1 |-------- 1 6 9 1-- 53 918 AR
934 PR 
595 ER
462 RR
44 29 H1 8 456 TRB
h 41 EHZE—I 427 VD3R
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2.1.3. THE THYROID HORMONE RECEPTOR & erb-A.
The avian erythroblastosis virus (AEV) is a transforming retrovirus which 
has a genome encoding two oncogenic sequences, v-erb-A and v-erb-B 
(V e n n s t r o m  et al, 1980). As previously mentioned, v-erb-B encodes a 
membrane protein which represents a truncated, constitutively active
E G F /T G F -a  receptor (Lax  et al, 1988). V-erb-A however was found to 
encode a thyroid hormone receptor transduced from the cellular proto­
oncogene c-erb-A (W e in b e r g e r  et al, 1986; S a p  et al, 1986). Thyroid 
hormone (triiodothyronine; T3) is secreted in precursor form (thyroxine; T4) 
from the thyroid in response to pituitary stimulation. This hormone 
modulates a vast array of biological response in different species;
: j
although generally speaking, in mammals, T3 is prinipally responsible for 
the regulation of metabolic rate and has various “permissive” actions. 
When c-erb-A was found to encode a T3 receptor, and the similarity noted 
between the v-erb-A oncogene product and the glucocorticoid receptor 
( W e i n b e r g e r  et al, 1985) there was an emergence of the term  
“superfamily” and the possibility of a universal mechanism of hormone 
action was entertained.
Originally AEV was known to induce sarcomas in vivo and to transform 
chicken embryo fibroblasts (CEFs) in vitro. The transformation was 
thought to occur as a result of v-erb-B ; v-e rb -A  enhancing the 
tumourigenicity of these transformed cells in the same manner it 
stimulates normal CEFs (G a n d r illo n  et al, 1987). A further publication 
from this group has since shown that expression of v-erb-A  alone is
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sufficient to transform CEFs in vitro (G an dr illo n  e ta l, 1989), and it has 
been proposed that the expression of such functionally altered nuclear 
receptors may trigger a transforming event that represents an initial step 
in the development of leukemia.
2.1.4. THE RETINOIC ACID RECEPTOR.
Retinoic acid (RA) is a potent morphogen directing the spatial 
organisation of cells during the embryonic development and regeneration 
of vertebrate limbs. These effects, however, are cell-specific; RA inhibits 
the proliferation of embryonal carcinoma and myeloid leukemia cells but 
stimulates the growth of keratinocytes (D a v ie s  et al, 1988). In humans, 
retinol (vitamin A) deficiency is associated with an increased risk of a 
variety of cancers. Retinoids have also been shown to inhibit tumour 
progression in vivo, and tumour promotion in vitro. (M o on  eta l, 1984).
A receptor for RA has been cloned (G ig uere  et al, 1987) and its similarity 
to the steroid receptors and thyroid hormone receptor noted. Recently 
Chambon and coworkers have shown that there are in fact two human RA
receptors; RAR-a and RAR-p; and that these are expressed together 
within the nuclei of RA-sensitive cells (G aub  et al, 1989). Presumably 
these two receptors are in competition both for the pool of RA ligand and 
for the RA responsive genes.
What is most interesting is the high level of homology between the RAR 
and the T3R; 62% and 33% of amino acids are conserved between the 
respective DNA and hormone binding domains of these two receptors
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(G ig uere  etal, 1987). This homology is highly significant, especially when 
the contrasting two-dimensional ligand structures of T 3 and RA are 
considered. Furthermore, there has been some recent, suggestions that 
these two receptors may act cooperatively at the DNA-binding level to 
regulate gene transcription (F orm an  etal, 1989). This theory will be further 
discussed in Introduction  section 2.5.4.
2.1.5. THE ARYL HYDROCARBON RECEPTOR.
Halogenated aromatic compounds are common environmental pollutants 
which are responsible for many species- and cell-specific toxic effects. 
These effects include the induction of aryl hydrocarbon hydroxylase 
activity, a cytochrome P-450-dependent enzyme activity involved in the 
metabolic activation of environmental carcinogens such as benzo(a)- 
pyrene (C o n n e y , 1982). These effects are thought to be mediated through 
toxin binding to the aryl hydrocarbon receptor (AhR), a soluble protein 
capable of binding aryl hydrocarbons such as 2,3,7,8,-tetrachloro- 
dibenzo-p-dioxin, the ligand showing highest affinity for AhR (P e r d e w ,
1988).
Work carried out by Gustafsson and colleagues has since shown rat AhR 
to be physicochemically indistinguishable from rat GR (C u t h il l  et al, 
1987). In addition, cDNA analysis has been used to confirm that AhR is in 
fact a member of the growing steroid receptor superfamily (Is s e m a n n  & 
G r een , 1990).
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2.1.6. THE OXYSTEROL RECEPTOR.
Cholesterol and its oxygenated derivatives are vital intermediatory 
metabolites of many biochemical pathways, not least of which includes 
the synthesis of steroid hormones. These pathways are, in part, regulated 
by the expressed levels of 3-hydroxy-3-methylglutaryl CoA reductase 
(T a ylo r  & Ka n d u t s c h , 1985). These workers identified a soluble protein 
termed the oxysterol binding protein and have proposed that this protein 
serves the function of a receptor for oxysterols that are regulating cellular 
cholesterol levels. Further work from this group (T a ylo r  et al, 1989) has 
shown that the oxysterol receptor bears some “general characteristics” to 
the other members of the steroid receptor superfamily although this 
remains a very tentative relationship.
2.2. STEROID RECEPTOR STRUCTURE AND FUNCTION.
Steroid receptors have three specific capabilities; ligand-binding, DNA- 
binding and gene activation. The cumulative knowledge of receptor action 
has been gleaned from research on individual receptor species. 
Consequently, some of the seemingly universal properties are part fact 
and part inference; so bearing this in mind, it is aimed to try and 
summarise the current understanding of (oestrogen) receptor action, 
avoiding broad parallelisms.-
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2.2.1. RECEPTOR SYNTHESIS.
Steroid receptors are synthesised on cytoplasmic microsomes from single 
mRNA's and it has been suggested that in vivo this occurs on the outer 
nuclear membrane, with the resultant protein transversing into the 
nucleus (C a r s o n -J u r ic a  et al, 1990). PR is the only receptor which is 
composed of two hormone-binding subunits, A and B, of Mr. 98 and 86 
kDa. in the human (M is r a h i et al, 1987); however these isoforms are 
synthesised from one mRNA by alternate translations initiating from two 
in-frame AUG codons (C o n n eely  etal, 1989). Translation of GR mRNA in 
vitro yields a large, nonactivated receptor which can then be activated to 
a DNA-binding form upon glucocorticoid binding; suggesting that the 
large heteromeric GR represents the post-translational GR in vivo (D enis  
& G u sta fsso n , 1989). Similarly, in vitro translation of PR also results in an 
nonactivated heteromeric receptor, further supporting these conclusions. 
(C arson -Jurica  et al, 1989; See Introduction  section 4.5.).
2.2.2. RECEPTOR ACTIVATION.
Steroid receptors can all be recognised in at least two distinct forms. A 
large heteromeric complex consisting of steroid-binding and nonsteroid- 
binding subunits, which have sedimentation coefficients of 8-1 OS; and 
smaller homomeric forms consisting only of steroid-binding subunit(s) 
with sedimentation coefficients of 4-5S (For a review see Ba u lie u , 1987a). 
The 8-1 OS forms have been termed “nonactivated”, as these are unable 
to bind to DNA, correspondingly the 4-5S DNA-binding forms have been
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termed “activated” (G r o d y  et al, 1982). The conversion process is known 
as receptor “activation” or “transformation” (S akai & G o r s k i, 1984). There 
is some bimodal usage of these terms but it should be noted that in the ER 
at least these represent separate processes (M O l l e r  e ta l,  1983). 
Receptor-activation can be defined as a dissociation of the nonsteroid- 
binding subunits from the 8-1 OS complexes producing a DNA-binding 
receptor (P uri & T o f t , 1984), whereas transformation of ER is seen as a 
further increase from 4S to 5S producing an ER species demonstrating 
slower oestrogen dissociation kinetics (MOller etal, 1983). Further cross- 
linking studies (M iller et al, 1985) suggest that this 5S form of ER consists 
of a dimer of two steroid-binding subunits.
Activation then, is seen as the dissociation of the nonsteroid-binding 
subunits from the steroid-binding/DNA-binding subunits. It appears that 
the nonsteroid-binding subunits are necessary for maintainance of the 
correct steroid-binding conformation of the nonactivated GR prior to ligand 
binding (B r e s n ic k  et al, 1989). Ligand binding is presumed to be the 
initiator of 10S GR dissociation (M en d el  et al, 1990); although this is not 
the only function of ligand-binding. Glucocorticoid antagonist-binding also 
results in the dissociation of GR to an activated form, but this 
dexamethasone-activated form is unable to interact productively with 
glucocorticoid-responsive genes (R ic h a r d -Fo y  eta l, 1987). Studies from 
other workers also suggest that both agonist- and antagonist-binding play 
important roles in gene activation, (see Introduction  section 2.5.5.)
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2.3. RECEPTOR PHOSPHORYLATION.
Apart from the binding of the hormone itself, phosphorylation is also 
thought to be an important mediatory factor regulating steroid receptor 
activation and action. Steroid receptors are phosphoproteins and 
consequently both phosphorylation and dephosphorylation have been 
proposed as regulators of various aspects of steroid receptor action: 
activation, DNA-binding, processing and recycling (for a comprehensive 
review see R ao  & Fox, 1987). The proposed phosphorylation-effected 
mechanisms vary between individual receptor species, however the ER 
system seems the most individual.
2.3.1. OESTROGEN RECEPTOR & PHOSPHORYLATION.
Auricchio, Migliaccio and coworkers have produced a great deal of
's .
evidence over the preceding decade to suggest that ER activity is 
regulated via a tyrosine phosphorylation system (A u r ic c h io  et al, 1990). 
This group initially purified two uterine enzymes, a phosphatase and a 
kinase (A u r ic c h io  et al, 1984), and showed that in vitro ER phospho­
rylation occurred on tyrosine residues and that it was under the influence 
of Ca2+-calmodu!in (M ig l ia c c io  et al, 1984). Antibodies directed against 
phosphotyrosine have been used to dem onstrate that tyrosine  
phosphorylation also occurs in vivo (M ig lia c c io  et al, 1986). Oestrogen 
has been shown to promote tyrosine phosphorylation, while anti- 
oestrogens correspondingly inhibit tyrosine .phosphorylation (A u r ic c h io  et 
al, 1990). This is presumably because they promote ER forms which are
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respectively recognised and not recognised by the kinase.
Tyrosine phosphorylation is presumed to be the mechanism whereby 
newly synthesised ER acquires ligand-binding ability. Incubation of in 
vitro translated ER with a highly purified uterine tyrosine kinase increases 
oestrogen-binding from 4% to almost 100% (M ig l ia c c io  et al, 1989), 
confirming earlier observations of kinase mediated ER “activation” 
(R a ym o u r e  etal, 1985). This process has been more appropriately termed 
potentiation (M cnaught eta l, 1990). These workers implicate both kinase 
and phosphatase activity as being important in the potentiation of ER 
(D ayani etal, 1990).
2.3.2. OTHER STEROID RECEPTORS & PHOSPHORYLATION.
There is a great deal of evidence suggesting that phosphorylation/de­
phosphorylation reactions are important mediatory mechanisms for other 
receptor species. A model presented for GR cycling suggests that the net 
phosphorylation of the steroid-binding and nonsteroid-binding subunits 
remains constant throughout activation, but that the DNA-binding subunits 
become de-phosphorylated upon tight DNA-binding (O rti et al, 1989a). 
Ligand-induced phosphorylation has been associated with receptor 
cycling. Both agonist-(dexamethasone) and antagonist (RU 486)-binding 
have been shown to increases GR processing by reducing its half-life, 
however only agonist binding results in GR phosphorylation, discounting 
phosphorylation as a processing mechanism. (H o eck  et al, 1989).
Similar results have been obtained for the PR. Phosphorylation of PR is
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hormone dependent (S ullivan  et al, 1988), yet newly synthesised PR is 
able to bind progesterone and DNA without any potentiating phos­
phorylation step (S h er id a n  et al, 1989). PR activation and subsequent 
processing are also independent of phosphorylation, although it seems 
that phosphorylation may affect the interaction of PR with its 
transcriptional element (S heridan  etal, 1988).
2.3.3. STEROID RECEPTORS AS KINASES.
There have been periodic reports of kinase activity associated with 
purified steroid receptor preparations. Baulieu and coworkers first 
identified an autophosphoryiative kinase activity associated with avian 
progesterone receptor (G a r c ia  et al, 1983). The phosphorylation was 
confined to different receptor components; specificity being governed by 
the presence of either magnesium or calcium ions. This group later 
refuted their initial conclusions (G a r c ia  et al, 1986), confirming that the 
magnesium-dependent phosphorylative activity was associated with a 
purifiable protein kinase distinct from known receptor subunits. These 
conclusions were also supported by others (H apgo od  et al, 1986).
A similar history applies to the glucocorticoid receptor. Initial reports 
(S ingh  & M o u d g il , 1984) demonstrated protein kinase activity of purified 
rat GR for a variety of substrates, although no autophosphoryiative activity 
was reported. However, further elegant work (S a n c h e z  & P r a t t , 1986) 
found that while immunoprecipitated GR demonstrated ion-dependent 
protein kinase activity, this was only true if polyclonal antiserum was used.
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The lack of any kinase activity with monoclonal antibody immuno- 
precipitated GR suggested that it was a kinase copurifying with, rather 
than a specific activity of the receptor.
Evidence for oestrogen receptor kinase activity is very scant, though Witliff 
and colleagues have made the significant observation that ER 
immunoprecipitated using a monoclonal antibody exhibited both protein 
kinase and phosphoinositide kinase activities (B a l d i et al, 1986). 
Autophosphorylation seems an unlikely possibility since the ER- 
associated kinase phosphorylation was on substrate serine residues; 
whereas Auricchio et al have demonstrated exclusively tyrosine 
phosphorylation of ER (see Intro ductio n  section 2.3.1.). Nonetheless, any 
relationship between a steroid receptor and a phosphoinositide-mediated 
response linked through phosphorylation would represent an important 
link between two distinct intracellular messenger systems.
2.3.4. STEROID RECEPTORS AS KNOWN KINASE SUBSTRATES. 
Theoretically, there may exist a battery of protein kinases that incorporate 
steroid receptors as substrates. One of the most interesting kinase 
activities that has been identified is that of the growth factor receptors. Fox 
and coworkers initially demonstrated that affinity purified EGF receptor 
could tyrosine-phosphorylate purified PR in response to the addition of 
EGF In vitro (G o s h -D a s t id a r  et al, 1984). PR was found to be a high 
affinity substrate for EGF-receptor, having a Km  of 100nM for the 
EGF-induced tyrosine phosphorylation. This group then observed that
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insulin receptor (but not platelet derived growth factor receptor) could also 
phosphoryiate PR on tyrosine residues, but while EGF increased XheVmax 
of EGFR phosphorylation of PR, insulin decreased the I/max of insulin 
receptor kinase activity (W oo e t a l ,  1986). As these receptors 
phosphorylated both on one common site, and on other differential sites, it 
was suggested that possible regulatory mechanisms were being 
observed. These experiments however, remain cell-free observations and 
fail to be reproducible when EGFR / ER positive MCF-7 breast cancer 
cells are used (R ao & Fox, 1987).
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2.4. STEROID RECEPTORS AND RNA.
There have been numerous reports of the association of RNA with steroid 
receptors, mainly with GR but also with ER and AR. (For a review see 
M o u d g il , 1987) The significance of RNA presence in steroid receptor 
complexes is still of debate; but it seems likely that RNA could aid in 
maintainance of structural integrity required for receptor action.
One particular group of workers has isolated and purified the RNA 
associated with the glucocorticoid receptor (Ali & V e d e c k is , 1987a). 
Vedeckis has shown the RNA to be specifically transfer RNA and this was 
largely confined to the tRNA representing the basic amino acids (Ali & 
V e d e c k is , 1987b). tRNAAr9 accounted for 51.8% of the total tRNA, while 
tRNALys and tRNAHis accounted for 17.1% and 9.2%  respectively. They 
propose that the tRNA could be involved in a ubiquitin-dependent 
degradation of the GR, and so aid in GR turnover. The involvement of 
tRNA in non-lysosomal protein degradation is well documented (F er b er  & 
C ie c h a n o v e r , 1986) and will be discussed-elsewhere (see In t r o d u c t io n  
section 3.2.5.). It should be noted, however, that although RNA has since 
been isolated from unactivated GR, only a proportion of this was found to 
be tRNA (U n g er  e ta l, 1988); and so the theories of Vedeckis e ta l require 
much further investigation.
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2.5. STEROID RECEPTORS AND GENETIC ACTIVATION.
2.5.1. THE DNA-BINDING DOMAINS OF STEROID RECEPTORS.
As discussed in In t r o d u c t io n  section 2.1.2., there exists a harmony of 
structure among the steroid hormone receptors (O ’Ma l l e y , 1990). All 
receptors analysed contain a 66 amino acid region of highly conserved 
amino acids. Green and Chambon conclusively demonstrated that this 
region was the DNA-binding domain by creating a chimaeric receptor 
(G reen  & C h a m b o n , 1987). They replaced the 66 amino acid stretch of the 
ER with that from the GR, and demonstrated oestrogen induction of a 
glucocorticoid-inducible gene.
Noticeably consistent within this region is a high local density of cysteine 
residues (Evans, 1988). Each member of the steroid receptor superfamily 
contains a single domain of the form: C ys-X (2)-C y s -X (13)-C y s -X (2)-C ys -  
X (15-17)-C ys-X (5)-C ys-X (9)-Cys-X(2)-C ys-X (4)-Cys (after B e rg , 1989; where 
X represents a variable amino acid residue). This type of region has been 
shown to exist in a number of DNA-binding proteins and is termed a 
“zinc-finger”, as it can be visualised as a finger of amino acids anchored 
by an atom of zinc and projecting from the surface of the protein (Evans & 
H o lle n b e rg , 1988). The cysteine-rich region of steroid receptors has been 
shown to represent two zinc-fingers (Freedm an et al, 1988); each having 
an individual function. Chambon has proposed that the first (N-terminal) 
finger determines the target gene specificity, while the second finger 
probably stabilises the DNA-receptor interaction (G reen  e ta l, 1988). 
Interestingly the superfamily of steroid hormone receptors can be divided
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into two subgroups on the basis of the zinc-finger motif (B e a to , 1989). GR, 
PR, AR, and MR display a common sequence, differing from the common 
sequence of ER, T 3 R and RAR, suggesting an early evolutionary 
divergence. This structural division is reflected in the ability of only the first 
group to act through the MMTV-hormone response element.
2.5.2. HORMONE RESPONSE ELEMENTS.
Hormone response elements (HRE's) are the DNA loci which participate 
in receptor-binding. The homology between the various HRE's is reflected 
by the corresponding similarity among the DNA-binding domains of the 
receptors. These elements are divisible into three classes with 
corresponding consensus sequences: oestrogen response elements 
(ERE's) GGTCAnnnTGACC; glucocorticoid response elements (GRE's) 
GAACAnnnTGTTC, and the thyroid hormone response elements (TRE's) 
GGTCATGACC (B e r g , 1989). Mutational studies have shown conversion 
of an ERE to a GRE by changing only two bases (Klock etal, 1987). 
Interestingly these HRE's are found as inverted repeat sequences, i.e. two 
half-sites having dyad axis of symmetry ( O malley, 1990). This type of motif 
forms a palindromic DNA-binding site, allowing steroid receptors to bind 
as dimers. This has in fact been observed (T sai et al, 1988) and it has 
been suggested that the receptor binds as a dimer to the major grooves of 
four subsequent turns of the DNA helix, each turn being contacted by a 
separate zinc finger (H am & Pa r ker , 1989).
There is much evidence demonstrating the mixed-matched binding of
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receptors and HRE's. Experiments carried out on the T47D human breast 
cancer cell line, which is biochemically and immunologically devoid of 
GR, demonstrated dexamethasone-activation of the PR-responsive MMTV  
after transfection using a GR expression vector (N o rd een  e ta l, 1989). This 
was a significant observation of dual control of an HRE by two steroid 
receptors in the same ceil line. AR, GR and PR have all been shown to act 
through the same 15 base pair sequence of MMTV (H a m  et al, 1 988 ); 
similarly RAR has been shown to induce transcription by binding to either 
synthetic or natural T3 response elements (U m eso n o  et al, 1988). This not 
only underscores the evolutionary relationship of the HRE's, but also 
opens up the possibility of synergistic regulation of the HRE's.
2.5.3. DNA-BINDING RECEPTOR DIMERS.
Steroid receptors are thought to exert their effect as dimers bound to the 
relevant palindromic HRE. Activated GR has been purified as a 
homodimer whether in the presence or absence of DNA (W r a n g e  et al, 
1989), and it seems likely that other steroid receptors bind to DNA in a 
similar manner. It has also been suggested that the binding of the 
receptor monomers occurs in a stepwise, cooperative manner (T sai eta l, 
1988) although this remains unclarified. Chambon generated mixtures of 
wild type and truncated ER and found that both homodimers and 
heterodimers were formed on subsequent incubation with an ERE (K um ar  
& C h a m b o n , 1 9 8 8 ), suggesting that dimer formation is necessary for 
effective DNA-binding.
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2.5.4. RECEPTOR COOPERATIVITY & SYNERGY.
Cooperative binding of receptors to HRE's has been demonstrated in 
vitro. O'Malley and coworkers have shown that dimeric PR binding to a 
tandem GRE/PRE increases in affinity by 100-fold when a second PR 
dimer binds (T sai et al, 1989). This resulted in a stable complex with a Kd 
for DNA of approximately 10‘n M. Similar synergistic results have been 
obtained from observations of activation of an ERE and adjacent 
G R E/PR E (C a t o  et al, 1988) where a progesterone and oestrogen 
combination was shown to illicit a response greater than the sum of the 
individual inductions.
Heterodimeric gene activation has also been noted in vitro. In T3- 
responsive rat pituitary cells, transcription can be observed in the 
absence of T3 (F o r m a n  et al, 1988). This seems to occur though
constitutively active c-erb -A -a l forming c -erb -A -a l/T3R  heterodimers 
capable of gene activation regardless of ligand. This group later observed 
that patients presenting thyroid hormone resistance syndrome display 
dominant-negative c-erb-A phenotypes; the transcriptionally inactive form 
of erb-A (F o r m a n  et al, 1989). They suggest that there is major in vivo 
formation of T3R /(neg)erb-A heterodimers which are transcriptionally- 
inactive and so may account for the T3 insensitivity of these patients.
More importantly dimerisation could prove to be a possible interaction 
mechanism of the various receptors within the superfamily to provide 
finely tuned hormonal responses.
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2.5.5. TRANSCRIPTIONAL ACTIVATION.
Steroid receptors bind to specific DNA sequences inducing transcription. 
Trans-activation is in part due to the activity of their short DNA-binding 
domain (H ollenberg  etal, 1987), however studies using deletion mutants 
and chimseric receptors have shown that a more significant proportion of 
the trans-activation activity lies at distant sites of the receptor (H ollenberg  
& E v a n s , 1988). Chambon and coworkers have identified at least one 
trans-activation domain within the hormone-binding domain of the ER 
(K um a r  et al, 1987). What is most interesting is that while both oestrogen 
and antioestrogen (4-OH tamoxifen) seem to cause receptor activation, 
only oestrogen-binding induces trans -activation (W eb s te r  e ta l, 1988). 
These studies confirm the dual role hypothesis of hormone-binding, and 
demonstrate that the inhibitory effect of antisteroidals arises from the 
formation of abortive complexes with HRE's (G u ic h o n -M a ntel  et al, 1988; 
R ichard-F o y  et al, 1987).
Trans -activation is thought to occur through the trans -activation domain 
of the receptor interacting with other transcription factors; possibly via 
protein-protein contacts with either the TATA box factor or even RNA 
polymerase II (H am  & Pa r k e r , 1989). It has' been suggested that different 
steroid receptors could compete for these factors, as transcriptional 
interference of endogenous PR and ER in MCF-7 and T47D cells has 
been observed (M eyer  etal, 1989).
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2.6. RECEPTOR INTRACELLULARITY.
Initially steroid receptors purified as either “cytosolic” or “nuclear” species, 
which led to the Gorski-Jensen two-step model of hormone (oestrogen) 
action (G o r s k i et al, 1968; J e n s e n  et al, 1968). The term cytosolic was 
generally interpreted as cytoplasmic (C la rk , 1984; Le a k e , 1976), and it 
was presumed that hormone-binding induced receptor-activation followed 
by translocation to the nucleus. However, knowledge of the intracellular 
location of steroid receptors greatly advanced when receptor-specific 
antibodies became available, as these facilitated immunocytochemical 
location of receptors in both tissues and cultured cells. 
Immunocytochemistry was first used to identify ER in the nuclei of target 
cells (K ing  & G r e e n e , 1984) casting doubt on the original Gorski-Jensen 
two-step translocation model. Work from Gorski's own laboratory 
confirmed this data (W elshons  etal, 1984) suggesting that the ER resides 
permanently In the nucleus and that its affinity for DNA is increased upon 
ligand-binding. These results have been confirmed in the human breast 
cancer cell lines MCF-7 and T47D (W e l s h o n s  et al, 1988) and also in 
human breast tissue (W alker  et al, 1988), where again oestrogen-binding 
failed to influence ER distribution.
Bauiieu and colleagues showed exclusive intranuclear residence of PR  
independent of hormanaf administration (G asc  et al, 1984). PR has since 
been located using electron microscopy to visualise immunogold 
detected anti-PR monoclonal antibodies (P e r r o t -A pp la n a t  eta l, 1986). 
These studies confirmed that PR resides within the nuclei of target cells
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revealing that it associates directly with condensed chromatin after 
progesterone administration. Similarly, the AR (H u sm a n n  et al, 1990) and 
VD 3R (C lem en s  et al, 1988) have both been shown to be predominantly 
nuclear proteins whether in the presence or absence of ligand. Hormone 
binding is again thought solely to increase the affinity of the receptor for 
DNA, rather than promoting any change in subcellular localisation.
The situation for GR is less well understood. There is strong evidence to 
suggest that GR coexists between the cytoplasm and the nuclei of target 
cells (W il k s t r Om  e ta l, 1987). These workers observed a hormone- 
dependent shift in the proportion of the two species: ligand withdrawal 
achieved by adrenalectomy resulted in a loss of nuclear GR, while 
dexamethasone significantly increased the proprotion of nuclear GR, 
although some cytoplasmic GR was always present. It has been 
suggested that the distribution of GR represents different stages in 
receptor recycling rather than an observation of an activation- 
translocation type of mechanism (Qi etal, 1989).
Most immunocytochemical studies address the localisation of the 
hormone-/DNA-binding subunits of steroid receptors, and very few  
comment on the distribution of the nonsteroid-binding subunits, however 
these reports are very relevant to the work described in this thesis and will 
be discussed in Introduction  section 4.8.
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3. Heat Shock and Heat Shock Proteins.
3.1. HEAT SH O C K ?
The terms heat shock and heat shock proteins are misnomers used to 
describe the phenomenon occurring during the cellular response to some 
environmental onslaught. These elderly terms have evolved from studies 
observing the physiological response to hyperthermia, the classical form 
of stress induction. Better terms would be stress response and stress 
proteins, as we now know there are many other environmental variants to 
heat. Unfortunately, however, convention has adopted the former terms; 
and so they will be used here.
3.2. THE HEAT SHOCK RESPONSE.
3.2.1. OBSERVING THE PHENOMENON.
Cellular response to heat was first visualised in Drosophila  embryos 
about thirty years ago, though it was not until 1978 that the effect of heat 
shock on mammalian and avian protein expression was reported (K elley  
& S c h l e s in g e r , 1978). The response is now known to be universal; 
occurring in every organism tested, from archebacteria to man (L in d q u is t ,
1986). The heat shock response is found in nearly all cell- and tissue- 
types of multicellular organisms; including cultured cells, and is 
characterised by the synthesis of a small number of highly conserved 
proteins. These are the heat shock proteins (hsp’s), and their expression 
is the sole quantifiable parameter of the heat shock response. (For a 
review see L in d q u is t , 1986). However, it should be noted that although
4 8
Introduction
the levels of hsp's are elevated by stress; many hsp's also exist in normal, 
unstressed cells. Hsp 70 has been purified from unstressed cells and hsp 
90 can comprise as much as 0.5-1.0%  of the protein in cytosol extracts 
(To ft  et alt 1987).
3.2.2. STRESS INDUCERS.
By definition, cellular exposure to elevated temperatures is the classic 
environmental stress inducing the heat shock response and hence hsp 
synthesis. These supraphysiological temperatures vary among different 
cells and species but are generally no more than 4-8°C above the normal 
physiological temperatures. Other known inducers of mammalian hsp's 
include ethanol, arsenite, heavy metals, amino-acid analogues, glucose 
deprivation-refeeding cycles and anoxia (Bu r d o n , 1986). However, not all 
inducers are effective in all cells tested. Similarly there are some inducers 
of hsp synthesis in Drosophila and other invertebrates that are not active 
in mammalian cells; such as phorbol esters, ouabain or sodium azide 
(Bu r do n , 1986; C raig , 1985).
It is interesting that so many diverse agents can effectively substitute for 
one another. This raises the question as to whether there could exist a 
common mechanism of hsp induction, action and regulation. It is possible 
that the damaging effects of all these agents could be directed against 
either existing proteins, or more probably nascent polypeptides; thus 
producing abberant proteins. The latter would be especially susceptible to 
the sorts of stressing agents listed above. Damaged proteins are thought
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to signal induction of the heat shock response and this has been 
confirmed using microinjection of denatured protein to induce hsp 
synthesis in Xenopus oocytes (A nanthan e ta l, 1986).
3.2.3. HEAT SHOCK PROTEINS.
Schlesinger defined heat shock proteins by two criteria: firstly, “their 
synthesis is strongly stimulated by an environmental stress, in particular, 
that resulting from a change in temperature a few degrees centigrade 
above the normal physiological one” and secondly that “their gene 
contains a conserved sequence of 14 base pairs in the 5' noncoding 
region, the Pelham box. This sequence serves as the promoter for hsp 
mRNA transcription.” (S c h lesin g er , 1986).
Hsp's are named according to their molecular weight in kiloDaltons 
(kDa.). They can be subgrouped into four families of different molecular 
weights; the first three are hsp 83-90, hsp 70, and hsp 20-30. The sole 
member of the fourth subgroup is ubiquitin, an 8 kDa. protein involved in 
nonlysosomal protein degradation (C iechanover  eta l, 1984). In eukaryotic 
cells each of these subgroups represents a gene family encoding closely 
related protein isoforms regulated by different gene promoters (C r a ig ,
1985).
Molecular weights are also vital for hsp detection, as this is the only 
biochemical parameter available to identify hsp's other than by 
immunological methodology. Hsp's consistently fail to show any catalytic 
activity; presumably their function is achieved by their association with
50
Introduction
target molecules and structures, and so antisera must be used to readily 
identify cellular hsp. It is probably for this reason that demonstration of a 
definite function of hsp's has evaded researchers for so long.
3.2.4. REGULATION OF THE HEAT SHOCK RESPONSE.
In mammalian cells, heat shock results in the shut down of normal protein 
synthesis coupled with the induction of hsp's. The translation of hsp 
mRNA in preference to preexisting mRNA is in part responsible for the 
altered protein expression profile.
firsilq
The control of protein expression appears 7at the translational level; 
as mRNA coding for non-heat shock proteins is not translated, although it 
remains translationally competent if tested in cell-free extracts (T ho m as  et 
al, 1982). It has been suggested that this effect is due to an increase in
phosphorylation of the a-subunit of eukaryotic initiation factor 2, e lF-2a  
(B u r d o n , 1986). This factor associates with a 90 kDa. phosphoprotein 
which has recently been confirmed as hsp 90 (R o s e  et al, 1989). The
activity of elF-2a is governed by its phosphorylation state, which is in turn 
dependent on the phosphorylation state of the associated hsp 90; 
implying that hsp 90 may play a pivotal role in the regulation of normal 
protein synthesis during the stress response.
Transcription of hsp mRNA has been shown to be immediate; increasing 
in concentration from one copy to 1000 copies of mRNA per cell within the 
first hour (B ie n z , 1982). Pelham discovered a common promoter region 
66 nucleotides upstream of the RNA start site of all Drosophila hsp genes
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( P e l h a m , 1982). Consisting of a TATA box and a short conserved 
sequence, it was found indispensable for hsp transcription. Further 
cloning work confirmed these small consensus sequences as heat shock 
regulatory elements (HSE) having the ability to confer heat inducibility on 
previously insensitive genes (P elham  & B ie n z , 1982). Two proteins were 
then identified which bound to the TATA box and the HSE (Wu, 1984). 
Tight binding of the one of these, the heat shock transcription factor 
(HSTF), to the HSE can be correlated with transcriptional activity, the 
TATA box factor seems to be permanently bound.
Bienz has proposed a hypothetical model of hsp induction whereby heat 
shock activates HSTF; either directly or through the actions of some other 
component, the activated HSTF is then able to tightly bind the HSE thus 
inducing rapid hsp transcription (B ie n z , 1985). It has also been suggested 
that ubiquitin could be involved in the regulation of HSTF activity as levels 
of this protein are influenced by the,intracellular levels of denatured 
proteins (B u r d o n , 1986).
3.2.5. UBIQUITIN.
Ubiquitin is a highly conserved, yet abundant protein of Mr. 8000 which 
has latterly been termed an hsp as it demonstrates heat inducibility (Bo nd  
& S c h l e s in g e r , 1985).- Much of the research on ubiquitin function 
however, has been concerned with its role in nonlysosomal proteolysis 
(For a review see C iechanover  eta l, 1984). Several molecules of ubiquitin
are conjugated to proteins through isopeptide bonds to e-N H 2 groups of
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lysine residues, forming target proteins for proteolytic degradation. This 
highly selective degradation system removes abnormal proteins in an 
energy dependent manner; as both the conjugation and the proteolysis 
are ATP-dependent. In addition it has been shown that conjugation is in 
part dependent on the presence of tRNA (F erber  & C iech a n o ver , 1986). 
Ubiquitin has been proposed as a regulator of hsp transcription acting as 
a modulator of HSTF activity (B u r d o n , 1986). Pelham suggested that 
inactive HSTF may, like histones, be normally maintained in a 
ubiquitinated form; and that the sequestering of ubiquitin for conjugation 
to stress induced damaged proteins would lower the pool levels of 
ubiquitin and result in the activation of HSTF (M u n r o  & P e l h a m , 1985). 
This hypothesis remains untested yet seems unlikely; as the pool 
ubiquitin, itself an hsp, would also increase with stress.
3.3. A ROLE FOR THE HEAT SHOCK RESPONSE.
The role of the heat shock response and the function of heat shock 
proteins has been the subject of many reviews (S c h l e s in g e r , 1986; 
L in d q u is t , 1986; & C r a ig , 1985) and although there is much speculation, 
there are very few conclusions. Thermotolerance is the best documented, 
and most obvious function of hsp's, although there are numerous other 
possible roles emerging. However, the universal demonstration of the 
response and the extremely high conservation shown among the hsp 
subgroups mean that they remain of fundamental importance to life.
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3.3.1. THERMOTOLERANCE.
Thermotolerance can be defined as the acquisition of cellular resistance 
to lethal levels of heat by previous exposure to lesser, sub-lethal doses. 
However this definition should be broadened to include the other 
stressing agents as heat is not the only inducer of the (thermo)tolerance 
phenomenon. There is much indirect evidence to suggest that the 
protective mechanism of thermotolerance is mediated through hsp's. This 
evidence is well reviewed by Lindquist and can be summarised as 
follows:
•  Agents inducing hsp synthesis also induce thermotolerance, and 
one agent can confer (thermo)tolerarice to another.
•  The synthesis and degradation of hsp's mirror the kinetics of the 
thermotolerance induction.-
•  Stages of development which do not facilitate hsp synthesis 
render the organism extremely sensitive to heat or other stress 
agents at that time.
•  Mutants selected for their ability to withstand exposure to high 
temperatures have been shown to constitutively express hsp's,
• i
and correspondingly mutants known to be thermointolerant 
have been shown to posses a defective hsp synthesis.
•  Finally, thermotolerance can be blocked if cycloheximide is added 
to cells immediately prior to heat shock.
The first direct evidence that implicates hsp’s as the mediators of
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thermotolerance has come from Welch and coworkers (R ia b o w o l  et al,
1988). They were able to show that heat shock was lethal to fibroblasts 
microinjected with monoclonal antibodies against hsp 70, whereas cells 
injected with non-specific antiserum survived the heat shock.
3.3.2. PROTEIN DEGRADATION.
Another possible function of hsp's which has already been raised (See 
In t r o d u c t io n  section 2.4.) is that of mediators of nonlysosomal protein 
degradation. This line of postulation is mainly derived from the ubiquitin 
mediated, ATP-dependent proteolytic system (C ie c h a n o v e r  et al, 1984). 
Interestingly it has been shown that this system is in part dependent on 
the presence of tRNA (F erber  & C iechano ver , 1986), in particular tRNAHis. 
Initial suggestions that hsp's and ubiquitin are complementary methods of 
dealing with the common problem of protein turnover (F in ley  et al, 1984) 
adopt extra significance in the light of more recent evidence. The 
glucocorticoid receptor has been found to be composed of both a heat 
shock protein (hsp 90; H ow ard  & D istelho rst , 1988a) and tRNAArs (A li & 
V e d e c k is , 1987b), opening up the possibility that hsp 90 is mediating GR  
turnover in a manner analogous to the function of ubiquitin. (see 
Introduction  section 2.2.)
3.3.3. STRUCTURAL ASSEMBLY.
It has been suggested that hsp 70 participates in the organisation of 
multi-subunit complexes, such as the ribosomal machinery, acting as a
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molecular scaffold to aid structural integrity (W e lc h  & S u h a n , 1986). 
Transcription is heat sensitive, and enhanced hsp 70 synthesis has been 
shown to increase the translational resistance to further heat shock (Y o s t  
& L in d q u ist , 1986)
3.3.4. PROTEIN TRANS LOCATION.
Hsp 70 has been shown to be part of the translocational machinery 
facilitating protein passage through the yeast endoplasmic reticulum and 
the eukaryotic mitochondrial membrane (D eshaies  e ta l , 1988). It has been 
suggested that hsp 70 could mediate this transfer through an unfoldase- 
type activity (V e r n e r  & S c h a t z , 1988), although this notion fails to be 
substantiated.
3.3.5. PROTEIN STABILISATION.
Hsp's have been proposed as stabilisers, potentiating the activity of 
biomolecules, largely on the observations on the association of hsp 90 
with the nonactivated forms of the steroid receptors (T o f t  et al, 1987; 
discussed in introduction section 4.). In this event, hsp 90 seems to be 
holding the steroid receptor in a state of readiness to bind ligand and 
become transcription activative.
An additional line of support for this role comes from early studies on the 
transforming gene product of Rous sarcoma virus, pp60src. This is a 
transforming tyrosine kinase made up of three subunits (H u n ter  & S e f t o n , 
1980) and regulated by tyrosine phosphorylation (P iw n ic a -w o r m s  et al,
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1987). One of these subunits immunoprecipitating with pp60src was 
originally shown to be hsp 90 (O pper m a n n  et al, 1981) and this was later 
confirmed by Toft and colleagues using immunocytochemical staining 
(S c h u h  et al, 1985). In addition, it was nonactivated pp60src that was 
shown to associate with hsp 90, suggesting that the hsp was acting as a 
regulator of enzyme activity. For both these two sets of biomolecules then, 
hsp 90 seems to be acting as a mediator of stability.
3.3.6. PROTEIN TARGETING.
It has been suggested that hsp's may participate in the targeting of 
important cell proteins, such as steroid receptors or pp60src, to an 
appropriate intracellular location. The main thrust of this argument derives 
from 1) the discussed association of hsp's with other important molecules, 
and 2) the discovery that hsp's are associated with the protein 
components of the cytoskeleton.
Japanese workers initially identified both hsp 90 and hsp 100 as actin- 
binding proteins; having the ability to cross-link actin filaments (Ko ya su  et 
al, 1986). They later went on to show that both hsp 90 (N ishida  etal, 1986) 
and hsp 100 (K o y a s u  et al, 1989) bound actin in a Ca2+-calm odulin- 
dependent manner; the presence of Ca2+ causing calmodulin to bind the 
hsp's and prevent them associating with the actin filaments. These 
workers imagined a scenario whereby a nonmuscle actomyosin system 
could provide transportational forces for hsp movement: an hsp shuttle on 
an actin network, transporting important biomolecules (K o y a s u  et al,
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1986). This colourful hypothesis remains untested, although hsp 90 has
also been shown to associate with both a -  and p-tubulin (S a n c h e z  et al,
1988). This group used immunofluorescence microscopy to visualise the 
association in intact cells. However, hsp 90 only bound to actin when 
purified preparations were used, but did not associate in intact cells; 
suggesting that the in vitro work of the Japanese group could be 
artifactual.
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4. Hsp 90 & Steroid Hormone Receptors.
4.1. THE 90 kDa. HEAT SHOCK PROTEIN (hsp 90).
Hsp 90 is a heat inducible protein (C a t e l l i et al, 1985) whose gene 
promoter contains the necessary heat shock responsive element (R ebbe  
et al, 1989; see In t r o d u c t io n  section 3.2.4.) although it accounts for 
between 1 and 2% of the cytoplasmic protein in unstressed HeLa cells 
(L e e s - M iller  & A n d e r s o n , 1989a). This presence represents 9 million 
monomers per cell; and as such hsp 90 is an exceptionally abundant 
protein. Biochemical data suggest that hsp 90 has an elongated shape, 
more akin to that of a structural protein than a globular protein (R o s e  et al,
1989).
These workers report both three-dimensional and immunological 
similarities between hsp 90 and the structural protein spectrin. These 
conclusions may be confusing earlier observations which studied the 
association of hsp 90 with various cytoskeletal protein components (See 
Intro duction  section 3.3.6.) The initial reports confirmed that it was hsp 90, 
not spectrin, however these authors also visualised hsp 90 as an elliptical 
protein, 25nM-long (Koyasu  etal, 1986).
In many mammalian species there seem to be multiple forms of hsp 90 
(R ebbe etal, 1989); however only two distinct human cDNA hsp 90 clones
have been identified. These have been termed hsp 89a  and hsp 89p 
(S imon  et al, 1987). Originally hsp 90 was noted to consistently migrate as 
a doublet during polyacrylamide gel electrophoresis (M e n d e l  & O r t i,
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1988) although this is now known to be due to the existence of the two
isoforms of 732 and 728 amino acids respectively. The hsp 89a and hsp
89(3 isoforms are phosphorylated on serine residues at two homologous 
sites (Lees -M iller & A n d e r s o n , 1989a), though phosphorylation seems to 
bear no relation to any functional regulation of steroid receptor interaction. 
In addition to heat and stress, hsp 90 synthesis has been shown to be 
regulated by both gonadotrophins (B e n -Z e 'EV & A m s t e r d a m , 1989) and 
oestrogens (R a m a c h a n d r a n  e ta l, 1988). These results are especially 
interesting as it opens up the possibility of complementary regulation of 
the oestrogen receptor-hsp 90 association.
4.2. COMMON NONSTEROID-BINDING RECEPTOR SUBUNITS.
As discussed in In tr o d u c tio n  section 2.2.2. steroid receptors exist in two 
major forms: large heteromeric complexes consisting of steroid-binding 
and nonsteroid-binding subunits; and smaller complexes consisting 
solely of steroid-binding subunits (Ba u l ie u , 1987a & b). It was noticed 
upon receptor purification that the nonsteroid-binding components always 
had a Mr of ~90 kDa. (D o u g h e r ty  et al, 1984; Atr a c h e  eta l, 1985). This 
protein was confirmed as a common component of ER, AR, PR and GR by 
Baulieu and colleagues (Joab  et al, 1984). They raised an antibody to 
unactivated PR which only recognised the nonsteroid-binding subunits of 
PR and found that the antibody also detected the nonsteroid-binding 
subunits of the other three steroid receptors. This 90 kDa. protein has 
since been immunologically identified with the MR (R a f e s t in -O blin  et al,
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1989), the AhR (P e r d ew , 1988) and the mouse oxysterol receptor (T aylor  
et al, 1989). However, there have been no reports of any 90 kDa. protein 
associating with T3R, VD3R, RAR or the product of erb-A.
3. THE NONSTEROID-BINDING COMPONENT IS HSP 90.
To investigate the significance of the 90 kDa. protein Toft and coworkers 
raised an antibody (AC 88) to a related 88 kDa. protein from the water 
mould Achlya ambisexualis (R iehl eta l, 1985). This organism contains a 
receptor for the morphogenic steroid antheridiol which exhibits the typical 
8 to 4S type of transformation in cell-free experiments. The AC 88 
antibody was found to be specific for the 90 kDa. component of PR, but 
the antibody was also found to detect the 90 kDa. protein in a wide range 
of mammalian tissues and species. Interestingly
Rous sarcoma virus transforming protein tyrosine kinase (pp60v‘src) 
was also shown to associate with the 90 kDa. protein; noticeably in its 
non-active form (S ch uh  et al, 1985). Similar results were obtained when 
other monoclonal antibodies were raised against hsp 90 (S ullivan  et al, 
1985). Nonactivated GR and AR were both shown to associate with the 90 
kDa. protein, which was again shown to exist in a large number of 
different mammalian tissues. AC 88 has since been used to show that this 
ubiquitous 90 kDa. protein is immunologicaily identical to hsp 90 (T o f t  et 
al, 1987). Hsp 90 fails to be associated with any enzymatic activity, and is 
unable to bind hormones or DNA (H ow ard  & D istelh o r st , 1988b).
Baulieu and coworkers raised a monoclonal antibody to chick 8S PR and
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found that the antibody recognised only the 90 kDa. nonsteroid-binding 
protein of PR (Joab  et al, 1984). This antibody was used in conjunction 
with peptide mapping to show that the 90 kDa. component was both 
immunologically and biochemically identical to the heat inducible avian 
hsp 90 (C a telli et al, 1985). This direct evidence was confirmed by the 
discovery that the 90 kDa. nonsteroid-binding protein of murine PR was 
immunologically identical to mouse hsp 90 (S a n c h e z  et al, 1985). This 
group went on to confirm that the association of hsp 90 with GR is 
confined to the non-activated form of GR by first removing “free” hsp 90 
and then immunoprecipitating GR using anti-hsp 90 antibodies (S a n c h e z  
etal, 1987).
4.4. STEROID RECEPTOR & HSP 90 STOICHIOMETRY.
Some information regarding the stoichiometric arrangement of hsp 90 
' with the different steroid receptors can be gleaned from earlier studies 
investigating the relative amounts of steroid-binding and nonsteroid- 
binding subunits in different receptor preparations. Such work carried out 
on ER suggested that the 8-9S heteromeric form of Mr~300 kDa. was 
actually composed of two 65 kDa. steroid-binding subunits in a dimer 
complexed with two 90 kDa. nonsteroid-binding subunits (R ed euilh  et al,
1987). Similarly, nonactivkted (8-1 OS) GR and PR have both been shown 
to interact with hsp 90, however in contrast to the nonactivated ER, these 
proteins appear to exist as complexes consisting of only a single steroid- 
binding subunit associated with the two' 90 kDa. nonsteroid-binding
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subunits (G u sta fsso n  e ta l, 1989; R adanyi e ta l , 1989). This difference in 
stoichiometry is reflected functionally in that the activation of ER seems 
distinct from the activation of GR and PR. The DNA-binding, transformed 
ER exists as a dimer prior to DNA-binding; whereas the GR and PR 
monomers seem to bind cooperatively to DNA (discussed in In tro du c tio n  
section 2.2.2.). Baulieu and colleagues recently confirmed their earlier 
proposal showing that the two hormone-/DNA-binding subunits of ER 
exist as a dimer, interacting “head-to-head” through their hormone- 
binding domains both before and after receptor activation (S abbah  et al,
1989). Interestingly, this group have also demonstrated that hsp 90 is 
present as a dimer whether free from, or complexed to chick PR (R adanyi 
et alt 1989). Taken as a whole, the evidence seems to suggest that two 
hsp 90 moieties are present in nonactivated steroid receptors (ER, GR & 
PR; see F ig u r e  2.), and these undergo synchronous dissociation upon 
ligand-induced receptor activation.
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Figure 2. The Subunit Stoichiometry of Steroid Hormone 
Receptors.
This diagram is a representation of the stoichiometric 
ratios of steroid-binding and nonsteroid-binding subunits 
present in three nonactivated, 8-1 OS steroid receptors. 
These schematic structures are mainly derived from 
information gleaned from purification and cross-linking 
studies (see text for citations).
Subunit Stoichiometry of Steroid Hormone Receptors.
nonsteroid-binding steroid- & DNA-
subunits (hsp 90) binding subunits
Oestrogen Receptor
Progesterone Receptor Glucocorticoid Receptor
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4.5. HSP 90 ASSOCIATES WITH NONACTIVATED RECEPTORS in vivo.
All observations discussed so far represent in vitro studies using purified 
receptor components. To date, no conclusive evidence has been 
proposed which proves that hsp 90 associates with steroid receptors in 
vivo. However, pulse chase experiments carried out using whole mouse 
lymphoma cells have shown that hsp 90 is associated with newly 
synthesised GR in a time dependent manner (H o w a r d  & D is t e l h o r s t , 
1988a). Furthermore, the inclusion of dexamethasone at the beginning of 
the pulse chase results in an inhibition of the association.
Translation of both PR and GR mRNA in vitro has been shown to yield 
nonactivated receptors (D enis  & G u s ta fs s o n , 1989; C a r s o n -J u r ic a  et al, 
1989). These receptors are then activated to a DNA-binding form upon 
ligand-binding; suggesting that the hsp 90-associated GR represents the 
post-translational GR in vivo.
Interestingly, when different in vitro translation systems are used 
contrasting results are obtained, in vitro translation of GR in reticulocyte 
lysate results in full length GR capable of high affinity steroid-binding; 
while GR translation using a wheat germ extract results in a full length GR  
that is incapable of hormone-binding (D alman  e ta l, 1989). Significantly, 
only the functional GR could be immunoprecipitated using an anti-hsp 90 
antibody, which was also'used to confirm the lack of detectable hsp 90 in 
wheat germ extract. These data again indirectly substantiate the existence 
of steroid receptor-hsp 90 heteromers in vivo.
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4.6. STRUCTURAL INTERACTIONS OF STEROID RECEPTORS & HSP 90. 
The sites of interaction between hsp 90 and the steroid receptors has 
been investigated by a variety of methods. Tryptic digestion of the 94 kDa. 
GR has been used to generate a 27 kDa. glucocorticoid-binding 
“mero-receptor” which remains immunoprecipitatable using anti-hsp 90 
antibodies (D en is  et al, 1988). This observation has been confirmed by 
expression studies of GR deletion mutants. These studies found that 
deletion of the glucocorticoid-binding domain produced a constitutively 
active GR; furthermore, deletion of only three amino acid residues from 
within the ligand-binding domain resulted in a GR population devoid of 
the 9S, heteromeric GR (P ratt etal, 1988). Both these results suggest that 
the hormone-binding domain, or some part of it, is responsible for 
mediating hsp 90-G R interaction. These conclusions have been 
confirmed by similar work carried out on PR. Studies using deletion 
mutants located a stretch of 140 amino acids within the progesterone- 
binding domain which were essential for both progesterone-binding and 
8S PR formation (C arson -J urica etal, 1989).
The gene sequence of chick hsp 90 has been analysed for possible 
interaction sites with the avian PR (B in a r t  et al, 1989). These workers
have identified two hydrophilic a-helical regions on the surface of hsp 90,
/
and proposed that these regions are responsible for structural association 
with steroid receptors.
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4.7. REGULATION OF THE RECEPTOR-HSP 90 INTERACTION.
Phosphorylation has been discussed in relation to its role as a possible 
regulator of steroid receptor activity (See In t r o d u c t io n  section 2.3.). 
Purified hsp 90 is a serine-phosphoproteiri (S a n c h e z  et al, 1986) and it 
has been shown to be a co-purifying substrate for rat liver type II casein 
kinase in vitro (D o u g h e r ty  eta l, 1987). Threonine phosphorylation of hsp 
90 by human double-stranded DNA-activated protein kinase has also 
been observed in vitro (Le e s -M iller  & A n d e r s o n , 1989b); however the 
significance of these observations remains doubtful as the affinity of hsp 
90 for the enzyme was very poor and threonine-phosphorylation has 
never been observed in vivo.
As discussed in Intro ductio n  section 2.2.21; phosphorylation as a result of 
ligand-binding has been proposed as a method of inducing steroid 
receptor transformation (O r ti et al, 1989a). The dissociation of hsp 90 
after steroid-binding could be triggered by a change in the 
phosphorylation state of either component (A u r ic c h io  e ta l,  1990). 
However this seems unlikely in the light of observations of GR cycling 
which demonstrated that the net phosphorylation of hsp 90 remained 
unchanged before and after glucocorticoid-binding (O rti et al, 1989b). No 
net change was observed in the phosphate content of the glucocorticoid- 
binding subunits either, although the authors do not reject the possibility 
of phosphate exchange.
Ligand-binding is thought to be the most potent effecter of the steroid
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receptor-hsp 90 dissociation. It has been suggested that the main 
difference between the action of hormones and anti-hormones is that anti­
hormones may act to prevent dissociation of hsp 90 and so form inactive 
receptor species (B a u l ie u , 1987a & b). This theory will be discussed 
elsewhere (see Part 1 D iscussion  section 5.)
The steroid receptor-hsp 90 complex cannot currently be reassembled in 
vitro from purified components. The only “man-made” 8-1 OS receptors 
have been formed from the in vitro translation of receptor mRNA in the 
presence of hsp 90 (D e n is  & G u s t a f s s o n , 1989; C a r s o n -J u r ic a  et al, 
1989). One possible problem may be that there is an extra, hitherto 
undiscovered component(s) which aid in the assembly of steroid 
receptor-hsp 90 complexes in vivo, but are lost or inactive in cell-free 
preparations. Two such proteins proposed as missing components are 
hsp 70 and a 59 kDa. protein termed p59 (S mith  et al, 1990). The hsp 70 
association seems hormone-independent, however the p59 protein was 
seen to dissociate from PR with similar kinetics to hsp 90 in response to 
progesterone exposure. Further work (R en o ir  et al, 1990) has confirmed 
that p59 is associated with PR, ER, AR & GR, and in addition p59 is bound 
to hsp 90 rather than the steroid-binding subunits. This confirms the 
similar steroid-induced dissociation of p59 and hsp 90 reported by Toft 
and colleagues (S m ith  et al, 1990) and furthers the “missing-component” 
hypothesis regarding the inability of researchers to construct nonactivated 
receptor in vitro.
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4.8. FUNCTIONAL INTERACTIONS OF STEROID RECEPTORS & HSP 90. 
Baulieu has suggested that the function of hsp 90 is to act as a cap, 
“masking” the DNA-binding domain of steroid receptors until hormone- 
binding induces hsp 90 dissociation (B a u l ie u , 1987a & b). These ideas 
are based on the original observations of this group that the 90 kDa. 
component was only found to associate with nonactive steroid receptors 
(C a telli et al, 1985; J oab  et al, 1984). They remain in agreement with 
many of the current observations discussed in the preceding paragraphs 
(See F igure  3.).
The “masking” scenario at first seems contradictory to the profusion of 
data suggesting that hsp 90 interacts with the hormone-binding domain of 
steroid receptors. However, the larger/longer hsp 90 could span both the 
DNA- and the hormone-binding domains of the ER; indeed, a dual 
interaction would seem necessary for ligand-regulation of DNA-binding 
ability.
O'Malley and colleagues have produced an antibody to a fragment of PR 
which represents a region of the PR located between the hormone- and 
DNA-binding domains and is predicted to be on the surface of the protein 
(W eig el  et al, 1989). Interestingly the antibody only recognises activated 
PR and not 8S nonactivated PR, suggesting that hsp 90 could be masking 
the DNA-binding domain. This observation parallels results from other 
previous experiments where purified hsp 90 was used to elute activated 
GR from a DNA-cellulose column (H ow ard  & D is telho rst , 1988b).
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Figure 3. A Schematic Model of Steroid Hormone Action.
This diagram attempts to summarise the current 
understanding of steroid receptor activation in terms of 
ligand-binding and DNA-binding. (Based on the 
oestrogen receptor)
In this simplified scheme, the nonsteroid-binding 
subunits are shown to interact with the DNA-binding 
domains of the steroid-binding subunits - the “masking” 
effect. Steroid-binding induces the dissociation of the 
subunits into homodimers (activation). The steroid- 
binding dimer then binds to palindromic hormdne 
response elements encoded within the DNA of steroid- 
responsive genes. The nonsteroid-binding subunits (hsp 
90) may then be recycled.
For the sake of simplicity, other effecters (eg. phospho­
rylation) are omitted from F ig u r e  3 ., as are any 
indications of the intracellular compartmentalisation of 
the various processes.
Schematic Model of Steroid Hormone Action.
Steroid enters the cell and 
binds to Steroid Receptors.
Nonactivated Steroid Receptors are 
present as multimers of Steroid-binding 
Subunits (white) and hsp 90 (black).
Steroid binding to receptor results in 
receptor activation; possibly because 
hsp 90-dissociation “unmasks” the 
DNA-binding site of the receptor.
%
The nonsteroid-binding subunits 
(hsp 90) remain in dimeric form 
whether free or released.
(Recycling ?)
Activated receptor dimers bind to 
palindromic DNA sequences within 
hormone response elements.
(This model is based on the observations of ER activity cited within the text.)
71
Introduction
Although there is an ever increasing understanding of the structural- 
functional relationship held by the hsp 90-steroid receptor complex in 
vitro, the significance of hsp 90 presence and its relation to steroid 
receptor activity in vivo has largely been overlooked. Early work from 
Baulieu and coworkers (G a s c  et al, 1984) made some, tentative 
suggestions of the action of PR in the chick oviduct: they carried out an 
immunohistochemica! study of both the DNA-binding subunits and the 90 
kDa. (hsp 90) subunits and found that progesterone-binding altered the 
intracellular distribution of these two components. Apart from these 
studies, there are relatively few in vivo investigations on the effect of 
ligand-binding on the hsp 90-steroid receptor complexes. 
Correspondingly, no researchers have investigated the possibility of a 
relationship existing between the actions of steroid receptors and the heat 
shock response. There is much direct and indirect evidence supporting 
the stabilising role of hsp 90 during normal steroid receptor function; yet 
the possibility that steroid receptor activity could then be modulated by the 
heat shock response remains uninvestigated. It is hoped that the work 
included in this thesis may answer some of these questions and address 
this fascinating association of two very distinct families of proteins.
I
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METHODOLOGY.
1. Buffers and Solutions.
M ethodology
1.1. BUFFERS.
1.1.1. PHOSPHATE BUFFERED SALINE (PBS), pH 7.2
170m M  NaCI; 1 mM Na2H P 04 and 2mM KH2P 0 4.
1.1.2. TRIS BUFFERED SALINE (TBS), pH 7.6
137mM NaCL and 5mM Tris-HCI adjusted to pH 7.6 using 1M HCI.
1.1.3. BICARBONATE BUFFER, pH 9.0
250mM Na2C 0 3 and 100mM NaCI adjusted to pH 9.0 using 1M HCI.
1.1.4. ETN BUFFER, pH 7.0
10mM EDTA; 10mM Tris-HCI and 100mM NaCI adjusted to pH 7.0 using
1M HCI.
1.1.5. NP-40 SOLUTION, pH 7.3
100mM NaCI and 10mM Tris-HCI adjusted to pH 7.3 using 1M HCI and
made 0.5% with Nonidet P-40 (NP-40).
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1.2. CELL CULTURE SOLUTIONS.
1.2.1 DULBECCO'S BUFFERED SALINE (PBS-A), pH 7.2
170m M  NaCI; 3.4mM KCI; 10mM Na2H P 0 4 and 2.0mM KH2P 0 4
1.2.2. VERSENE SOLUTION, pH 7.4
125mM NaCI; 2.7mM KCI; 6.3mM Na2H P 0 4.3.2m M  KH2P 0 4 and 0.5mM  
EDTA adjusted to pH 7.4 using 1M HCI.
1.3. RECEPTOR ASSAY SOLUTIONS.
1.3.1. HED-BUFFER, pH 7.4
20mM HEPES; 1.5mM EDTA and 0.25mM dithiothreitol (DTT) made 10%  
glycerol and adjusted to pH 7.4 using 1M NaOH. DTT is only added on 
the day of use.
1.3.2. DEXTRAN COATED CHARCOAL.
A solution of 20mM HEPES and 1.5mM EDTA (pH 7.4; 100 ml) was made 
0.5%  in sieved, pre-washed charcoal and 0.005%  in dextran before 
mixing for 30 minutes at room temperature. The resulting solution is 
stored at 4°C only up to 8 weeks and must be well mixed before use.
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2. Cell Culture Methods.
2.1. CELL LINES.
Three established cell lines were used; the human breast cell line MCF-7, 
and two human prostate cell lines LNCaP and DU-145. The MCF-7 cell 
line was purchased from the European Collection of Animal Cell Cultures, 
Porton Down, Salisbury, England; while both LNCaP and DU-145 cells 
were a gift of Dr. C. Eaton, Tenovus Institute for Cancer Research, 
University of Wales College of Medicine, Cardiff.
MCF-7 is a stable epithelioid cell line originally obtained from the pleural 
effusion of a female patient with breast cancer whose disease responded 
to endocrine therapy (H o r w it z  et al, 1975b). Ligand binding assay has 
shown this cell line to contain significant levels of ER, PR, AR and GR, and
p
so it has been used as an in vito model for breast cancer and its treatment
N
by endocrine therapy.
The LNCaP cell line was established from a metastatic lesion of human 
prostatic adenocarcinoma, the second most frequent tumour of males in 
the USA (H o r o s ze w ic z  et al, 1983). This cell line is androgen-dependent 
and androgen-responsive, containing both AR and ER. DU-145, however, 
is androgen-independent. It was also originally isolated from a metastatic 
tumour (Sto n e  et al, 1978).
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2.2 ROUTINE GROWTH AND SUBCULTURE.
2 .2.1. CULTURE CONDITIONS.
All cell lines were routinely grown at 37°C in an air atmosphere enriched
to 5% C 0 2. A humidified atmosphere was generated during prolonged
growth in multiwell-style plates to prevent media evaporation. Flasks of 
various capacities (surface areas) were used depending on the mass of 
cells required: 25cm2 containing 5ml of medium, 75cm2 containing 10ml 
of medium and 150cm2 containing 25ml of medium. Fresh culture media 
were generally renewed every 48 hours. All manipulations were carried 
out aseptically within the confines of a clean, laminar air flow cabinet.
2.2.2. GROWTH MEDIA.
Initially, Dulbecco's modification of Eagles medium (DMEM) was used for 
routine subculture (D u lb e c c o  & F r e e m a n , -1959). This is available as a 
phenol red-free powdered medium (Sigma) which can be reconstituted 
and sterilised in the laboratory, although an 18mM HEPES supplement is 
still required. Unfortunately, it did not prove possible to maintain any 
long-term, contamination-free cell culture using this preparation of phenol 
red-free DMEM. This was due principally to mycoplasma contamination 
as confirmed by Hoechst staining (see M eth o d o lo g y  section 2.3.3.). Cells 
grown in this medium seemed particularly prone to mycoplasma 
contamination, the source(s) of which were never established. As a result, 
routine growth was established using R PM I-1640, a commercially 
available phenol red-containing liquid preparation (Gibco BRL Ltd.). This
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medium requires no nutritional or buffering supplements as it incorporates 
18mM HEPES (M o o r e  etal, 1967).
2.2.3. SUPPLEMENTS AND ANTIBIOTICS USED.
During routine subculture, all growth media was supplemented with 10%  
foetal calf serum (FCS). However, during hormone experiments, heat 
inactivated, dextran coated charcoal-stripped, dialysed FCS (HIDCCFCS) 
was used at 2.5% (Leake e ta l, 1987a).
Initially, cells were exposed to different combinations of penicillin, 
gentamycin, streptomycin and nystatin when DMEM was being used. 
However no antibiotic supplements were used in conjunction with the 
RPMI-1640 medium hopefully preventing any proliferation of microbial 
resistance often associated with long term antibiotic inclusion.
2.2.4. DRUG AND HORMONE SUPPLEMENTS USED.
Drugs and hormones were dissolved in absolute alcohol to form 1x10"4M 
stock solutions which were stored at -18°C. These solutions could then be 
added aseptically to RPMI-1640 to provide working solutions of minimal 
alcohol content, (see individual protocols for details of the ligands used).
2.2.5. SUBCULTURE TECHNIQUE.
Cells were deemed ready to undergo passage when the substrate 
surface area was estimated 80-90%  confluent. The cells were washed 
using PBS-A (c.10ml), and then 0.05% trypsin in a versene solution was
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added to each flask (1 ml for a 25cm2 flask; 3ml for a 75cm2 flask, and 5ml 
for a 150cm2 flask). To neutralise the trypsin, fresh culture medium (2-3 
volumes) was added and rapid pipetting was employed to form an even 
cell suspension. This cell suspension was then dispensed into new 
culture flasks containing an appropriate amount of fresh culture medium 
so that the ratio between the donor and recipient surface areas was 
between 1:3 and 1:5. All solutions were prewarmed to 37°C.
2.3. MANAGEMENT OF CELL LINES.
2.3.1 CRYOPRESERVATION OF CELL LINES.
Whenever possible, frozen stocks of cells were prepared while the cell 
line was still at an early passage number. This meant that all experiments 
could be carried out using cells of a similar, early passage number. It was 
found that when one confluent 150cm2 flask (approximately 22x106 cells) 
was harvested and the cells frozen as suspension (1.0ml) then there was 
efficient recovery of a large number of cells after thawing from storage. 
Prior to freezing, cells were grown in numerous 150cm2 flasks using 
RPMI-1640 medium. The cells were washed and harvested as described 
in M e t h o d o l o g y  section 2.2.4. but in this case the cell suspension was 
transferred to a sterile universal tube; and centrifuged for 3 minutes at 
1000g (4°C). After discarding the supernatant, the pellet was re­
suspended in a 10% DMSO in FCS solution (1ml). The cells were then 
transferred to a sterile ‘Biofreeze’ vial (Nunc Inc.) and frozen overnight at 
-70°C, before ultimate long term storage under liquid nitrogen.
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2.3.2. GROWTH OF CELLS FROM FROZEN.
The frozen vials were removed from liquid nitrogen and thawed in the 
palm of the hand for between 5-15 minutes; allowing some ice to remain 
in order to minimise the cytotoxic action of DMSO. After sterilising the 
outside of the vial using 70% ethanol, the semi-frozen cell suspension 
was added to a sterile universal tube containing fresh, prewarmed (37°C ) 
culture medium. This was then centrifuged for 3 minutes at 1000 g before 
discarding the supernatant and resuspending the cells in 37°C medium 
and transferring the cell suspension to a new tissue culture flask (25cm2 
or 75cm2 ) also containing 37°C medium.
2.3.3. MYCOPLASMA TESTING OF CELL'LINES.
Cell lines were routinely screened for the presence of contaminating 
mycoplasma using a modification of an established method (C h en  et al, 
1977). This involved growing cells on sterile microscope slides under 
standard conditions for 72 hours, before discarding the medium, washing 
the cell monolayer with PBS-A, and fixing the cells as described in 
M eth o d o lo g y  section 6.2.1. The cells were then incubated with 100ng/ml 
Hoechst 33258 for 10 minutes at room temperature, before the washing 
and dehydration steps described in M e t h o d o l o g y  section 6.4.2. 
Fluorescent microscopy was used to determine the presence of 
extra-nuclear DNA.
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3. Steroid Receptor Assays.
3.1. LIGAND BINDING ASSAYS.
3.1.1. ASSAY PRINCIPLE.
These assays can determine the total specific steroid receptors present in 
a variety of tissues (Le a k e , 1981). The principle used is based on the 
calculations of Scatchard (S c a tc h a r d , 1949): cytosol is incubated over a 
concentration range of radioactive hormone with or without a 100-fold 
excess of unlabelled hormone to determine specific receptor binding. The 
soluble hormone-receptor complex can be separated from any free 
hormone by the process of dextran coated charcoal (DCC) adsorption; 
free steroid is adsorbed to the DCC whereas receptor-steroid complexes 
are not.
The scientific principle, radioactive standard preparation and assay 
methodology are identical for both oestrogen and androgen receptor 
assays.
3.1.2. RADIOACTIVE STEROID STANDARDS.
The ten standards are prepared so that there are seven radiolabelled 
standards within the stated range (Standards 1-7). An additional three 
duplicate standards of the highest three concentrations are prepared and 
to these 100-fold excess of non-labelled steroid (in ethanol) is added 
(Standards 8, 9 & 10). Unlabelled steroid is added first to tubes 8, 9 & 10 
and then the solvent evaporated using compressed air. The appropriate 
volumes of ethanol containing [3H]-steroid was then added to each of the
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ten vials before equalising the alcohol content of each vial by adding 
ethanol alone. HED-buffer was then added in order to bring all standards 
to a volume of 3.0ml. These were stored for only two months at 4°C.
Aliquots (50p,l) of each standard were counted to obtain a value of the 
“totals".
The concentrations and ligands used for each of the receptor assay 
standards were as follows:
•  For ER assay: 0.4, 0 .6 ,1 .0 ,1 .5 , 2.0, 3.0 & 4.0nM [3H]-oestradiol-17p was 
used as the radiolabel with a 100-fold excess of diethylstilboestrol (DES) 
as the competitor in the highest three concentrations. (After addition of 
“cytosol” the final concentrations of steroid were 0.1 to 1.0nM.) The
[3H]-oestradiol-17p had a specific activity of 98Ci/mmol.
•  For AR assay: 1.0, 1.5, 2.0, 4.0, 6.0, 8.0 & 10nM [3H]-mibolerone was 
used as the radiolabel with a 100-fold excess of mibolerone as the 
competitor in the highest three concentrations. (After “cytosol” addition the 
final androgen concentrations were 0.25 to 2.5nM.) The [3H]-mibolerone 
had a specific activity of 76Ci/mmol. in addition, the AR-assay standards 
were made 100nM with Org 2058 and 100nM with triamcinolone 
acetonide in order to prevent nonspecific-binding to PR or GR (L eake  & 
H abib , 1987).
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3.1.3. LIGAND BINDING ASSAY (LBA) PROTOCOL
Accurate ligand binding assay relies on the correct preparation of a 
suitable extract from tissues or cell cultures. (See specific E x p e r im e n t a l  
sections). All solutions and conditions were maintained at 4°C.
The standards (50pl) were added to each of ten 60x6mm polypropylene
test-tubes (RT-30) and mixed with 150jxl of “cytosol” extract. Steroid- 
binding took place by incubating either for 18 hours at 4°C (overnight) or 
for 2 hours at 20°C. After incubation, dextran coated charcoal solution
(DCC; 200(0.1) was added in order to remove unliganded (free) steroid. 
This treatment continued on ice for 15 minutes; vortexing every five 
minutes, before centrifuging for 5 minutes at 1000g to pellet the DCC-
adsorbed steroid. Aliquots (200(ol) of each supernatant were transferred to 
scintillation vials and 4ml of Ecoscint A (National Diagnostics) added. The 
viais were counted for tritium, each for 3 minutes, and the cpm used to 
carry out computerised Scatchard calculations.
Scatchard analysis (S c a tc h a r d , 1949) of ligand binding assay data was 
routinely carried out using a BBC microcomputer programmed as 
described by Leake et al, (1987b).
3.1.4. “TWO-POINT COMPETITION” STEROID RECEPTOR ASSAY 
Ten-point LBA of cell culture extracts is not always possible as sufficient 
cytosol is seldom available, and so the abbreviated two-point assay is 
used. This assay is basically a straightforward competition between the
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tritiated ligand and the excess of unlabelled competitor (L eake  & H a b ib , 
1987). Carried out at least in duplicate, the assay incubates cytosol
(150pl) with both the standards containing the highest concentration of 
tritiated ligand (standards 7 & 10). All timings and manipulations are 
similar to the ten-point LBA allowing receptor concentrations to be 
calculated per ml of extract.
3.2. ENZYME IMMUNO ASSAY (EIA).
3.2.1. ASSAY PRINCIPLE.
This assay system relies on direct antibody recognition of the oestrogen 
receptor rather than detection based upon its steroid binding ability; it is a 
solid phase enzyme immunoassay based upon the “sandwich” principle. 
Beads coated with anti-ER (rat monoclonal) antibody are incubated for 18 
hours (8°C) with specimens or standards or controls. During this 
incubation, ER present in the specimen is bound to the solid phase, 
unbound materials present in the specimen are then removed by 
aspiration of fluid and washing of beads. A second anti-ER antibody 
conjugated with horseradish peroxidase is then incubated with the beads 
for 60 minutes (37°C) and the conjugate becomes bound to any ER on the
beads. Unbound conjugate is removed by aspiration when the beads are
/
washed. The beads are then incubated for 30 miutes (20°C) with an 
enzyme substrate solution (hydrogen peroxide and o-phenylenediamine) 
to develop a colour which is a measure of the amount of bound 
ER-conjugate. The enzyme reaction is stopped by the addition of 0.5M
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H2S 0 4 and the absorbance at 492nm determined. The intensity of the
colour formed by the enzyme reaction is proportional to the concentration 
of ER in the sample within the working range of the assay. A standard 
curve is obtained by plotting the ER concentration of the standards 
against their absorbance. (For a full description of the methods see the 
technical instructions (Ref.: 83 -4281 /R 4) provided by the kit 
manufacturers: Abbott Laboratories, Diagnostic Division, North Chicago, 
Illinois 60064.)
4. Protein and DNA Assays.
4.1. BRADFORD PROTEIN MICROASSAY.
4.1.1. ASSAY PRINCIPLE.
This assay is based on the principle that the absorbance maximum for an 
acidic solution of Coomassie Brilliant Blue G-250 shifts from 465nm to 
595 nm when binding to protein occurs (B radford , 1976).
4.1.2. PROTEIN STANDARDS.
Protein standards were created for the range of 0-15jig/ml protein. 
Commercial albumin standard No. 23210, (Pierce Inc.) which is supplied 
as 2.0mg/ml, was appropriately diluted in order to form standards of 2, 4,
6, 8 ,10 , & 15pg/ml. These were stored for only two weeks at 4°C.
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4.1.3. ASSAY PROTOCOL
The sample to be assayed was diluted into the approximate assay range 
using distilled water or an appropriate buffer solution. Where reagents 
were used that slightly altered the assay standard curve (eg. SDS or 
NP-40), an alternative set of assay standards was created which 
incorporated the interfering agent. A duplicate set of standards (0.8ml) 
and triplicate diluted samples (0.8ml) were added to 60x6mm poly­
propylene test-tubes. Bradford assay reagent (200pl) was then added and 
the tubes vortexed. The tubes were left to stand at room temperature for 
30 minutes, vortexing after 15 and 30 minutes, before measuring the 
absorbance of each solution at 595nm. The protein content of each 
sample was calculated from the standard curve. (See sample standard 
curve, F igure 4.)
4.2. HOECHST DNA ASSAY.
4.2.1. DNA STANDARDS.
Standards were prepared from a 100jig/ml solution of calf thymus DNA 
dissolved in ETN buffer. The concentration of this solution was verified
using the formula that 1 unit of absorbance at 260nm is exactly 50|ig/ml.
The standards prepared'we re: 0, 5, 10, 15, 20, 25, 30, 40 & 50jig /m l; 
producing a reproducibly linear standard curve up to 50mg/ml. These 
were stored for only one month at -18°C.
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4.2.2. ASSAY PROTO CO L
The method used was modified from the original Leake and Habib 
methodology (L ea k e  & H a b ib , 1987) and used exclusively for the DNA 
assay of cultured cell monolayers; usually grown on multiwell plates. The 
assay is dependent on the intercalation of the Hoechst dye with 
solubilised DNA; the resulting complex is fluorescent with a maximum 
emission at 450nm.
Samples were solubilised by incubating for 30 minutes (37°C) in 0.2%
SDS in ETN buffer. Aliquots (1 OOjllI) of each solubilised specimen were 
transferred to RT-30 test tubes to which 3.0ml of ETN buffer containing
Hoechst 33258 (100ng/ml) and RN’ase (5.0jig/ml) was added. The tubes 
were mixed thoroughly by vortexing and incubated at room temperature 
for 30 minutes in the dark. The fluorescence enhancement at 450nm was 
then measured using a Hitachi Perkin-Elmer M PF-2A  fluorescent 
spectrophotometer with an excitation wavelength of 360nm and both slit 
widths at 5nm. (See sample standard curve, F igure  5.)
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F igure 4. Bradford Protein Assay Calibration Graph.
The reproducibility of this assay is shown in this typical 
calibration curve. The assay was carried out in duplicate 
as described in M e t h o d o l o g y  section 4.1. and used to 
construct a calibration graph. The equation of the line 
was derived using the computer program “Cricket Graph” 
on an Apple Macintosh PC, and used to calculate the 
values of protein present in unknown samples.
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Figure 5. Hoechst DNA Assay Calibration Graph.
The reproducibility of this assay is shown in this typical 
calibration curve. The assay was carried out in duplicate 
as described in M e t h o d o l o g y  section 4 .2 . and used to 
construct a calibration graph. The equation of the line 
was derived using the computer program "Cricket Graph” 
on an Apple Macintosh PC, and used to calculate the 
values of DNA present in unknown samples.
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5. Electrophoretic Methods.
5.1. POLYACRYLAMIDE GEL ELECTROPHORESIS.
The methodology is a modification of that of Laem mli (1970).
5.1.1. STOCK GEL SOLUTIONS.
The stacking buffer used was 0.125M Tris-HCI (pH 6.8) containing 0.4%  
SDS; the resolving buffer was 0.375M Tris-HCI (pH 8.8) containing 0.8%  
SDS. Both buffers were stored at 4°C for no longer than 8 weeks. A 30%  
electrophoresis grade acrylamide and 0.8%  N,N '-m ethylene bis- 
acrylamide solution was prepared and filtered using Whatman no.1 filter 
paper before storing for no more than 4 weeks at 4°C. A solution of 1.5%  
ammonium persulphate was prepared 15-30 minutes prior to use, then 
discarded after each polymerisation.
5.1.2. GEL CONSTITUENTS AND THEIR POLYMERISATION.
The molecular weights of the proteins under investigation meant that a 
7.5% slab gel was used. This should resolve proteins within the range of 
45-300 kiloDaltons (kDa.).
The constituents of the resolving gel were; distilled water (23ml), resolving
buffer (5ml), acrylamide (10ml) and ammonium persulphate solution
/
(2ml). The constituents of the stacking gel were; distilled water (11ml), 
resolving buffer (5ml), acrylamide (2ml) and persulphate solution (1 ml).
To initiate polymerisation TEMED (25jil) was added last to each mixture 
and the solution poured between clean glass plates (200x200mm). A slab
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gel was formed so that there was a 25mm deep stacking gel on top of a 
7.5% resolving gel.
5.1.3. ELECTROPHORESIS TANK BUFFER.
The tank buffer was a 0.025M  Tris, 0 .192M Glycine (pH 8.3) buffer 
containing 0.1% SDS. A x10 stock solution was prepared and stored at 
4°C for no longer than 8 weeks.
5.1.4 RUNNING BUFFER.
Samples were dissolved in running buffer to an approxim ate  
concentration of 0.1-1.0mg/ml protein. This consisted of 0.0625M Tris-HCI
(pH 6.8) containing 10% sucrose; 5% p-mercaptoethanol; 2% SDS and
0.002%  bromophenol blue (H a m e s , 1981). Between 10|il and 30jil of 
sample buffer was applied per well.
5.1.5. MOLECULAR W EIGHT STANDARDS.
To assess the molecular weight of observed proteins, calibration standard 
proteins were applied to the gel in conjunction with unknown samples. 
These standards, supplied as a kit (Boehringer Mannheim GmbH), were
dissolved in running buffer and used to construct calibration curves for/
molecular weight based on their relative mobility. The standards used 
were: lactate dehydrogenase (Mr 36,400); glutamate dehydrogenase (Mr
55,400); p-galactosidase (Mr 130,000) and a2-macroglobulin (Mr 
170,000).
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5.1.6. ELECTROPHORETIC CONDITIONS-
Whenever possible gels were run overnight in a cooled incubator (4°C) to 
make most efficient use of laboratory time. A constant current of 20mA and 
75V maintained for 9 hours was sufficient for complete protein separation.
5.2. STAINING AND PRESERVATION OF GELS
5.2.1. COOMASSIE BLUE STAINING AND DESTAINING.
A 0.1%  coomassie blue staining solution was used to stain gels by 
soaking the gel for 2 hours in 500ml of stain. 0.1%  Coomassie brilliant 
blue R250 was dissolved in 500ml of a 42% methanol and 16% acetic 
acid solution. The gel was destained by five 60 minute soakings at 4°C in 
a destain solution of 30% methanol and 10% acetic acid.
5.2.2. SLAB GEL DRYING.
All gels were dried op to Whatman 3MM chromatography paper using a 
layer of clingfilm to form an upper protective layer. Gels were dried for 2 
hours at 80°C under constant vacuum unless a fluorographic agent was 
included (See M eth o d o lo g y  section 5.3.2.) in which case 4 hours at 60°C  
was the drying conditions chosen.
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5.3. AUTORADIOGRAPHY.
5.3.1. STANDARD AUTORADIOGRAPHY.
Autoradiography was carried out after first drying gels as described in 
M eth o d o lo g y  section 5.2.2.; if there was a delay between the initial drying 
of the gel and any subsequent autoradiography, then the gel was redried 
for 20 minutes at 80°C  to remove any absorbed moisture. For 
[35S]-methionine labelled gels, Kodak X-OMAT S film was used. Dried 
gels were brought into contact with the film and sandwiched between two 
sheets of Whatman 3MM chromatography paper, all operations being 
carried out in a dark room. The sandwich was placed inside an 
autoradiography cassette, which was wrapped in black polythene and 
placed in a -70°C refrigerator. The individual exposure times depended 
on the cpm available, estimated, by scintillation counting. X-ray films were 
developed using a Kodak X-OMAT processing machine.
5.3.2. FLUOROGRAPHY.
A fluor was introduced into the gels to enhance autoradiography when 
there was only a very small number of cpm. This involved soaking the gel 
for 2 hours in a solution of 14% salicylic acid dissolved in 1M NaOH. This 
step was incorporated after the coomassie blue destaining stage 
(M e t h o d o l o g y  section 5.2.1.) but an extra distilled water prewash was 
also included at this stage as any excess acetic acid results in salicylate 
precipitation. Fluorographic gels were then dried for 4 hours at 60°C as 
described in M ethodology  section 5.2.2.
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5.4. WESTERN BLOTTING.
Immunoblotting methodology was a modification of previously published 
methods (Tow bin  et al, 1979).
5.4.1. ELECTROPHORESIS.
Electrophoresis was carried out using 7.5% gel as previously described
(see M e t h o d o l o g y  section 5.1.). Previously prepared samples (15-30{il 
per well) were added in duplicate so that the gel was in two identical 
halves. This meant that after transblotting the nitrocellulose blot could be 
cut in two; one half was used for immunoblotting and the other half for 
amido black protein staining.
5.4.2. ELECTROPHORETIC TRANSFER.
Transblotting was carried out using specific apparatus (BioRad); which 
consisted of a cassette and pads for mounting the gel, and a tank which 
allowed the cassette to stand vertically between two electrodes immersed 
in buffer. When mounting the gel and the nitrocellulose film within the 
cassette, each layer was added separately, immunotransfer buffer being 
added from a wash bottle to prevent any air bubbles. At this point, small 
cuts were made on the nitrocellulose to mark where the corresponding 
gel lanes would be and where it could be halved. Electrophoretic transfer 
was carried out using a constant current of 200mA (45V) for 5 hours at 
4°C. The transfer (tank) buffer was 200mM glycine, 25mM Tris and 6mM  
SDS dissolved in a 20% methanol solution.
94
M ethodology
5.4.3. PROTEIN FIXATION TO THE NITROCELLULOSE.
After transfer and safe removal from the cassette, the nitrocellulose was 
carefully cut into the two identical sections and both sections washed for 
15 minutes using TBS at room temperature. Fixation of the proteins to the 
nitrocellulose was achieved by soaking in 0.2% gluteraldehyde in TBS for 
45 minutes at room temperature under constant gentle agitation. After 
fixation the nitrocellulose was washed in fresh TBS for 15 minutes.
5.4.4. PROTEIN TRANSFER VERIFICATION.
Protein transfer was verified in two ways. Firstly by conventional 
coomassie blue staining of the gel after the transfer to show that no 
significant bands remained; and secondly, by amido black staining of one 
of the nitrocellulose halves. 0.1%  Amido black dissolved in a 45%  
methanol and 10% acetic acid solution was used to stain the 
nitrocellulose for 5 minutes. The excess stain was then poured off, and the 
nitrocellulose destained using a 90%  methanol and 2%  acetic acid 
solution.
5.4.5. IMMUNOBLOTTING.
The remaining nitrocellulose section to be blotted was first incubated at 
8°C overnight, using constant gentle agitation, with a solution of 5%  
Marvel® dissolved in TBS. This was in order to minimise any non-specific 
antibody binding.
After this initial blocking step, proteins of interest were visualised using a
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blotting system of mouse monoclonal primary antibodies, detected using 
horse radish peroxidase (hrp) labelled sheep anti-mouse secondary 
antiserum (M e t h o d o l o g y  section 6.1.2). All the subsequent operations 
were carried out at room temperature using freshly made 5% Marvel® in 
TBS solution. Constant gentle agitation was induced by placing the 
nitrocellulose inside a sealed, clean jar which was mounted between two 
rollers.
After aspirating off the excess 5% Marvel® solution, primary antibody, 
appropriately diluted using more 5% Marvel® solution, was incubated for 
120 minutes at room temperature. The nitrocellulose was then washed 
five times using 5% Marvel® solution for a total of 60 minutes. Secondary 
hrp-antibody (SAPU), diluted 1:50 using 5% Marvel® was then incubated 
for 90 minutes, again at room temperature. Next, after three 5% Marvel®  
washes of 10 minutes each, there was a further three 10 minute washes 
only this time using TBS alone. (The developer solution was prepared at 
this point, see below.) The developer solution was added for 10 minutes 
or until bands were obvious; no increased staining being noted after 15 
minutes. The nitrocellulose was washed in distilled water and dried 
between two sheets of filter paper.
5.4.6. IMMUNOBLOT DEVELOPER SOLUTION.
Prepared immediately prior to usage; a 0.3% chloronaphthol in methanol 
solution was added to TBS and mixed. To this solution was added 4.5%
hydrogen peroxide solution (150pl) to form the developer solution.
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6. Immunocytochemistry.
6.1. ANTISERA.
6.1.1. PRIMARY, MONOSPECIFIC ANTISERA.
All antisera used were aliquoted into 25jil lots and stored at -70°C to 
prevent cyclical freeze-thawing antibody deactivation. The monospecific 
antibodies used were as follows:
•  Anti-ER monoclonal antibody:
ERP-31 is a mouse monoclonal antibody produced from murine ascitic 
fluid and was a gift of Dr. B. Westley, University Department of Pathology, 
Royal Victoria Infirmary, Newcastle upon Tyne. ERP-31 was used for 
immunoprecipitation of ER.
•  Anti-AR monoclonal antibody:
• i.
AN1-15 is a rat monoclonal antibody raised against human AR and kindly 
donated by Professor S. Liao, Department of Biochemistry and Molecular 
Biology, The Ben May Institute, Chicago, Illinois.
•  Anti-AR polyclonal antibody:
A rabbit polyclonal IgG antibody to AR was also donated by Professor S. 
Liao and used for AR detection by three-stage immunohistochemistry (see 
M ethodology  section 6.3).
•  Anti-hsp 90 monoclonal antibody:
AC 88 is a mouse monoclonal antibody raised against an 88kDa. protein 
purified from the water mould Achlya ambisexualis (R ie h l  e ta !, 1985). 
This antibody is specific for hsp 90 of a variety of tissues and species
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(S ch uh  et al, 1985), and was obtained as a gift of Dr. David Toft, Dept, of 
Biochemistry and Molecular Biology, Mayo Clinic and Medical School, 
Rochester, Minnesota.
6.1.2. SECONDARY, SPECIES-SPECIFIC ANTISERA.
The species-specific antibodies used were all obtained from the Scottish 
Antibody Production Unit (SAPU), Law Hospital, Carluke, Strathclyde. All 
antisera were supplied as a liquid preparation and were aliquoted and 
frozen on receipt.
•  Anti-mouse antibody:
Sheep anti-mouse IgG was used in .th e  production of fluorescent 
antiserum capable of detection of mouse monoclonal antibodies (see 
M ethodology  section 6.4.1.)
•  Anti-rabbit antibody:
Donkey anti-rabbit IgG was used in the production of fluorescent 
antiserum capable of detection of rabbit polyclonal antibodies (see 
M ethodology  section 6.4.1.)
•  Anti-rat antibody:
Sheep anti-rat gamma-globulin was used in the production of fluorescent
antiserum capable of detection of rat monoclonal antibodies (see
/
M ethodology  section 6.4.1.)
•  Hrp-anti-mouse antibody:
Sheep anti-mouse IgG was used in the detection of mouse monoclonal 
antibodies during immunoblotting (see M eth o d o lo g y  section 5.4.5.)
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6.2. FIXATION.
6.2.1. ACETONE-METHANOL FIXATIVE.
A solution of acetone and methanol (1:1 (v/v), Analar reagents) was 
prepared and precooled to -18°C before use.
Fixation was achieved by placing the microscope slide on top of an ice
pack and covering the section or cell monolayer in 200jil of fixation 
solution for 30 seconds. The excess acetone-methanol was then 
aspirated and the sections allowed to air dry for 5-6 minutes, when no 
remaining moisture was evident.
6.2.2. ACETONE FIXATION.
The whole slides were dipped into a coplin jar containing acetone and 
allowed to soak for 5 minutes before air drying the sections. If immuno- 
cytochemical staining was to be carried out at a later date; slides were 
fixed for only 1 minute, dried and stored at -70°C. After thawing to room 
temperature, the slides were refixed for 5 minutes and again air dried 
prior to staining.
6.3. ANDROGEN RECEPTOR IMMUNOHISTOCHEMICAL ASSAY.
Tissue sections cut in the Dept, of Pathology, Western Infirmary, Glasgow,
/
and cell monolayers were fixed as described in the preceding section
6.2.2. Nonspecific-staining was abolished by a 5 minute incubation with 
5% BSA in TBS. After this time, all test slides had the TBS solution 
removed and were incubated with rabbit polyclonal anti-AR antibody (see
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M e th o d o lo g y  section 6.1.1.) diluted 1:200 in 5% BSA in TBS. After a 60 
minute incubation at room temperature, excess serum was removed by 
TBS washings and replaced by mouse anti-rabbit serum diluted 1:40 with 
5% BSA in TBS. This secondary incubation was again carried out at room 
tem perature, this time for 30 minutes, before adding alkaline  
phosphatase-labelled rabbit anti-mouse serum dilluted 1:25 ( S e e  
M e t h o d o l o g y  section 6.1.2.). This final serum was incubated for 60 
minutes at room temperature.
After washing off excess serum, the staining was visualised using 
Histom ark® (Kirkegard Perry, Inc.) which utilises fast violet stains to 
produce either red or blue staining as required. The slides were sealed 
using Aquamount (BDH, Ltd.) *
6.4. FLUORESCENT IMMUNOCYTOCHEMICAL STAINING.
Monospecific antibodies directed against hsp 90 and AR were detected 
using various species-specific, antisera which were fluorescein labelled 
and therefore visible by fluorescent microscopy.
6.4.1. FLUOROCHROME LABELLING OF ANTISERA.
Species specific antiserum (25ml), obtained from SAPU was dialysed for 
48 hours against 11 of pH 9.0 bicarbonate buffer at 4°C, fresh buffer being 
added after 24 hours. After dialysis the serum was removed and the 
protein concentration estimated in order to optimise the IgG to
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fluorochrome ratio for conjugation. The appropriate amounts of 
fluorochrome were weighed out and dissolved in bicarbonate buffer 
(1.0ml; 4°C) so that there would be 0.05mg of fluorochrome present for 
every 1.0mg of protein during conjugation. Fluorescein isothiocyanate
(FITC) was used; this emits green visible light (X = 515nm) when exposed 
to excitatory ultra violet light.
The antiserum (0.25ml) and fluorochrome solution (0.25ml) were brought 
together in a polytube and left to react overnight at 4°C under constant 
mixing. After conjugation, the excess unbound fluorochrome was 
separated from the dye conjugated antiserum using a column of
Sephadex G-25 (300x16mm). The column was first calibrated using 50pl 
of a 1:1 (v/v) mixture of 1% blue dextran and 0.1 M potassium dichromate. 
The whole reaction mixture (0.5ml) was added to the column and the 
eluting fractions collected (0.922ml; 20 drops) using an LKB Redirac 2112 
fraction collector. The labelled IgG conjugate eluted between fractions 
14-18; the excess free label eluting after some 50 fractions.
The obviously fluorescent fractions were assayed for labelling efficiency
• i
by estimating the molar ratio of fluorescence to protein (Jo h n s t o n  & 
T h o r p e , 1983). This was found by measuring the absorbance of the 
conjugate at 280nm and 495nm. The molar ratio should be between 2 
and 4 and was calculated using the following formula:
MOLAR RATIO =  2.87 x Ab. M95nm>
Ab. (280nm) - [0.35 X Ab. (495nm)]
101
M ethodology
Fractions of molar ratio *  3 were selected and stored at -70°C prior to 
usage.
6.4.2. FLUORESCENT IMMUNOCYTOCHEMICAL STAINING.
This method is modified from that of C raw ford  et al. (1985) which exploits 
the fluorescent detection of a monoclonal antibody using a species 
specific fluorochrome conjugated secondary antiserum.
Cell monolayers were grown on 8-chamber slides (see F ig u r e  14.). 
Excess culture medium was aspirated and the cells washed using PBS-A 
before acetone methanol fixation (M ethodolog y  section 6.2.1.). 
Non-specific binding of the secondary antibody was eliminated by a 20 
minute incubation of the tissue using 3% sheep serum (SAPU) in PBS. 
The excess serum was then removed and primary antiserum, diluted 
appropriately* using 0.1% BSA in PBS, was added and incubated for 2 
hours at room temperature in a humidified box. (*See individual protocols 
for antibody dilution.)
After incubation, the primary antiserum was aspirated and the cells 
washed five times by adding 0.1% BSA in PBS and agitating slides for 
three minutes. Fluorescent secondary antiserum diluted 1:500 using 0.1%  
BSA in PBS was added and incubated for 2 hours again in the humidified 
box. After incubation, excess serum was removed and the cells washed 
five times as before. Nuclear counterstainirig was achieved by a 5 minute 
incubation with 100ng/ml Hoechst 33258, followed by similar washing
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steps.
After removing the plastic upper chambers, the slide was dehydrated. This 
involved sequential 60-second dips in 50%; 75% ; 100% , and 100%  
alcohol. The slide was then cleared by two dips in xylene before being 
sealed using a xylene-based mountant (DPX-mountant; BDH). 
Immunofluorescence was visualised within 24 hours using a Lietz 
“Orthoplan” fluorescent microscope.
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Part 1. 
Experimental
The Association of hsp 90 and ER 
in the MCF-7 Human Breast 
Cancer Cell Line.
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C hapter  1 .
The Effect of Heat Shock on MCF-7 Cell Growth.
Introduction .
In order to assess the role of heat shock proteins, and hsp 90 in particular, 
various experiments were carried out which exploited the overproduction 
of hsp's - the heat shock, or stress response (L in d q u is t , 1986). Initially it 
was decided to characterise the normal range of thermal tolerance 
exhibited by the MCF-7 human breast cancer cell line; as this would 
provide a threshold level to calibrate future experiments investigating the 
thermotolerance response displayed by these cells.
The experiment was designed so that cells would receive a measured 
dose of supraphysiological heat. The exposure time was kept constant 
over the range of temperatures between (37°C and 45°C) used to heat 
shock the cells. Cell viability was measured by assaying cell growth 24 
hours and 48 hours after completing heat shock.
M ethods .
MCF-7 cells w ere subcultured as described in M e t h o d o l o g y  section 2 .2 .
so that a 20%  confluent .monolayer was formed within ten 6-well
/■
(15.7cm 2/well) plastic tissue culture plates. The cells were allowed to 
“plate-down” for 24 hours and fresh culture medium was added  
immediately prior to commencing the experiment.
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Heat shock was achieved using a carefully controlled and monitored 
water-bath (F igure  6 .). The plates were sealed watertight using plastic film 
(NescoFilm®), before being floated on the water surface for two hours. 
The temperature of the culture medium was verified using a thermometer 
placed within a similarly mounted plate containing only growth medium. 
After subjecting the cells to the various temperatures for two hours, the 
cells were allowed a recovery period of 24 hours. After this time the 
contents of three wells were washed using PBS-A and solubilised by a 30 
minute incubation with ETN buffer containing 0.2% SDS (4ml) at 37°C
(M e t h o d o l o g y  section 1.1.4.). Aliquots (100jil) of soiubilised cells were 
then assayed for DNA using the Hoechst DNA assay described in 
M e t h o d o l o g y  section 4.2. After another 24 hours the remaining three 
wells of each plate were washed, harvested and assayed for DNA as 
before.
R esults.
The results shown in F ig u r e  7. represent the mean of two experiments, 
each experiment consisting of 3 wells of cells for each temperature at 
each time. The parameter being measured is cell growth and so results
are expressed as DNA (pg/ml); the amount of DNA present in the cell 
monolayer.
106
Figure 6. Physical Induction of Heat Shock.
The technique used to induce heat shock is shown in 
F ig u r e  6 .; this simple apparatus was used to ensure 
reproducible temperature selection.
Flasks and microscope slides were placed within a glass 
trough containing a layer of glycerol 1mm deep; whereas 
multi-well plates were sealed water tight and allowed to 
float on the surface of the water. The efficacy of heat 
transfer from the water to the cells was assessed by 
measuring the temperature inside vessels containing 
only culture medium.
   JSi Flask of Growing Cells.
8-Chamber Microscopy Slide. 
ii—ii—ii—ii 6-Well Plate.
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Figure 7. The Effect of Temperature on MCF-7 Cell Growth
MCF-7 cells were subjected to two hours exposure to the 
temperatures shown and then their growth, in terms of 
the amounts of DNA, was measured after 24 and 48 
hours. (Day 1 black, and Day 2 striped, respectively)
Error bars represent the Standard Deviation of the data.
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C onclusions .
For most cell lines in culture, a short period after death (24 to 48 hours), 
cells tend to detach from the lower surface of the chosen culture vessel. 
However, MCF-7 cells attach very firmly and so tend to remain in contact 
with the substrate until some form of mechanical abrasion is used. In 
addition, the majority of these “cells” remain intact. For these two reasons 
it is impossible to correlate absolute values of DNA with cell viability and 
so it was decided to assess cell DNA at both 24 hours and 48 hours after 
heat shock, as the difference between the two values should indicate 
whether or not cell growth is sustained.
The effectiveness of thermal killing depends on two factors: exposure time 
and exposure temperature. Earlier work (not shown here) suggested that 
varying the length of heat shock altered the effectiveness of a single 
temperature. Thus, it was decided to maintain a constant exposure time of 
2 hours in order to make best use of laboratory time and to simplify future 
experimental protocols.
As can be seen from F ig u r e  7., the lethal temperature for MCF-7 cells is 
between 42°C and 43°C; this represents an approximate 6°C increase on 
the normal physiological temperature.
The effect on temperature is best visualised by comparing the DNA values 
of the 24 hours and 48 hours recovery periods; the difference between 
these two values is an estimate of the cell growth. A constant cell growth 
rate over the second 24 hour period is displayed among the cells
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subjected to temperatures up to 42°C. This growth rate corresponds to an 
increase in celluiar DNA of between 25-30% over the 24 hour period. 
However, in the ceils subjected to temperatures greater than 42°C there is 
actually a net loss of DNA over the same period. These results show that 
cell growth is inhibited at these higher temperatures and that the loss of 
DNA represents cells that have died, become detached, and then lost 
during the pre-assay washing steps.
This experiment gives a measure of the normal threshold level of MCF-7 
cell thermal tolerance. From this experiment, it was then possible to go on 
to establish whether sub-lethal temperatures could induce thermo­
tolerance to temperatures above 42°C.
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C hapter 2.
Thermotolerance of MCF-7 Cells.
Introduction.
Thermotolerance is the acquisition of heat resistance through previous 
exposure to sub-lethal temperatures (see Intro duction  section 3.3.1.). The 
intracellular process mediating this protective mechanism is presumed to 
depend on the production of heat shock proteins (hsp's; L in d q u is t , 1986). 
It was decided to investigate whether the MCF-7 cell line could acquire 
thermotolerance and so survive temperatures exceeding 43°C; shown to 
be lethal to this cell line after 2 hours exposure (E xper im en ta l  chapter 1.).
M ethods.
MCF-7 cells were subcultured as described in M e th o d o lo g y  section 2.2. 
so that a 20% confluent monolayer was formed within three 6-well plastic 
tissue culture plates. After 24 hours, fresh culture medium was added 
immediately prior to commencing the experiment.
Heat shock was again achieved using the water-bath technique (see 
previous chapter); however various heat shock treatments (HST) were 
used:
•  HST 0 Cells maintained at 37°C throughout (controls)
•  HST 1 2 hours exposure at 41 °C followed by a 24 hour recovery 
period at 37°C.
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•  HST 2 2 hours exposure at 44°C followed by a 24 hour recovery 
period at 37°C.
•  HST 1 +2 2 hours exposure at 41 °C followed by a 24 hour 
recovery period at 37°C; prior to a further 2 hours exposure at 
44°C followed by a 24 hour recovery period at 37°C.
MCF-7 cells were exposed to either HST 0; HST 2 or HST 1+2.
After these heat shock treatments the contents of three wells were washed 
and solubilised as described in the previous chapter. After another 24 
hours the remaining three wells of each plate were washed and
harvested. Aliquots (100jil) of solubilised cells were then assayed for 
DNA using the Hoechst DNA assay described in M e t h o d o l o g y  section
4.2.
R esults.
As mentioned in the preceding chapter, the critical factor to be considered 
is cell growth, as reflected by the change in DNA content over the 24 hour 
period (DNA [Day 2] - DNA [Day 1)). These values are more representative of 
the true level of cell viability than a value of absolute DNA.
The results quoted are the mean of three experiments; each experiment/
consisted of three different wells of cells for each HST, at each time point. 
This means that the columns shown on the histogram (F ig u r e  8 .) 
represent the mean of nine individual data points.
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F igure 8. Demonstration of MCF-7 Cell Thermotolerance.
MCF-7 cells exposed to HST 2 alone (44°C; 2 hours 
followed by 37°C; 12 hours) were compared to cells 
subjected to HST 0 (37°C throughout) and cells given a 
prior exposure to HST 1 (41 °C; 2 hours followed by 
37°C; 12 hours) before also being exposed to HST 2; 
and termed HST 1+2.
The total growth-time of all treatments was identical.
The effects of the different heat shock treatments on cell 
growth was assessed by measuring the amounts of DNA 
after 24 and 48 hours. (Day 1 and Day 2 respectively)
Error bars represent the Standard Deviation of the data.
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*Although the s ig n if ic a n c e  o f the change in  growth o f the co n tro l c e l ls  over 
the 24 hour period  is  cast in  doubt as a re s u lt  o f the la rg e  standard  
d e v ia tio n  in cu rred  a f te r  Day 1, i t  should be noted th a t the patern  o f  
growth in h ib it io n  observed is  consis ten t w ith  these conclusions.
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C onclusions .
Initial observation of F ig u r e  8 reveals that the absolute values of DNA in 
both the HST 2 and HST 1+2 treated cells are markedly lower than the 
control values, though significant (p<0.001) only in HST 2. This altered 
profile is due to the thermal-killing of cells which then become detached 
and are lost during the pre-assay washing stages. As previously stressed, 
these values are not directly proportional to cell viability, though, it may 
be significant that the HST 1+2 treated cells fared better than the HST 2 
cells in terms of total DNA.
However what is more interesting is the changes in DNA content over the 
second 24 hour interval. Whereas the HST 1+2 treated cells show a 
growth increase over this period that is comparable to the control cells 
maintained at 37°C; the cells treated using HST 2 alone show no growth 
over the 24 hours. In other words, these cells are no longer viable.
This experiment shows that transient (2 hour) exposure to the sub-lethal 
temperature of 41 °C can induce some protective property allowing the 
same cells to withstand a subsequent supralethal temperature (44°C). 
These results are typical of the thermotolerance response and provide 
direct evidence that the MCF-7 breast cancer cell line demonstrates this 
phenomenon.
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C hapter  3.
Hsp 90 Induction in MCF-7 Cells.
Introduction.
Having established that the MCF-7 breast cancer cell line displays the 
typical thermotolerance phenomenon, it was decided to assess whether 
the levels of hsp 90 were altered during the response. Hsp 90 seems to 
play a key role in the regulation of the cellular thermotolerant response to 
heat shock (see In tr o d u c tio n  section 3.2.4.) although it seems to be its 
phosphorylation state rather than amount that is important (R o s e  et al, 
1989). Hsp 90 heat inducibility has previously been demonstrated using 
heat shocked chick embryo fibroblasts (C a t e l l i et al, 1985). These 
investigators used V8-protease digestion and two-dimensional peptide 
mapping to confirm hsp 90 heat inducibility. In this study, it was decided to 
use immunological methodology to detect the levels of hsp 90 present in 
MCF-7 cells subjected to different regimen of heat shock; using the mouse 
monoclonal AC 88 antibody (see M e t h o d o l o g y  section 6.1.1.), which is 
specific for hsp 90 of many species and from different tissues (R iehl et al, 
1985). This antibody was a generous gift from Dr. David Toft of the Mayo 
Clinic; although AC 88 has recently become commercially available from 
StressGen Biotechnologies Corp., Sidney, Canada. The experiment was 
designed so that the MCF-7 cells were subjected to different degrees of 
thermal stress, and then any proteins synthesised during recovery from 
heat shock were labelled using [35S]-methionine incorporation. Immuno-
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precipitation using AC 88 antibody, followed by autoradiography was then 
used to assess the different levels of hsp 90 present in the cells as a result 
of the various HST's.
M ethods .
1. CELL CULTURE AND HEAT SHOCK INDUCTION.
The various elevated temperatures to which the cells were exposed were 
again achieved using the water-bath technique described in E xp er im en ta l  
chapter 1. The different HST* regimen were:
•  Group A HST 1 alone
•  Group B HST 2 alone
•  Group C HST 1+2
•  Group D HST 0 (37°C control for group A).
•  Group E HST 0 (37°C control for groups B & C).
(* Details of heat shock treatments (HST) are described 
within Experimental chapter 1.)
Cells were grown in 25cm2 flasks to minimise the amount of radioactive 
culture medium required. Immediately prior to commencing the various 
HST, the standard RP.MI medium was removed and replaced with 
methionine-free RPMI medium (Flow Labs. Inc.) that was supplemented 
with only 2.5% HIDCC-dialysed FCS (M e th o d o lo g y  section 2.2.3.). After 
removing the flasks from the elevated temperatures, the methionine-free
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medium was made 50jiCi/ml with [35S]-methionine. The cells were 
exposed to this label for the 12 hours of the recovery period until they 
were harvested and processed for immunoprecipitation. Groups D and E 
represent control cells grown at 37°C throughout and labelled with 
[35S]-methionine during similar recovery periods to groups A and B/C 
respectively.
The cells were harvested using the “rubber-policeman technique”: this 
involved removing residual culture medium from within the flasks, 
washing the cell monolayers with PBS-A, and then physically scraping 
the cells from the substrate using an angular glass rod sheathed in 
PTFE-rubber. The free cells were collected in a volume of added PBS-A 
(3.0ml; 4°C), and the suspension transferred to suitable tubes and 
centrifuged to provide a pellet of whole-cells. This pellet (approximately 
3.5 million cells) was solubilised on ice using NP-40 solution containing
0.5M NaCl (2.0ml; M etho do lo g y  section 1.1.5.) and centrifuged at 13,000 
rpm for 3 minutes using an MSE Microcentaur microfuge. The resultant 
supernatant was the solubilised cell extract used for hsp 90 immuno­
precipitation. DNA assay (see M eth o d o lo g y  section 4.2.) was carried out 
on the pellet from this centrifugation.
2. IMMUNOPRECIPITATION OF HSP 90.
To immunoprecipitate hsp 90, AC 88 monoclonal antibody was first pre­
adsorbed onto a suspension of heat-killed Staphylococcus aureus  
bacteria termed Pansorbin® (Calbiochem); this formed an insoluble agent
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capable of immunoprecipitating hsp 90 from the solubilised cell extract.
A 10% suspension of Pansorbin (1.0ml) was washed twice using NP-40 
solution (4.0ml; 4°C) by successive vortexing and centrifugation (60 
seconds at 13,000 rpm using an MSE Microcentaur microfuge). The final 
pellet was suspended at 10% (w/v) in NP-40 solution (1.0ml; 4°C). 10%
BSA (1 Ojxl) was added to this suspension which was known as “washed 
Pansorbin”.
To minimise nonspecific immunoprecipitation, the cell extract was
“cleared” using a small amount of the washed Pansorbin. 20jil of the
washed Pansorbin was added to 200pl of cell extract and mixed gently on 
a rotator for 60 minutes at 4°C. At the end of this time centrifugation was 
used as before to produce a supernatant of cleared cell extract. 
Preadsorption of AC 88 onto washed Pansorbin was achieved by
incubating antibody (50jj.I, pre-diluted 1:100 in NP-40 solution) with
washed Pansorbin solution (500pl), again by mixing gently on a rotator for 
60 minutes at 4°C. After preadsorption, the suspension was divided into
five 100pl aliquots before centrifuging as before and discarding the 
supernatant. These pellets represent the five immunoadsorbant agents 
used to immunoprecipitate hsp 90. The remainder of the washed
Pansorbin (500pl) was treated similarly, except that 1% BSA was 
substituted for AC 88; these five pellets being used as the controls for 
non-specific immunoprecipitation.
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Immunoprecipitation was achieved by incubating aliquots of each cleared
cell extract (1 OOjxl) with either an immunoadsorbing pellet or a control 
pellet for 120 minutes using constant rotation at 4°C.
After incubation, the suspensions were centrifuged as before and the 
supernatants discarded. The pellets were then washed three times by
resuspension in successive solutions (100pl) by vortexing followed by 
centrifugation for 30 seconds at 13,00 rpm using the MSE microfuge. The 
three solutions were; NP-40 solution; NP-40 solution containing 0.5M  
NaCI, and NP-40 solution containing 0.1% SDS.
The final pellets were dissolved in running buffer (50jil; M e t h o d o l o g y  
section 5 .1 .4 .), boiled for 60 seconds and analysed by 7.5%  
polyacrylamide gel electrophoresis (see M e t h o d o l o g y  section 5.1.). 
Autoradiography was carried out as described in M e t h o d o l o g y  section 
5.3.
The bands on the gel corresponding to Mr =90,000 were then excised
and p-scintillation counting of the acrylamide sections was used to 
determine the total amount of radioactivity immunoprecipitated. The use of 
Ecoscint A permitted a 36% counting efficiency from the segments of 
undissolved acrylamide.
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R esults.
The results of this experiment are shown in the following three figures. 
F ig u r e  9. is a photograph of the coomassie blue-stained 7.5%  PAGE gel 
that was used to resolve the protein products of the immunoprecipitation. 
F ig u r e  10. is an autoradiogram developed from this gel. The histogram 
shown in F ig ure  11. illustrates the relationship between the different heat 
shock treatments and the amounts (measured as cpm [35S]-methionine 
immunoadsorbed) of hsp 90 purifiable from the cell extracts.
The electrophoretic patterns of the nonspecific-immunoprecipitates are 
not shown as scintillation counting of these pellets found that they
contained levels of p-radiation not significantly different from background 
levels. This suggests that AC 88 immunoprecipitation is highly specific.
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Figure 9. The Effect of Heat on the Total Amount of
Immunoprecipitatable hsp 90 from MCF-7 Cells.
Hsp 90 was immunoprecipited from cells subjected to 
different Heat Shock Treatments (HST). HST 1 was 2 
hours exposure to 41 °C followed by 12 hours recovery at 
37°C. HST 2 was 2 hours exposure to 44°C followed by 
12 hours recovery at 37°C.
The five lanes of coomassie blue stained protein on the 
gel represent immunoprecipitated hsp 90 from cells 
subjected to different regimen of HST. Reading lanes 1-5 
from left to right the regimen were:
1. HST 1
2. HST 2
3. HST 1+2
4. HST 0 (Control for HST 1)
5,. HST 0 (Control for HST 2 & HST 1 +2)
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Figure  10. Heat Shock Induction of MCF-7 Cell hsp 90 
Assessed by [35S]-Iabelled hsp 90.
This autoradiogram was developed from the gel shown 
in F ig u r e  9. This then represents the level of [35S]- 
methionine incorporated into AC 88 immunoprecipitated 
material during the 12 hour recovery period subsequent 
to heat shock, and prior to hsp 90 immunoprecipitation. 
The five lanes represent the different regimen of HST. 
Reading lanes 1-5 from left to right the regimen were:
1. HST 1
2. HST 2
3. HST 1+2
4. HST 0 (Control for HST 1)
5. HST 0 (Control for HST 2 & HST 1 +2)
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Figure  11 . Quantitation of Heat Shock Induction of MCF-7 
Cell hsp 90.
This histogram shows the relative amounts of hsp 90  
synthesised during MCF-7 cell recovery from heat shock. 
The protein bands corresponding to the molecular weight 
of hsp 90 were excised from the gel shown in F ig u r e  9.
and the [35S]-methionine incorporated quantified by p- 
scintilation counting. The results were expressed in terms 
of the DNA present in the original cell extract used for 
hsp 90 immunoprecipitation.
Data represents the mean of two experiments for each 
condition. Each value is the cpm. recovered from the 
90kDa. region of the gel after immunoprecipitation and 
PAGE.
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*P lease note th a t to  assess the le v e l o f hsp 90 In d u c tio n , lanes 2 & 3 
should be compared to  the c o n tro l (HST 0) fo rthese lanes which is  lane 3. 
The c o n tro l fo r  lane 1 is  lane 4,
When lanes 2 & 3 are compared to lane 5, there  is  a s ig n if ic a n t  d iffe re n c e  
in  the observed le v e l o f im m unoprecipitated hsp90 -  lane 3 showing the  
most increased le v e ls .
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C onclusions .
The low amounts of protein resolved by the gel shown in F ig u r e  9. 
suggest either that there is relatively little hsp 90 present in the original 
cell extract, or alternatively that AC 88 immunoprecipitation is inefficient. 
As hsp 90 is a highly ubiquitous protein, present in significant 
concentrations in most cell types, it is unlikely that the former is the case. 
More probably, it seems likely that in our hands AC 88 is an inefficiently 
immunoprecipitating antibody. However, the fact that there is only a single 
band in each of the five lanes demonstrates that AC 88 immuno­
precipitation is nonetheless very specific.
When a calibration curve of molecular weight versus mobility is calculated
it is found that the predominant band of all five lanes has a Mr *87 ,500 . 
This is assumed to be hsp 90 and is further confirmation of the specificity 
of antibody AC 88.
F igure 9. shows that the greatest amount of hsp 90 is recoverable from the 
extract of cells treated by HST 1+2 (lane 3): the cells displaying thermo- 
tolerance. In addition, F igure 10. demonstrates that these cells contain the 
greatest amount of [35S]-methionine labelled-hsp 90, suggesting that hsp 
90 synthesis was greatest in this cell group during recovery from heat 
shock. Together, F ig u r e s  9. and 10. show that there is a significant 
amount of hsp 90 both present, and synthesised during recovery from 
heat shock. This is in accordance with other workers who have found that 
hsp 90 is present in abundant levels even in unstressed cells (L e e s -
1 24
Pa r t 1 Experimental
M iller &  A n d er so n , 1989b).
Since heat shock is known to reduce the overall level of cell viability it is 
impossible to make a direct comparison of the immunoprecipitates with 
each other. This is because the hsp 90 purified from heat shocked ceils 
(lanes B and C) was purified from extracts of fewer cells due to the 
elevated temperatures. For this reason the DNA content of each extract 
was estimated prior to immunoprecipitation in order to equate the amount 
of immunoprecipitated hsp 90 with the original number of cells.
The results shown in the histogram in F ig u r e  11. represent the cpm 
present in the excised bands from the gel shown in F ig u r e  9. expressed in 
terms of the amount of DNA present in the original cell extract. This allows 
a more relevant assessment of the effect of the different heat shock 
treatments on hsp 90 synthesis.'As can be readily observed, there is an 
enhanced amount of hsp 90 present in the cells exposed to the double 
heat shock (HST 1+2). This is the cell group that shows the greatest 
resistance to heat (see Experim ental  chapter 2): the thermotolerant group, 
suggesting that hsp 90 plays an integral role in the mediation of the 
thermotolerance phenomenon.
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C hapter 4.
The Influence of Elevated Temperatures on the 
Oestrogen-Binding Capacity of MCF-7 Cells.
Introduction.
It has been established that the level of hsp 90 is modulated by heat in 
MCF-7 cells and that its expression is reflected in the thermotolerance 
status of the cells in question. As discussed in Intro ductio n  section 4., hsp 
90 has been demonstrated to associate with the nonactivated form of 
steroid receptors; seemingly to mask the DNA-binding site of these 
receptors until ligand-induced dissociation results in receptor activation 
(B a u l ie u , 1987a & b). If this is the biological role of hsp 90 in relation to 
steroid receptors, then, given our observations that hsp 90 is strongly 
influenced by heat and as such may play a role in the mediation of MCF-7 
cell thermotolerance, it was decided to investigate whether temperature 
could have an effect on the steroid-binding capacity of heat treated cells. 
Temperature is known to induce receptor activation in the absence of 
ligand in vitro (S a k a i & G o r s k i, 1984). However, no workers have 
discussed the possibility that temperature could effect the steroid-binding 
capacity of receptors in vivo or in vitro by thermal-modulation of the 
levels of receptor-associated hsp 90.
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4.1. THE EFFECT OF HEAT ON MCF-7 CELL OESTROGEN - 
BINDING CAPACITY.
M ethods .
MCF-7 cells were subjected to similar heat shock treatments (HST's) as 
described in E x p e r im e n t a l  chapter 1 again using the same techniques. 
Cells were subcultured in 150cm2 flasks 24 hours prior to commencing 
the experiment so that a 20% cell monolayer was present. After exposing 
the cells to either 37°C (controls), HST 2 alone, or HST 1+2 the medium 
was removed from the flasks, the cell monolayer washed twice using ice 
cold PBS-A and the cells harvested by freeze-thawing. This involved 
adding ice cold HED-buffer (3.0ml; M e th o d o lo g y  section 1.3.1.) to each 
flask which was then floated on liquid nitrogen for 15 seconds. The flasks 
were then moved to a 37°C incubator for 10 minutes to allow rapid 
thawing, before transferring the contents to suitable tubes, and 
centrifuging at 1000g and 4°C using an MSE ‘Mistral’ for 5 minutes. The 
resultant supernatant “cytosol” extract was used to determine the 
oestrogen-binding capacity of the heat treated cells by assaying for ER 
using the ten-point method described in M e th o d o lo g y  section 3.1.3. The 
protein content of each sample was determined by the method of Bradford 
as described in M ethodolog y  section 4.1.
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Results.
The results described in T able 1. represent the means of four separate 
experiments, each experiment consisting of triplicate ER assay so that the 
values represent the mean of 12 assays. Results are quoted in terms of 
femtomoles of oestrogen receptor per mg of protein.
T able 1. THE EFFECT OF HEAT SHOCK ON THE OESTROGEN BINDING  
CAPACITY OF MCF-7 HUMAN BREAST CANCER CELLS.
Treatment ER (fmol/mg protein) Std. Devn. No. of Expts.
HST 0 20.09 5.64 12
HST 1+2 2.25 5.56 12
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4.2. THE KINETICS OF HEAT ABOLITION OF OESTROGEN-BINDING.
M ethods .
In order to investigate the transience of the observed abolition of MCF-7 
cell oestrogen-binding capacity, the experiment was repeated in such a 
manner as to allow sampling of the ER-binding ability at different time 
points immediately after (during recovery from) heat shock. To allow 
sampling, cells were subcultured and allowed to form monolayers of 20%  
confluence in twenty 25cm2 flasks. Ten of these were subjected to HST 
1+2, while the remainder were maintained as 37°C controls throughout. 
Time zero (To) was taken as the time upon removal of the flasks from the 
second elevated temperature - the beginning of the second recovery 
period. Cells were harvested as described in the previous experiment at 
ten time intervals from To to 24 hours later; a control flask being harvested 
in conjunction with each heat treated flask. The “two-point competition” 
ER-assay was carried out in triplicate for each flask (see M e t h o d o l o g y  
section 3.1.4.). Protein was again determined by the method of Bradford 
as described in M ethodolog y  section 4.1.
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Figure  12. The Kinetics of Thermal Inhibition of MCF-7 Ceil 
Oestrogen Binding Capacity.
The amount of “available” ER in cells at different time 
points immediately commencing recovery from heat 
shock (To). Each point is the mean of three wells. 
Capacity to bind [3H]-oestradiol was determined by the 
two-point competition assay.
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Results.
F ig u r e  12. shows the effect of heat on the oestrogen-binding capacity of 
MCF-7 cells. This experiment was only carried out once, although each 
data point represents the mean of triplicate ER assay of each set of heat 
shock-treated cells. This time course study would have benefited from a 
longer total sampling period, perhaps up to 48 hours; however this is 
logistically impossible as the experiment dictates that cells are growing 
continuously for almost 72 hours, by which time full confluence has been 
reached and ER content is one of many parameters which are altered in 
the switch from growing to confluent cells.
C onclusions .
The results of the first experiment in this chapter (4.1.) show the dramatic 
effect of heat on the oestrogen-binding ability of MCF-7 cells (T able  1.). It 
• can be seen that the amount of ER present in the control cells slumps to a 
level below the detection limit of the assay as a result of heat shock. The 
value obtained for the observed concentration of ER in the heat shocked 
cells is actually less than the standard deviation of the data. This is 
because in ten out of the twelve assays carried out the amount of ER 
present was lower than the ligand-binding assay could detect; and so a 
value of zero was obtained. The two positive results cannot be discounted 
though it is possible that the large number of tissue culture flasks being 
used meant that not all flasks received the full heat treatment.
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In view of these results it was decided to investigate the kinetics of this 
almost total abolition of MCF-7 cell oestrogen-binding ability by heat 
shock (4.2.) The results shown in F ig ure  12. illustrate the time dependent 
abolition of ER-binding ability by heat. Interestingly, there is a delay of 
approximately 3 hours between the end of thermal shock and the loss of 
measurable ER ligand-binding, suggesting that there is some mechanism 
involved that is initiated by heat, but is not dependent on the continued 
presence of heat.
ER only becomes redetectable by ligand binding assay 1 0 - 1 2  hours after 
returning the cells to 37°C. Noticeably, the1 cells in experiment 4.1. were 
assayed after 12 hours at 37°C, suggesting that we may have been 
observing the cells at the point where the inhibitory effect was in 
remission. This is another possible explanation for the two positive values 
that appear with the ten zero values of ER for the heat shocked cells in 
experiment 4.1.
The concentration of ER present in the control cells seems to tail-off after 
approximately 12 hours of sampling. Howbver, this represents the point 
when the faster growing control cells are approaching 100% confluence 
and ER are normally down-regulated.
What is most interesting about this data (F ig u r e  12.) is that the kinetics of 
ER-binding inhibition mirror the synthesis of hsp's (C raig  et al, 1985). This 
tentatively suggests that the effect of heat could be an indirect inhibition of 
ER-binding ability through its stabilising-association with excess hsp 90.
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C hapter  5.
The Influence of Elevated Temperatures on 
Oestrogen Receptor Levels in MCF-7 Cells, as 
Determined by Enzyme-immunoassay.
Introduction.
The results of the experiments described in the previous chapter suggest 
that heat causes a temporary abolition of oestrogen-binding capacity in 
MCF-7 human breast cancer cells. Furthermore, the effects of temperature 
are time dependent and mimic the kinetics of hsp synthesis (C raig  eta l, 
1985). It was decided to investigate how the transient increase in 
temperature could modulate ER concentration determined by immuno­
assay rather than by ligand-binding ability.
This is because among potential mechanisms of heat-induced regulation 
of oestrogen-binding; temperature could have effects on 1) the amount of 
ER, or 2) on the binding ability of ER.
To distinguish between these two pathways it was decided to use an 
immunological assay to detect the levels of ER after heat shock. This type 
of assay is independent of either the DNA- or ligand-binding functions of 
steroid receptors and so is ideally suited to answer the questions raised 
by the previous experiments. (Assuming that the antibody is not directed 
against an epitope involved in the steroid-binding process).
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M ethods.
This experiment was designed so that the cells being investigated were 
treated exactly as those of Experiment 1 of the previous chapter; that is to 
say that control cells and cells subjected to HST 1+2 were both assayed 
for ER. In addition, a set of cells were grown in the presence of 50nM  
cycloheximide during the second recovery period so that the normal 
turnover of ER could be taken into account.
The assay used to immunologically detect ER was a commercially 
available enzyme-immunoassay (EIA) from Abbott Laboratories (see 
M e t h o d o l o g y  section 3.2.). This is a relatively simple sandwich assay 
used routinely to determine the levels of ER in breast tumour biopsies. 
Protein values were again estimated by the method of Bradford 
(M ethodology  section 4.1.).
R esults.
The results of the ER-EIA are shown on F ig u r e  13. These results 
represent the mean of three experiments (three wells for each condition in 
each experiment), each of which was assayed in duplicate by Abbott 
Laboratories ER-EIA kit.
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Figure  13. The Effect Heat Shock on MCF-7 Cell Oestrogen 
Receptor.
This F igure  shows the effect of heat shock on MCF-7 cell 
ER as assayed using Enzyme-immunoassay kit (Abbott). 
Cells were harvested after the second 12 hour recovery 
period.
Error bars represent the Standard Deviation of the data.
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C onclusions.
F igure  13. demonstrates that the effects of heat on ER-binding ability must 
be independent of the absolute number of ER present, as approximately 
two-thirds of the ER remain after heat shock. The ligand-binding assay 
predicts that there should be virtually no detectable ER 12 hours after heat 
shock; however the EIA demonstrates that at this time 67% of ER remain. 
The difference between these two assays is the former relies on ligand- 
binding ability, whereas the latter is an immunological detection of ER 
protein. The implication therefore is that heat shock has minimal effect on 
the levels of ER protein, but instead directs its inhibition at the oestrogen- 
binding function of the receptor.
The cells incubated with cycloheximide show a significant (16%) loss of 
ER protein, although not as great as the heat shocked cells. Heat shock is 
known to halt normal protein synthesis at the same time as enhancing hsp 
synthesis (B u r d o n , 1986; see In tr o d u c tio n  section 3.2.4.). No doubt this 
explains the 16% part of the 33% reduction in heat shocked ER due to the 
inhibition of protein synthesis. It does seem therefore that there is some 
additional, more direct action of heat on ER levels; protein denaturation 
for example.
In conclusion, it seems that although the effect of heat shock is to partially 
decrease the amount of immunologically detectable ER; heat shock does 
not reduce the amount of ER protein by the amounts predicted by the loss 
of ligand binding ability described in the preceding chapter. This suggests 
that hsp 90 may specifically block ligand binding by ER.
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C hapter 6.
Hsp 90 Immunocytochemical Localisation.
Introduction.
Hsp 90 is an abundant protein comprising between 1% and 2% of total 
soluble protein (L e e s -M iller  & A n d e r s o n , 1989a). However there have 
been few immunocytochemical studies describing the intracellular 
distribution and localisation of hsp 90 either in vitro or in vivo. It was 
decided to investigate the subcellular distribution of hsp 90 and to 
observe any variation in the distribution occurring as a result of heat 
shock, as this may aid in an interpretation of the effects of heat shock on 
the oestrogen-binding ability of ER.
This type of immunocytochemical study has successfully been carried out 
for other HSP's, notably hsp 70, in different cell lines (R ia b o w o l  et al, 
1988; W elc h  & S u h a n , 1986). These investigators observed both an 
induction and also a nuclear localisation of hsp 70 in response to heat 
shock. Little information has been obtained for hsp 90.
Indirect fluorescent immunocytochemical staining was used to visualise 
hsp 90: this procedure involves detection of an appropriate monoclonal 
antibody with a fluorescein isothiocyanate (FITC)-labelled, species- 
specific, secondary antibody. When the fluorescent label attached to the 
secondary antiserum is exposed to the excitatory ultra-violet light 
generated by a fluorescent microscope, the label emits visible green light
( X  = 450nm).
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Methods.
MCF-7 cells were subcultured so that a 20% monolayer was formed in the 
culture vessels and treated either as 37°C controls or as HST 1+2 (double 
heat shocked) cells. The vessels used were commercially available 
microscope slides that come complete with a detachable upper chamber 
forming eight 25mm2 chambers (LabTek® Chamber Slides, Nunc Inc.). 
These slides (see F igure  14.) are invaluable tools to assist in the staining 
of cell monolayers as they allow concurrent staining of different antibodies 
on the same slide, and in addition require minimal amounts of antisera to 
ensure adequate staining.
The complete method of fluorescent immunocytochemical staining is 
described in M e t h o d o l o g y  section 6.4.2.; while the method used to 
prepare a suitable FITC-labelled secondary antibody is described in 
M eth o d o lo g y  section 6.4.1. The primary serum used to detect hsp 90 was 
mouse monoclonal antibody AC 88, diluted 1:500 times. This was 
visualised using an FITC-labelled sheep anti-mouse serum also diluted 
1:500 times, Hoechst 33258 being used as a nuclear counterstain.
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F igure  14. The 8-Well LabTek Chamber Slide.
This photograph shows the piece of equipment used to 
grow cells for immunocytochemical assay.
The dimensions of the glass slide are 25mm x 63mm; the 
individual wells had a surface area of 36mm2 and had an 
optimum capacity of 0.5 ml.
F igure 15. M CF-7 Cell M orphology.
This photograph shows the typical “cobble-stone” 
appearance of the MCF-7 epithelioid breast cancer cell 
line.
These cells were photographed upon achieving 100%  
confluence. Phase contrast microscopy was used with 
the culture medium being replaced with PBS-A.
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Results.
F igure  15. shows the normal morphology of the MCF-7 breast cancer cells 
growing as a confluent monolayer and visualised using standard phase- 
contrast microscopy (120x); note the typical “cobble-stone” appearance of 
this epithelial cell line.
Each F ig u r e  is represented as a pair of micrographs, a. and b. 
Respectively, these show the Hoechst nuclear counterstain (blue) and the 
FITC-fluorescence (green) of the same microscope field. This allows 
assessment of the hsp 90 staining in terms of both cytoplasmic and 
nuclear localisation. All photographs of immunofluorescence were taken 
using a microscope magnification of x400. The results can be 
summarised in the following figures:
F ig u r e  16b. shows the nonspecific FITC staining, ie. staining in the 
absence of primary antibody AC 88.
F ig ure  17b. shows the specific FITC-staining of hsp 90 in MCF-7 cells 
cultured constantly at 37°C.
F ig u r e s  18b. and 19b. show the specific FITC-staining of hsp 90 in 
heat shocked (HST 1 +2) MCF-7 cells.
Taken together these four figures indicate a pronounced effect of heat 
shock on hsp 90 intracellular localisation.
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Figure  16. Fluorescent Immunocytochemical Localisation of 
hsp 90 in MCF-7 Cells.
F igure  16b. shows the FITC-fluorescence contributed by 
nonspecific staining. Primary anti-hsp 90 antibody was 
omitted from the staining proceedure.
F ig u r e  16a. shows the corresponding Hoechst nuclear 
counterstain of the same field shown in F igure  16b.
(Microscope magnification x400 in both photographs)
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Figure 17. Fluorescent Immunocytochemical Localisation of 
hsp 90 in MCF-7 Cells.
F ig u r e  17b. shows the  specific  an ti-hsp  90  FITC- 
fluorescence of cells grown at 37°C throughout (HST 0).
F ig u r e  17a. shows the corresponding Hoechst nuclear 
counterstain of the same field shown in F igure  17b.
(Microscope magnification x400 in both photographs)
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F igure  18. Fluorescent Immunocytochemical Localisation of 
hsp 90 in Heat Shocked MCF-7 Cells.
F ig u r e  18b . show s th e  specific  an ti-hsp  9 0  FITC- 
fluorescence of cells subjected to HST 1+2 (double heat 
shock).
F ig u r e  18a . shows the corresponding H oechst nuclear 
counterstain of the sam e field shown in F igure  18b.
(Microscope magnification x400 in both photographs)
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F igure 19. Fluorescent Immunocytochemical Localisation of 
hsp 90 in Heat Shocked MCF-7 Cells.
F ig u r e  19b. is a neighbouring field from the the specific 
anti-hsp 90 FITC-fluorescence of cells subjected to HST 
1+2 (double heat shock) as the cells shown in F ig ur e  18.
F ig u r e  19a. shows the corresponding Hoechst nuclear 
counterstain of the same field shown in F ig ure  19b.
(Microscope magnification x400 in both photographs)
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C onclusions .
The technique of fluorescent immunocytochemical staining is a reliable 
method of staining cell monolayers and so is a valuable research tool. 
Best results were obtained when the cells were 50-75%  confluent, as 
staining observed from clusters of cells is extremely difficult to interpret.
As can be seen looking at F ig u r e s  16-19. the staining is highly specific. 
There is virtually no fluorescence from the cells incubated with only 
secondary serum, the nonspecific-binding controls (F ig ure  16b.)
These photographs reveal some very interesting properties of hsp 90. At 
37°C hsp 90 seems to be located in a broadly cytoplasmic environment 
although there is some definite nuclear staining (F ig u r e  17b.) Heat shock 
has two main effects: firstly, the general level of fluorescence is enhanced 
(F ig u r es  18b. & 19b.). This is not surprising, since the amount of hsp 90 
present was shown to be upregulated by heat in Exper im enta l  chapter 3. 
The second obvious effect of heat is the distinct nuclear localisation of hsp 
90 in the heat shocked cells (F ig u r es  18b. and 19b.). This type of heat- 
induced hsp nuclear localisation has been previously noted for hsp 70 in 
heat shocked fibroblast cells (R iabow ol  et al, 1988), yet this seems to be 
the first report of any hsp 90 nuclear translocation. There also seems to be 
some plasma membrane association of hsp 90 which becomes enhanced 
after heat shock. This type of staining has never been reported for hsp 90 
although other workers have suggested that it may be present as part of 
the plasmamembrane superstructure in an analogous manner to spectrin 
(N ishida etal, 1986).
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C hapter 7.
Coimmunoprecipitation of hsp 90 & ER.
Introduction.
There are many investigations into the association between hsp 90 and 
steroid receptors (see In tr o d u c tio n  section 4.) using a variety of different 
techniques. Many of these reports however, do not fully address the 
problem of nonspecific interaction of the two proteins. It was decided to 
attempt to immunoprecipitate ER using an anti-ER monoclonal antibody, 
and then use Western immunoblotting to try and identify hsp 90 present in 
the immunoprecipitate. If hsp 90 was detectable, it would add to the 
evidence that suggests that the interaction of the two proteins is a true in 
vivo complex, and not an in vitro artifact.
M ethods.
M C F-7 cells (300cm 2) were harvested as described in P a r t  1 
E x p e r im e n t a l  chapter 3. Immunoprecipitation was carried out on the 
extract of these cells as described in this previous chapter using anti-ER 
monoclonal antibody ERP-31 diluted 50 times (M e t h o d o l o g y  section 
6.1.1.). The immunoprecipitate pellet was run out on a 7.5% PAGE gel as 
described in M e th o d o lo g y  section 5.1. and the gel was used to transfer 
the protein products to nitrocellulose (see M e t h o d o l o g y  section 5.4.3.). 
This nitrocellulose was subjected to immunoblotting (M e t h o d o l o g y  
section 5.4.5.) using anti-hsp 90 monoclonal antibody AC 88.
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F igure  20. Nitrocellulose Blot of Immunoprecipitated ER.
This photograph shows the nitrocellulose blot stained 
using amido black to reveal protein transferred from an 
SDS-PAGE gel used to resolve immunoprecipitated ER.
Pa r t  1 E x p e r im e n ta l
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R esults.
F ig u r e  20. is a photograph of the nitrocellulose blot of the ERP-31 
immunoprecipitate stained using amido black as described in 
M e t h o d o l o g y  section 5.4.5. Unfortunately, no positive results were 
obtained when AC 88 immunoblotting of this nitrocellulose was carried 
out (data not shown).
C onclusions.
The lack of positive hsp 90 immunoblotting on the nitrocellulose blot of the 
ER immunoprecipitate could be attributed to a variety of causes; including 
the possibility that there is no association between hsp 90 and ER. 
Discounting this reason purely on the grounds that it is at odds with the 
overwhelming body of the literature, the most obvious reason for failure is 
the experimental design itself. It is possible that anti-ER antibody 
immunoprecipitation results in a highly purified form of ER that is devoid of
any hsp 90. This is in fact reflected in the single band of Mr « 6 4 ,0 0 0  
present on the nitrocellulose blot. One possible reason for this type of 
immunopurification could be that the antibody is specific for activated ER, 
and so may recognise a site on the ER protein that is normally masked by
hsp 90. This would mean that it would be impossible to immunoprecipitate
/
any 8-1 OS heteromeric complexes incorporating hsp 90.
Another reason for the lack of reactivity of AC 88 is that it may not 
recognise hsp 90 on the nitrocellulose blot, though AC 88 has previously
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been shown to be capable of efficient immunoblotting of hsp 90 during 
Western blotting (D.O. Toft, personal communication).
This experiment was repeated on numerous occasions without success. 
When the antibodies were reversed so that ERP-31 immunoblotting of 
AC 88-immunoprecipitated hsp 90 was attempted there was still no 
positive staining to show the presence of ER in the hsp 90 immuno­
precipitate. However, these disappointing results do not distinguish 
between an incorrect model of ER and hsp 90 association and 
inappropriate experimental design. Indeed, the possibility that the 
antibody only recognises activated ER should be further explored. 
Conversely, AC 88 may have precipitated the ER-hsp 90 complex but the 
techniques used failed to dissociate the complex to reveal the anti-ER 
antibody epitope on the ER.
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The overall aim of these studies was to gain some understanding of the 
functional relationships existing between hsp 90 and steroid hormone 
(oestrogen) receptors. This association represents a link between two 
very distinct families of proteins, each of which is of vital cellular 
importance.
As one approach to this question of the association of the two proteins, it 
was decided to investigate the modulation of oestrogen receptor activity 
by heat in breast cancer cells. This represents a novel approach, as 
researchers have almost exclusively studied endocrine effects on the hsp 
90-steroid receptor association, as opposed to the effects of thermal 
parameters. Yet thermal aspects of breast cancer have received recent 
attention (M cCu r d y , personal communication) and thermal therapy of both 
prostate cancer and benign prostatic hyperplasia is also gaining ground 
(SeeP art2  of this thesis).
1. THERMAL KILLING OF MCF-7 CELLS.
It was important to characterise the normal range of thermal-tolerance 
displayed by MCF-7 human breast cancer cells. This allows the definition 
of a titration point which can be used during the designation of either 
thermotolerance or thermo-//?- tolerance of cells subjected to different 
temperature regimes. The conclusion drawn from the results of Part 1, 
E x p e r im e n t a l  chapter 1. is that MCF-7 breast cancer cell growth is 
inhibited by temperatures greater than 42°C.
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There has been a great deal of work on the effects of temperature on the 
growth of both normal and malignant cells, due mainly to the intense 
interest in thermal-therapy of various neoplasms such as carcinoma of the 
colorectum, prostate and cervix (P ilepich  etal, 1987). Effective treatment 
of these tumours is possible because their accessibility allows efficient 
heat transfer from external apparatus. For this reason thermal-therapy has 
not been used extensively to suppress the growth of more deep-seated 
tumours, such as breast cancer (D e w h ir s t  et al, 1987). The great 
advantage of this approach, if successfull in a definable group of patients, 
is that surgery and the associated complications may be avoided in this 
group of patients.
This value obtained for MCF-7 cell temperature lethality is in agreement 
with the levels of heat lethality (42.5°C) demonstrated by a wide variety of 
normal tissues such as heart and liver (F ie l d , 1987), but it is 
approximately 2°C lower than the critical lethal temperature of those 
malignant tissues studied. This does not fit in with the general hypothesis 
that reproductive cancer cells are more "heat-sensitive than their normal 
counterparts. This may be explained by the fact that Field e ta l  were using 
intact tissues and not monolayer cell cultures, where heat conduction is 
inherently poorer, and so higher temperatures may be required to 
“penetrate” the tumour mass. In addition, these figures are only valid 
when a common reference exposure time is chosen.
• rj.
The problem of the time and temperature relationship during heat shock -
152
Pa r t 1 D iscussion
the “isoeffect dose” - means that it is difficult to compare the work of 
different authors (S a p a r e t o , 1987). When the log of exposure time (in 
minutes) is plotted versus the exposure temperature (°C) for the 
equivalent thermal effect (isoeffect) then a straight line is produced 
between 42°C and 46°C for most tissues. However, thermotolerance 
heating (prior exposure to sub-lethal temperatures) and step-down 
heating (prior brief exposure to lethal temperatures) both negate this 
linear relationship (F ie l d , 1987). For this reason it was decided to 
maintain a constant time of heating throughout all exposures.
2. MCF-7 CELL THERMOTOLERANCE.
The cumulative aim of these studies was to assess the effects that varying 
the population of intracellular hsp 90 had on the oestrogen-binding 
capacity of MCF-7 cells. By definition, simple heat shock is the obvious 
method of upregulating the levels of hsp's; hsp 90 in particular has been 
demonstrated to be extremely heat inducible (C a te lli,1 9 8 5 ). Alternatively, 
it has been shown that the acquisition of thermotolerance is accompanied 
with the overproduction of hsp's (L in d q u is t , 1.986) when compared to heat 
shock alone. In addition, the surviving cell population is considerably 
more viable.
Thermotolerance is defined as the acquisition of cellular resistance to 
lethal temperatures by prior exposure to sub-lethal elevated temperatures 
(C r a ig , 1985). Mammalian fibroblasts in monolayer cell culture have been 
shown to become thermotolerant to lethal temperatures as a direct result
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of a prior mild heat shock followed by a 12 hour recovery period (W elch & 
S u h a n , 1986). Correspondingly, these double heat shocked cells 
accumulated hsp 70 at a faster rate and demonstrated higher overall hsp 
70 levels than their single heat shocked equivalents. This double step 
induction has been cited as a possible cellular mechanism for ensuring 
efficient stress protection during cellular “siege” situations (Y o s t  & 
L in d q u ist , 1986).
In order to vary the amount of hsp 90 in the MCF-7 cell-line, it was 
decided to exploit the double heat shock-thermotolerance reaction of 
these cells. As demonstrated by the results shown in Part 1, Exper im en ta l  
chapter 2., MCF-7 cells subjected to 44°C fail to undergo any significant 
growth subsequent to the exposure to this lethal temperature. This 
observation confirms the result of Part 1, Ex p e r im e n t a l  chapter 1. when 
42°C was identified as the watershed in terms of cell survival. However, 
cells exposed to an initial heat shock of 41 °C followed by a 12 hour 
recovery prior to 44°C exposure show growth rates comparable with 
those of the cells maintained at 37°C. It is therefore concluded that the 
thermotolerance response was induced by the initial mild heat treatment, 
allowing these MCF-7 cells to withstand a temperature known to be lethal 
to unprimed MCF-7 cells.
✓ ; I
3. THERMAL INDUCTION OF hsp 90.
As previously mentioned, hsp 90 has been shown to be a thermally 
inducible protein (C atelli et al, 1985) and its gene promoter is known to 
contain the appropriate heat shock response element that confers
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heat-inducibility on hsp 90 transcription (R ebbe etal, 1989). The results of 
Part 1, Ex p e r im e n ta l  chapters 1. & 2. suggested that the MCF-7 cell line 
demonstrates the thermotolerance response, and this response is known 
to be accompanied by the overproduction of hsp's (W elch & S u h a n , 1986). 
This inferred that there existed a non-endocrine method of increasing the 
amount of hsp's present within these cells. However, it was decide to 
investigate whether the instigation of the thermotolerance response was 
accompanied by an upregulation in the levels of hsp 90 in particular.
The results of Part 1, Exper im en ta l  chapter 3 demonstrate that there is a 
small, yet measurable increase in the levels of immunoprecipitatable hsp 
90 in MCF-7 cells subjected to the thermotolerance-inducing double heat 
shock treatment. The amounts of protein immunoprecipitated are very low, 
and with hindsight a more sensitive experimental protocol should have 
been used. However, even with the limited amounts present, the 
resolution is sufficient to demonstrate the heat-inducibility of hsp 90 
during thermotolerance-induction. (Assuming an equal proportion of hsp 
90 was immunoprecipitated in each case.)
These results are extremely interesting in the light of a recent report 
suggesting that hsp 90 may play a pivotal role in the regulation of normal 
protein synthesis during heat shock (R o se  et al, 1989). Hsp 90 is involved 
in the shut-down, and subsequent return, of translation of normal protein 
mRNA during heat shock. The variation of intracellular hsp 90 during heat 
shock may represent both a regulator and a product of the pattern of 
hsp-induction.
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Apart from heat, it is possible to increase the levels of hsp 90 using 
oestrogens (R a m a c h a n d r a n  et al, 1988); although the experiment 
described here has shown that the levels of hsp 90 in MCF-7 cells can be 
upregulated in a non-endocrine manner while still retaining a viable 
population of cells. In addition, for the purposes of this study of the 
relationship of hsp 90 and ER, it would not be relevant to use oestrogen to 
upregulate hsp 90, since oestrogen is known to rapidly modulate ER 
levels in oestrogen-sensitive cells.
4. THERMAL INHIBITION OF OESTROGEN-BINDING.
The results of Part 1, Ex p e r im e n t a l  chapters 4. & 5. demonstrate the 
contrasting effects of. heat shock on both the amount of immuno- 
detectable ER, and on ER binding ability. Heat shock results in an almost 
total abolition of the oestrogen-binding capacity of the M CF-7 cells. 
However, since the actual amount of ER recognised by the anti-ER  
antibody kit was only reduced by approximately 33% it is apparent that 
some mechanism is reducing the oestrogen-binding capacity of ER in 
heat shocked MCF-7 cells.
There is only one prior report of thermal modulation of ER activity in vivo. 
This unique observation (W o l f f e  et al, 1984) reported the abolition of 
oestrogen- activated transcription of vitellogenin mRNA by heat shock. 
Interestingly these workers also noted that heat shock resulted in a loss of 
biochemically detectable ER, and a corresponding accumulation of hsp's. 
The observations of W olffeef al are remarkably similar to the data
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presented within this thesis, although this group did not use 
immunological methods to detect ER.
Since knowledge of the association of hsp 90 with the steroid receptors 
was not widespread at the time of this previous report (W o lffe  etal, 1984) 
the investigators did not comment on the possibility of an hsp 
90-mediated suppression of ER-binding ability. However, when these 
earlier observations are taken into account with those reported in Part 1, 
E xper im en ta l  chapters 4., 5. & 6. they may be interpreted to indicate that, 
after heat shock, nonactivated-nuclear receptor remains although steroid- 
binding is in some way inhibited by excess and/or relocated hsp 90.
COULD hsp 90 MEDIATE A HEAT SHOCK-INDUCED SUPPRESSION  
OF OESTROGEN-BINDING CAPACITY?
The difference between the results of ligand-binding ER-assay and 
immunological-ER assay suggest some functional modification of the heat 
shocked ER. Therefore, the distinction must be made between the levels 
of total receptors and the levels of available receptors. The mechanism 
behind this functional modification is unclear, though the heat-induced 
nuclear localisation of hsp 90 as visualised by immunocytochemistry (Part 
1, Ex p e r im e n t a l  chapter 6.), could be responsible for some blocking 
mechanism, (see F igure 3.)
This supposition is based on the work of Baulieu, who has produced a 
model for antisteroid action. He proposes that the inhibitory action of
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antisteroids is due to the production of nonactivated receptors; created as 
a result of antisteroid-binding producing a heteromeric receptor that is 
incapable of undergoing activation (B a u l ie u , 1987a & 1987b). This 
functionally inactive receptor consists of steroid-binding subunits with 
their DNA-binding sites masked by tightly bound hsp 90 subunits; locked 
together as a result of antihormone-binding.
The antisteroidal theory of Baulieu does not entirely agree with the data 
concerning the binding of the antioestrogen tamoxifen (H am  & P a r k e r , 
1989); the antiprogestin RU-486 (G u ic h o n -M a n t e l , 1988) and other 
antisteroids. There is evidence that antisteroid-binding is able to produce 
an activated receptor that is capable of DNA-binding (tamoxifen-ER has 
partial agonist activity and can induce PR-synthesis), although it seems 
that RU-486 binding to PR is non-productive and incapable of initiating 
trans-activation (R ic ha rd -F o y  et al, 1987). It must therefore be concluded 
that the model of Baulieu is not entirely correct as regards antisteroid 
activity, yet it does provide an interesting concept for theorising the 
function of hsp 90.
Leaving aside the action of antisteroids perse, it remains highly likely that 
hsp 90 has a role to play in the regulation of receptor activity. Applying the 
observations reported within Part 1, Exp er im en tal  chapters 4., 5. & 6. to a 
modification of Baulieu's model, it suggests that heat shock may induce a 
significantly increased amount of nuclear located hsp 90 which may then 
suppress the binding ability of the remaining nuclear ER by affecting the
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dissociation kinetics of the heteromeric nonactivated receptor. In this 
sense, excess nuclear hsp 90 is promoting the nonactive form of nuclear 
ER, in a manner analogous to the antisteroidals of Baulieu’s model, (see 
F igure 40.)
It is unclear how this suppression of ER binding function could occur; 
although there exist a variety of possible scenarios:
Firstly, it is possible that the excess of available hsp 90 present within the 
heat shocked nucleus could inhibit the ligand-induced dissociation 
reaction during receptor activation. This argument is based on the 
assumption that the greater concentration of free hsp 90 would result in 
altered dissociation kinetics of the ER-hsp 90 complex during receptor 
activation; and so promote the nonactivated form of the receptor. 
Alternatively, hsp 90 may compete directly with DNA for binding of 
activated receptors. This type of activity has been observed in vitro. Hsp 
90 has no affinity for DNA itself although it has been shown to compete 
with activated glucocorticoid receptor for DNA-binding (H o w a r d  & 
D is t e l h o r s t , 1988b). Hsp 90 inhibition was specific to GR as it had no 
effect on the binding of other proteins to DNA. However, only non-specific 
DNA-binding was investigated in this study, and not specific GR DNA- 
binding sites.
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F igure  40. Possible hsp 90-mediated suppression of MCF-7 
cell ER binding capacity following heat shock.
This figure schematically shows a possible mechanism 
where excess nuclear hsp 90, present as a result of heat 
shock, could result in a suppression of oestrogen-binding 
ability. (See text for details)
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One possible model is that hsp 90 may mediate the passage of steroid 
receptors from the polysome through the nuclear membrane. This type of 
shuttle function has been demonstrated for hsp 70 (V.e r n e r  & S c h a t z , 
1988) and it is in agreement with the nuclear staining of hsp 90 seen in 
the fluorescent micrographs (Part 1, Experim ental  chapter 5 .). It is possible 
that the upregulation of nuclear hsp 90 observed in these photographs 
arises as a result of hsp 90 accumulation at the sites of passage through 
the nuclear membrane. This could result in a block in the transfer of ER 
from the synthesis site to the activation-site and so an accumulation of 
inactive receptor.
One argument against any hsp 90-mediated type of mechanism is based 
on simple arithmetic. The number of hsp 90 proteins per cell is in vast 
excess of the total of all steroid receptors, even during unstressed 
conditions (D alman  et al, 1989). Hsp 90 is present at a concentration of
1jiM in L-cell cytosol, outnumbering GR, the predominant steroid receptor, 
by a ratio of 100:1. It is unlikely then, that the observed change in hsp 90 
concentration could greatly effect the kinetics of ER-hsp 90 association. 
However, this assumption is derived from estimates of cytosolic hsp 90 
concentration; but as shown in the fluorescent micrographs (Part 1,
s
E xp er im en tal  chapter 5 .), there is a  much more significant increase in hsp 
90 levels in the nuclei of the heat shocked cells.
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6. Hsp 90 AS A NUCLEAR PROTEIN.
There have been very few reports concerned with the intracellular 
localisation of hsp 90. One possible reason for this is that the highly 
conserved nature of hsp 90 has hindered the production of an antisera 
capable of immunocytochemical detection. Two earlier reports used 
immunocytochemistry to visualise components of the progesterone 
receptor; monoclonal antibodies were used to detect avian PR in chick 
oviduct (G a s c  et al, 1984; P e r r o t -A p p la n a t  et al, 1986). The various 
antisera were raised against purified nonactivated-PR. This meant that a 
comparison of the different binding affinities of the antibodies yielded an 
estimation as to the intracellular localisation of the steroid-binding and 
nonsteroid-binding subunits. Briefly, these reports suggested that 
activated PR was a nuclear species, and that hsp 90 was a predominantly 
cytoplasmic protein. This finding was in agreement with the purification 
terminology suggesting that activated steroid receptors were nuclear 
proteins and the nonsteroid-binding subunits cytosolic (S akai & G o r s k i, 
1984). Interestingly, these workers did observe slight staining of hsp 90 
within the target cell nuclei (G a sc  et al, 1984), but they failed to apply any 
significance to its presence.
Further work from this group has used the anti-hsp 90 antibody produced 
by Toft and colleagues (AC 88) to locate hsp 90 in the nuclei of rabbit 
uterine cells (G asc  etal, 1990). This recent observation represents the first 
report of hsp 90 localisation in the nuclei of steroid hormone target cells, 
and is confirmation of the results contained within this thesis when AC 88
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was used to visualise hsp 90. Interestingly, other workers have studied 
the distribution of PR and hsp 90 in chick oviduct using a variety of 
monoclonal antibodies, including AC 88 ,~ observing only cytoplasmic 
staining of hsp 90 (P ekki & T u o h im a a , 1990). This continues to be an area 
of considerable debate.
Gasc and coworkers do not report any investigation into the localisation of 
hsp 90 before or after heat shock, and so the nuclear accumulation of hsp 
90 reported herein remains unique. Post heat shock-nuclear 
accumulation of hsp 70 has been conclusively demonstrated, where it 
was associated with cellular resistance to supraphysiological 
temperatures (R iabowol etal, 1988).
The role of hsp 90 nuclear accumulation is unclear. The obvious possible 
function is one of protein stabilisation, in analogy to hsp 70 (see 
In tr o d u c tio n  section 3.3.1.). However hsp 70 and hsp 90 show no other 
similarity in terms of either structure or function, and it seems unlikely that 
evolution would provide a parallel set of proteins to provide similar 
functions. Alternatively, it may be the case that the role of hsp 90 
accumulation and thus suppression of oestrogen-binding capacity 
represents a general role in the masking of various potential gene 
activators, although further investigation is required.
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Part 2. 
Experimental
The Effect of Temperature on the Androgen 
Responsiveness of two Human 
Prostate Cancer Cell Lines.
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A Role for hsp 90 in Prostatic Disease.
1. CANCER OF THE PROSTATE.
Prostatic cancer accounts for one quarter of male cancer deaths in 
Scotland and its incidence is second only to lung cancer in the Western 
World (Cancer Registration Statistics Scotland, 1984). This malignant 
disease must be distinguished from the very common benign prostatic 
hypertrophy (BPH) which occurs in most males after the age of 50. The 
incidence of both these diseases rises with the age of patients, and so 
they represent an increasingly important problem as the longevity of 
western populations rises.
2. PROSTATIC DISEASE AND ANDROGENS.
Both prostatic cancer and BPH respond to androgen suppression. 
Charles Huggins was the first to note that hormonal manipulation was an 
effective method to suppress a proportion of metastatic prostate cancer 
(H uggins  & H o d g e s , 1941) and despite recent technological advances this 
remains the prevailing method of treatment at this time.
The significance of the androgen-responsive nature of these diseases
has led to a variety of methods being devised to quantitate the presence✓
of AR in biopsied prostate tissue. These have included AR ligand binding 
assay (K irkali et al, 1990), immunohistochemical localisation (T ak ed a  et 
al, 1990) and AR mRNA Northern blotting (C hang  et al, 1989). However, 
there is some evidence to suggest that receptor-positivity is not in itself
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sufficient to predict androgen-responsiveness of the tumour (K irkali et al, 
1990).
3. ENDOCRINE THERAPY OF PROSTATIC DISEASE.
Earlier work from Huggins showed that oestrogen played a suppressive 
role in the formation of prostate cancer metastases (H u g g in s  & H o d g e s , 
1941); and as a result of this discovery androgen ablative orchiectomy 
(castration) or supplemental oestrogens were instigated as methods of 
treatment. However, the detrimental psychological effects of these 
treatments led to the search for suitable antiandrogens that were devoid 
of any oestrogenic properties.
Various “antiandrogens” have been used clinically: these include
Cyprostat® (cyproterone acetate), Flutamide® (a-a-a-trifluoro-2-methyl-
4'-nitroA77-propionotoluidine), and Megace® (17oc-acetoxy-6-dehydro-6- 
methyl-progesterone). Only flutamide is a nonsteroidal antiandrogen, both 
cyproterone and megestrol are steroid derivatives and as such have 
positive effects mediated by other steroid receptors.
For example, megestrol acetate has been shown to bind to AR and result 
in an activation, rather than inhibition, of androgenic activity (P o y e t  &
L a b r ie , 1985) and so can not be defined as an antiandrogen. The/
metastatic suppressive action of this compound is thought to be exerted 
through its progestational activities; as administration can result in a 
decrease in the levels of both luteinising and follicle stimulation hormones 
and thus a decrease in the levels of circulatory androgen.
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Cyproterone is an effective antiandrogen, although some androgenic 
activity, and significant glucocorticoid and progestational activities have 
also been noted in vivo (P o y e t  & La b r ie , 1985). These activities have 
undesirable implications for the endocrine therapy of both prostatic 
cancer and BPH and so flutamide is the antiandrogen of choice.
Flutamide is a nonsteroidal-antiandrogen that shows no androgenic, 
progestational or glucocorticoid activities in vivo (P o y e t  & La b r ie , 1985). 
However, in vitro both flutamide (and its activated derivative 4-hydroxy- 
flutamide) have been shown to result in the proliferation of androgen- 
sensitive human prostate tumour cells (O lea  et al, 1990; W ild in g  et al, 
1989). Not surprisingly, this discrepancy between the in vivo anti- 
androgenic and in vitro androgenic dual qualities of flutamide raises 
profound questions as to the mechanism of its clinical efficacy.
4. THERMOTHERAPY OF PROSTATIC DISEASE.
In the last decade an alternative method of treatment has arisen for the 
clinical management of both prostatic ;cancer and BPH: localised 
hyperthermia (M endecki et al, 1980). This therapy involves short doses of 
microwave heat and is based on the observation that many types of 
tumour cells are more sensitive to elevated temperatures than normal 
cells (C r il e , 1963; see next section). The hyperthermic effect is obtained 
using temperatures of between 41 °C and 44°C, though temperatures 
above 42.5°C (± 0.5°C) have also been observed to result in significant 
damage to normal tissues (Leib etal, 1986).
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Success of this treatment is mainly due to the accessibility of the 
malignant gland to an external heat source, which is introduced 
non-surgically transrectally (M e n d e c k i et al, 1980). There are various 
techniques capable of generating the heat but the common principles 
necessitate that the area of heating is defined by the size and shape of 
the applicator while the depth of heating is a function of the frequency and 
wavelength of the microwaves (M endecki et al, 1980).
In two separate studies Servadio and colleagues have investigated the 
use of microwave hyperthermia in the treatment of both prostate cancer 
( S e r v a d io  et al, 1987) and BPH (L in d n e r  et al, 1990). A marked 
improvement was observed in 50% of patients (146 in total) that was 
almost totally maintained after 12 and 24 months. These workers do not 
conclude whether this treatment represents a cure for either disease, 
however they do suggest that it is at least a very effective palliative 
measure, and that it is preferable whenever surgery is contraindicated. 
Interestingly, the most successful results were obtained when patients 
received adjuvant therapy in the form of cyproterone acetate in 
conjunction with the hyperthermia (L indner  etal, 1990), suggesting that a
certain synergy exists between these two treatments.
✓
5. HYPERTHERMIA OF MALIGNANT DISEASE.
There is a variety of reasons why malignant cells seem to be endowed 
with thermosensitivity: in general, most tumour cells are intrinsically more
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sensitive to heat than normal cells (G io v a n e lla  et al, 1976). Malignant 
tissues contain hypoxic cells that are sensitive to heat (K im  et al, 1975). 
Local hyperthermia enhances the immunological response against the 
tumour (Janiak  & S zm ig ielski, 1982).
The exploitation of the thermosensitivity of tumour cells has led to different 
hypotheses regarding thermotherapy; one area of particular confusion is 
the isoeffect relationship between dose and exposure time. As an attempt 
to compare the work of different laboratories, a system was introduced 
that converted different time/temperatures to a single unit: the equivalent
heating time at 43°C (EQ43; D e w e y  et al, 1977). Unfortunately, this
to
classification of isoeffective dose fails^correlate well with In vitro data. 
This is mainly due to nonuniform heating of tumours within deep seated 
tissues (O ve r g a a r d , 1987) and more importantly, the inability of the EQ43 
to allow for the complicated kinetics of thermotolerance (S a pa r eto , 1987). 
As a result of this, less than complete understanding of thermal 
quantitation it is difficult to distinguish between thermal-killing, and 
thermal sensitisation of neoplastic tissue (G e r w e c k , 1985). Simply, are 
increased temperatures direct effecters, or just mediators of neoplastic 
suppression?
In the case of prostatic cancer, the mechanism responsible for the 
thermal-suppression of neoplastic growth is unclear; nonetheless, 
treatment of prostatic cancer has greatly benefitted from the instigation of 
thermal-therapy (S ervadio  et al, 1987). Thermal-therapy involves heating
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tumour tissue to between 41-45°C  for up to 30 minutes: this range 
incorporates the regimen that were shown in Part 1 to be capable of both 
hsp 90 and thermotolerance induction. It is unlikely then that exposure to 
temperatures elevated to 41°C-43°C  is sufficient to result in tumour 
necrosis p e r s e .
As an attempt to investigate the treatment of prostatic cancer by thermal 
therapy, it was decided to use two human prostate cell lines to construct 
an in vitro model of the clinical scenario.
In addition, the question of flutamide's paradoxical activity in vivo and in 
vitro was also investigated. This antiandrogen is used in conjunction with 
thermal- therapy; the combination of heat and endocrine treatments 
resulting in a synergistic suppression of neoplastic prostate cell growth 
(S ervadio  et al, 1987). It was therefore of interest to investigate whether 
the in vitro androgenic activity of flutamide was maintained when used in 
conjunction with thermal stress.
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C hapter  1.
Immunocytochemical Localisation of AR and 
hsp 90 in Prostate Cells.
Introduction.
Before investigating any interrelationships between the actions of heat 
and antiandrogens during the treatment of prostate cancer, it was decided 
to verify the presence of both androgen receptor (AR) and hsp 90 in the 
prostate cancer cell lines LNCaP and DU-145. These cells are androgen- 
dependent and androgen-independent respectively (See M e t h o d o l o g y  
section 2.1.).
Two different methodologies were used. Firstly, an immunocytochemical 
method was used in conjunction with antibodies against AR and hsp 90 to 
stain for these proteins in both LNCaP and DU-145 cells as well as in two 
sections of benign prostate disease. A second immunofluorescent 
procedure was used to verify the presence of AR in the two prostate cell 
lines, though this procedure is not suitable for immunohistochemical 
staining of tissue sections.
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M e th o d s .
LNCaP and DU-145 cells were subcultured as described in M eth o d o lo g y  
section 2.2. into 8-well microscopy slides. No exogenous ligands were 
added to the RPMI-1640 culture medium and the cells were allowed to 
grow for 48 hours until approximately 80% confluence was achieved. 
After this period the culture medium was removed and the cell 
monolayers were washed using PBS-A prior to fixation. The cells to be 
stained using the immunofluorescent technique were fixed using the 
acetone-methanol process described in M eth o do lo g y  section 6.2.1., while 
all other cells and the tissue sections were1 fixed by the acetone process 
described in M ethodolog y  section 6.2.2.
Immunocytochemical localisation (see M e th o d o lo g y  section 6.3.) of AR 
was achieved using a polyclonal rabbit antibody (raised against AR) 
diluted 400 times. Immunocytochemical localisation of hsp 90 employed 
AC 88 mouse monoclonal antibody diluted 1000 times. (See  
M ethodolog y  section 6.1. for a full list of antisera.)
Fluorescent immunocytochemistry (see M eth o d o lo g y  section 6.4.2.) was 
achieved using the polyclonal anti-AR antibody diluted 500 times. This 
was detected using a donkey anti-rabbit serum labelled with FITC as 
described in M ethodology  section 6.4.1.
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R esults.
The results of the immunocytochemical studies are shown in the following 
figures. Figure 21. is a photograph of slides of DU-145 cells stained for 
both AR (red) and hsp 90 (blue). F ig u r e s  22a. & 22b. are high power 
views of these slides; showing non-specific and specific staining of hsp 90 
respectively. F ig u r e  22c. is a high power photograph of the DU-145 cells 
stained for AR. (LNCaP cells showed similar but brighter staining;- data 
not shown.)
F ig u r e s  23a. & 23b. are photomicrographs of benign prostate sections 
stained for hsp 90; F igure  23a. differs from F ig u r e  23b. in that the red 
carbalum nuclear counterstain has been omitted. (Microscope  
magnification x300)
F ig ure  24b. is a fluorescent micrograph of LNCaP cells stained for AR, 
while F ig u r e  25b. is a similarly stained micrograph of DU-145 cells. 
(Microscope magnification x400). The Hoechst nuclear counterstain of 
each field (F ig u r e s  24a. & 25a.) is shown to allow assessment of AR 
intracellularity.
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F igure 21. Immunocytochemical Localisation of AR and 
hsp 90 in DU-145 Cells.
This photograph shows the AR (red) and hsp 90 (blue) 
staining present in DU-145 cells. The 4 wells furthest 
from the name label represent specific-binding.
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Figure  22. Immunocytochemical Localisation of AR and 
hsp 90 in DU-145 Cells.
F ig u r e  22a. shows the nonspecific AR staining (staining 
in the absence of primary anti-AR polyclonal antibody).
F ig u r e  2 2 c . shows the specific AR staining (staining in 
the presence of primary anti-AR polyclonal antibody).
F ig u r e  22b. shows the specific hsp 90 staining (staining 
in the presence of primary anti-hsp 90 AC 88 monoclonal 
antibody).
(All microscope magnification x400)
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F igure 23. Immunohistochemical Localisation of hsp 90 in 
Benign Prostate Hyperplasia (BPH).
F ig u r es  23a. & b. show a section of BPH stained for hsp 
90 using monoclonal antibody AC 88.
F ig u r e  23a. shows hsp 90 staining in the absence of 
carbalum nuclear counterstain (red; included in F ig u r e  
23b.) in order to emphasise hsp 90 cytoplasmic 
localisation.
(Microscope magnification x300 in both photographs)
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Figure  24. Fluorescent Immunocytochemical Localisation of 
AR in LNCaP Cells.
F igure  24b. shows the specific anti-AR FITC- 
fluorescence of LNCaP cells.
F ig u r e  24a. shows the corresponding Hoechst nuclear 
counterstain of the same field shown in F igure  24b.
(Microscope magnification x400 in both photographs)
Pa r t  2 E xper im en ta l
177
i
Figure  25. Fluorescent Immunocytochemical Localisation of 
AR in DU-145 Cells.
F igure 25b. shows the specific anti-AR FITC- 
fluorescence of LNCaP cells.
F ig u r e  25a. shows the corresponding Hoechst nuclear 
counterstain of the same field shown in F igure  25b.
(Microscope magnification x400 in both photographs)
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C onclusions .
From Figure 21., showing two slides of DU-145 cells stained for both AR 
(red) and hsp 90 (blue) it should be noted that four of the wells were used 
for nonspecific-binding; staining in the absence of the anti-AR and anti- 
hsp 90 primary antibodies. These are the four wells nearest the name- 
tag, and they demonstrate both the specific nature of the staining as well 
as the positive identification of both AR and hsp 90 proteins in DU-145  
cells. However it should be noted that DU-145 cells showed no growth 
response to androgen (see Part 2. Experim ental  section 4.)
F ig ur es  22a. & 22b. are high power views of the slide stained for hsp 90; 
these show non-specific and specific staining respectively. Hsp 90 can be 
observed in all cells and is present mainly in the cytoplasm. AR, however, 
is present in different amounts in individual cells (F ig u r e  22c ). The AR 
staining does seem to be predominantly nuclear.
F ig u r e s  23a. & 23b. are photomicrographs of benign prostate sections 
stained for hsp 90; best assessment of hsp 90 intracellularity can be 
obtained from a comparison of these two photographs. F ig u r e  23a. shows 
the tissue stained for hsp 90 in the absence of brown/red nuclear 
counterstain; and it is very clear that the nuclei are devoid of stain, 
especially in the cells surrounding the gland.
F ig ur e  24b. shows the presence of significant levels of nuclear AR in 
LNCaP cells, while F igure 25b. confirms that there are also AR present in 
DU-145 cells. Compared to the LNCaP cells, the DU-145 AR are located 
in the cell nuclei although there is much less staining overall. This reflects
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the lower levels of AR present in these cells (see Part 2. E x p e r im e n t a l  
chapter 5.) as detected by ligand binding assay.
In conclusion, this work has confirmed the presence of hsp 90 in the 
cytoplasm of both LNCaP and DU-145 cells, as well as in prostate tissue 
sections. AR has also been located in the nuclei of both LNCaP and 
DU-145 cells, although LNCaP cells possess significantly higher levels of 
AR and were separately shown to grow in response to exogenous 
androgen. In addition the standard immunocytochemical staining 
procedure has been verified by the fluorescent immunocytochemical 
procedure to confirm these results.
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C h a pter  2.
Prostate Cell Temperature Responses.
Introduction.
It is important to establish whether or not prostate cancer cells can 
develop thermotolerance during the hyperthermic treatment of cancer of 
the prostate. To this end, studies on LNCaP and DU-145 human prostate 
cancer cell lines can be of great relevance (S a p a r e t o , 1987). Repeated 
low-dosage thermal stress could inadvertently create a thermotolerant 
population of neoplastic cells. For this reason it was decided to use the 
LNCaP and DU-145 cell lines as a model system to investigate the effects 
of heat on prostate cell growth in vitro.
It is important to distinguish a point of thermo-kill; the lethal temperature 
for a given cell line, so that the induction of thermotolerance can be 
assessed. Previous work (Part 1. E x p e r im e n t a l  chapter 1.) using the 
MCF-7 human breast cancer cell line suggested that 2 hours exposure to 
any temperature greater than 42°C was lethal to this cell line. For this 
reason, 41 °C was initially chosen as a sub-lethal temperature for these 
two prostate cell lines. However, as the results show, this was an incorrect 
assumption, and further investigation was required.
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M e th o d s .
LNCaP and DU-145 cells were subcultured as described in M eth o d o lo g y  
section 2.2. so that 20% confluent monolayers were formed within 6-well 
(15.7 cm2/well) plastic tissue culture plates. The two cell lines were 
allowed to “plate-down” for 24 hours and fresh culture medium was added 
immediately prior to commencing the experiment. Heat shock was 
administered in an analogous manner to the experiments using MCF-7 
cells described in Part 1. E x p e r im e n t a l  chapter 1. After subjecting the 
prostate cells to the various heat shock treatments (HST), they were 
harvested at 24 and 48 hours after heat shock. The harvesting 
methodology was identical to that described in Part 1. Ex p e r im e n t a l
chapter 1; aliquots (100pl) of these solubilised prostate cells being 
assayed for DNA using the Hoechst DNA assay described in 
M ethodology  section 4.2.
1 8 2
Part 2 E xpe r im e n ta l
R esults.
The results of this experiment are shown in the following four figures; 
these experiments were carried out only once, however each column of 
the histogram represents the mean of duplicate DNA assay of triplicate 
wells of cells.
F ig u r e s  26. and 27. show the effect on LNCaP and DU-145 cell viability 
respectively of HST 0, HST 2 alone, and HST 1+2 in combination. These 
heat shock treatments were identical to those used in Part 1. E xperim ental  
chapter 1 during the induction of thermotolerance in MCF-7 cells (ie. 41 °C 
and 44°C for HST 1 and HST 2).
F ig u r es  28. and 29. show the effect on LNCaP and DU-145 cell viability 
respectively of HST 0*, HST 2* alone, and HST 1*+2* in combination. 
These heat shock treatments were reduced in terms of the temperature 
magnitude so that HST 1* was a 2 hour exposure at 39°C followed by a 
12 hour recovery period, and HST 2* was a 2 hour exposure to 42°C  
followed by a 12 hour recovery period.
It should be noted that the total time of potential cell growth was 
maintained as equal throughout the different heat shock treatments.
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Figure 26. The Effect of Temperature on LNCaP Cell 
Viability.
LNCaP cells exposed to HST 2 (44°C; 2 hours followed 
by 37°C; 12 hours) alone were compared to cells 
subjected to HST 0 (37°C throughout) and cells given a 
prior exposure to HST 1 (41 °C; 2 hours followed by 
37°C; 12 hours) before subsequent HST 2, ie HST 1+2. 
The effects of the different heat shock treatments on cell 
growth was assessed by measuring the amounts of DNA 
after 24 and 48 hours. (Day 1 and Day 2 respectively)
Error bars represent the Standard Deviation of the data.
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Figure  27. The Effect of Temperature on DU-145 Cell 
Viability.
DU-145 cells exposed to HST 2 (44°C; 2 hours followed 
by 37°C; 12 hours) alone were compared to cells 
subjected to HST 0 (37°C throughout) and cells given a 
prior exposure to HST 1 (41 °C; 2 hours followed by 
37°C; 12 hours) before subsequent HST 2, ie. HST 1+2. 
The effects of the different heat shock treatments on cell 
growth was assessed by measuring the amounts of DNA 
after 24 and 48 hours. (Day 1 and Day 2 respectively)
Error bars represent the Standard Deviation of the data.
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F igure  28. The Induction of Thermotolerance in LNCaP 
Ceils.
LNCaP cells exposed to HST 2* (42°C; 2 hours followed 
by 37°C; 12 hours) alone were compared to cells 
subjected to HST 0 (37°C throughout) and cells given a 
prior exposure to HST 1* (39°C; 2 hours followed by 
37°C; 12 hours) before subsequent HST 2*, ie. HST  
1* + 2 * .
The effects of the different heat shock treatments on cell 
growth was assessed by measuring the amounts of DNA 
after 24 and 48 hours. (Day 1 and Day 2 respectively)
Error bars represent the Standard Deviation of the data.
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Figure 29. The Induction of Thermotolerance in DU-145 
Cells.
DU-145 cells exposed to HST 2* (42°C; 2 hours followed 
by 37°C; 12 hours) alone were compared to cells 
subjected to HST 0 (37°C throughout) and cells given a 
prior exposure to HST 1* (39°C; 2 hours followed by 
37°C; 12 hours) before subsequent HST 2*, ie. HST  
1* + 2*.
The effects of the different heat shock treatments on cell 
growth was assessed by measuring the amounts of DNA 
after 24 and 48 hours. (Day 1 and Day 2 respectively)
Error bars represent the Standard Deviation of the data.
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C onclusions .
The results demonstrated in F ig u r es  26. and 27. show that both LNCaP 
and D U-145 human prostate cells appear to be susceptible to 
temperatures greater than 41 °C.
These conclusions are drawn from the fact that in the case of LNCaP cells 
(F ig u r e  26.), there is significantly lower levels of DNA present after either 
HST. Not only has the exposure to 41 °C failed to induce LNCaP thermo­
tolerance to 44°C, but it has effectively been a lethal dose, as these HST 
1+2 treated cells show only minimally greater growth levels when 
compared to those treated to HST 2 alone. (The presence of a small 
number of thermotolerant LNCaP cells may be indicated by the slight 
increase in the 48 hour DNA levels of the HST 1+2 treated cells, although 
this is of questionable statistical significance.) A similar conclusion can be 
drawn for the DU-145 cells (F ig u r e  27.); there is an overall inhibition of 
growth in either HST treated cell group. In addition, there is a significant 
loss in DU-145 DNA over the 24 hour period between assays suggesting 
that cell death is resulting in detachment of many cells.
With these results in mind, it was decided to reduce the temperatures of 
the corresponding heat shocks by 2°C (i.e. initial treatment at 39°C; 
second treatment 42°C). The results of these experiments can be seen in 
F igures 28. and 29.
F ig u r e  28. shows that the LNCaP cell line demonstrates a very strong 
resistance to the lethal temperature of 42°C as a result of prior exposure 
to 39°C. This thermotolerance response is observed very clearly in the
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maintainance of the growth rate of the HST 1*+2* treated LNCaP cells 
when compared to the growth rate of the control cells over the 24 hour 
period.
A similar phenomenon is observed in the DU-145 cell line. F ig u r e  29. 
shows that the HST 1*+2* treated DU-145 cells not only contain 
significantly higher levels of DNA than the HST 2* alone treated cells; but 
in addition the growth rate is, like in the LNCaP cell line, comparable with 
that of the control cells. Once again, the HST 2* alone treated cells show 
a loss of DNA over the 24 hour period emphasising that unprepared 
exposure of DU-145 cells to 42°C results in cell death and detachment.
In conclusion, both LNCaP and DU-145 cells are unable to withstand 2 
hours exposure to 42°C, unless primed by a 2 hour exposure to 39°C. 
Presumably, this phenomenon is occurring as a result of heat shock 
instigation of the thermotolerance response.
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C hapter 3.
Immunocytochemical Localisation of Hsp 90 in 
Heat-Shocked Prostate Cells.
Introduction.
In view of the results reported in Part 1 Ex p e r im e n t a l  chapter 6. it was 
decided to investigate if the observed nuclear accumulation of hsp 90 in 
heat shocked MCF-7 cells was a phenomenon confined to this breast 
cancer cell line. Similar hsp 90 accumulation in either LNCaP or DU-145 
cells could implicate a thermal modulation of nuclear AR in an analogous 
manner to the proposed suppression of oestrogen-binding ability 
observed in the heat shock breast cells. Any thermal modulation of the 
endocrine response to either androgens or antiandrogens would 
represent an important factor in the design of any combined antiandrogen 
and hyperthermic therapy for prostatic cancer and might shed light on the 
mechanism of heat-induced tumour cell kill.
M ethods .
The protocol for heat shock induction, cell processing and hsp 90 
immunofluorescent staining was identical to the methods used for hsp 90 
staining in MCF-7 cells (Part 1 Experim ental  chapter 6.) with the exception 
of the reduced HST temperatures. Both LNCaP and DU-145 cells were 
stained for hsp 90, comparing 37°C control cells with heat shocked (HST  
1*+2*) cells.
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R esults.
The immunofluorescent photomicrographs in F igures  30-33. are shown 
as pairs (termed a. and b.)f to allow comparison of the Hoechst nuclear 
counterstaining and the FITC-hsp 90 staining (respectively blue and 
green). All photographs were taken using a microscope magnification of 
x400.
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Figure  30. Fluorescent Immunocytochemical Localisation of 
hsp 90 in LNCaP Cells.
F ig u r e  30b. shows the  specific  an ti-hsp  90 FITC- 
fluorescence of cells grown at 37°C throughout (HST 0).
F ig u r e  30a. shows the corresponding Hoechst nuclear 
counterstain of the same field shown in F igure  30b.
(Microscope magnification x400 in both photographs).
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Figure  31. Fluorescent Immunocytochemical Localisation of 
hsp 90 in Heat Shocked LNCaP Cells.
F ig u r e  31b. shows the specific anti-hsp 90 FITC- 
fluorescence of ceils subjected to HST 1*+2* (double 
heat shock).
F ig u r e  31a. shows the corresponding Hoechst nuclear 
counterstain of the same field shown in F igure  31b.
(Microscope magnification x 400 in both photographs)
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Figure  32. Fluorescent Immunocytochemical Localisation of 
hsp 90 in DU-145 Cells.
F ig u r e  32b. show s the  specific  an ti-hsp  90 FITC- 
fluorescence of cells grown at 37°C throughout (HST 0).
F ig u r e  32a. shows the corresponding Hoechst nuclear 
counterstain of the same field shown in F igure  32b.
(Microscope magnification x400 in both photographs).
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Figure 33. Fluorescent Immunocytochemical Localisation of 
hsp 90 in Heat Shocked DU-145 Cells.
F ig u r e  33b . show s the specific  an ti-hsp  90  FITC- 
fluorescence of cells subjected to HST 1 *+ 2 * (double  
heat shock).
F ig u r e  33a. shows the corresponding Hoechst nuclear 
counterstain of the same field shown in F igure  33b.
(M icroscope magnification x400 in both photographs)
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C onclusions .
A studied comparison of F ig u r es  30b. and 31b. shows that heat shock 
results in an apparent overall increase in LNCaP hsp 90 staining, though 
the difference is relatively minor. There is a more distinctive nuclear 
staining in the heat shocked LNCaP cells shown in F ig u r es  31b. than the 
control LNCaP cells shown in F ig u r e  30b. This is similar to, but not as 
prominent as the change in staining pattern observed when heat shocked 
MCF-7 cells were compared to their 37°C controls. This suggests that the 
nuclear accumulation of hsp 90 is not a phenomenon peculiar to the 
MCF-7 breast cell line.
There is resounding confirmation of the more general nature of this 
observed effect when the heat shocked DU-145 cells (F ig ur e  33b.) are 
compared with their 37°C equivalents (F igure  32b.). There is evidence of 
distinctive nuclear accumulation of hsp 90 and of association with the 
nuclear membrane in particular. This pattern of hsp 90 localisation is 
previously unreported. Hsp 70 has been observed to accumulate in the 
nucleus of heat shocked fibroblasts, but this seemed to represent 
nucleolar localisation (W elch & S u h a n , 1987), and not nuclear-membrane 
association.
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C hapter 4.
Prostate Cell Responses to Exogenous 
Agonists and Antagonists.
Introduction.
Hyperthermic therapy of prostate cancer is usually administered in 
conjunction with some form of radio-/endocrine-therapy (L in d n e r  et al, 
1990; H o lm es  etal, 1990). Having assessed the effects of temperature on 
the growth of the two human prostate cell lines LNCaP and DU-145 it was 
important to characterise the growth response of these cell lines to 
exogenous ligands. In order to simplify the understanding of these 
investigations, the cells were maintained at 37°C throughout.
M ethods.
The ligands of interest were the androgen 5-oc-dihydrotestosterone
(5aDHT), and the nonsteroidal antiandrogen a-a-oc-trifluoro-4-hydroxy- 
2-methyl-4'-nitro/77-propionotoluidine or hydroxy-flutamide (OH-Flut.).
• i
These were both dissolved in absolute alcohol to form stock solutions of 
1 x10 ’4M which could then be diluted into culture medium to produce
s
working concentrations of negligible alcohol content.
LNCaP and D U-145 cells were subcultured so as to form 20%  
monolayers within 24-well multiwell tissue culture plates. After 24 hours 
establishment, the RPMI-1640 medium was removed, the cells washed
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using PBS-A, and the medium replaced with RPMI containing 2.5%  
HIDCC-dyalised-FCS (M e t h o d o l o g y  section 2.2.3.). Either OH-Flut. or
5aD H T was then added to duplicate wells to cover the range 1x10'6M to 
1x10‘l4M. Quadruplet control cells were included for each cell line.
After a 48 hour incubation at 37°C, the culture medium was removed and 
the cell monolayers washed using PBS-A. The cells were then harvested 
and assayed for DNA as described in the Part 1. E x p er im en ta l  chapter 1. 
However, due to the smaller surface area only 1.0ml per well of 0.2%  
SDS in ETN solution was used to solubilise the contents of each well, and
only aliquots of 20pl were assayed for DNA by the Hoechst method 
(M ethodology section 4.2)
Results.
The results are expressed in the form of dose-response curves. F igure  34.
shows the growth response of LNCaP cells to both OH-Flut. and 5aD H T, 
whereas F ig u r e  35. illustrates the dose response curves exhibited by 
DU-145 cells.
The data points are obtained from the triplicate DNA assay of duplicate 
ligand tests.
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F igure 34. Dose Response Curve for 4-hydroxy-flutamide
and 5a-dihydrotestosterone in LNCaP Cells.
LNCaP cells were exposed to 4-hydroxy-flutamide
(OH-Flut) and 5a-dihydrotestosterone (5aDHT) over a 
range of concentrations from 1x10-6M to 1x10-l4 M for 48 
hours.
Data points represent duplicate wells of cells assayed for 
DNA in triplicate.
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Figure  35. Dose Response Curve for 4-hydroxy-flutamide
and 5a-dihydrotestosterone in DU-145 Cells.
DU-145 cells were exposed to 4-hydroxy-flutamide
(OH-Flut) and 5a-dihydrotestosterone (5aDHT) over a 
range of concentrations from 1x1 O^M to 1x10-14M for 48 
hours.
Data points represent duplicate wells of cells assayed for 
DNA in triplicate.
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C onclusions .
F ig u r e  34. shows that LNCaP cell growth responds positively to the
influence of the androgen 5aDH T. However, the positive stimulation of 
LNCaP growth by the antiandrogen OH-Flut. conflicts with the view of the 
in vivo antiandrogenic effect of this drug (P o y e t  & La b r ie , 1985) but is in 
agreement with a recent report that suggests that this drug does have an 
androgenic activity (O lea  et al, 1990). The possible mechanism behind 
this anomalous dual activity will be examined elsewhere (see D is c u s s io n  
section 4.)
F ig u r e  35. demonstrates equally convincingly that the DU-145 prostate 
cell line is an androgen-independent cell line in terms of growth 
regulation; as there was no significant response to either OH-Flut. or
5ocDHT.
These two cell lines were exposed to three other ligands in a similar
manner to OH-Flut. and 5aD H T. These were flutamide, the non- 
hydroxylated form of OH-Flut., cyproterone acetate (commercially 
available as Cyprostat®) and testosterone. Cyproterone acetate is a 
steroid derivative which has been observed to be an androgenic agent 
both in vivo (P o y e t  & La b r ie , 1985) and in vitro (O lea  et al, 1990). This 
activity is said to be independent of its recognised progestational and 
glucocorticoid action; although in our hands LNCaP cells fail to show any 
response to cyproterone acetate (data not shown).
There was a similar lack of response to flutamide or testosterone in either 
cell line (data not shown), possibly because these compounds represent
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the systemic, nonactivated forms of OH-Flut and 5aDH T. LNCaP cells 
may be lacking some activating metabolic process that renders these 
compound inactive in vitro. For example, the LNCaP colony used here
may have been deficient in 5a-reductase though time did not permit 
exploration of this possibility.
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C hapter 5.
The Effect of Heat and Exogenous Ligands on 
Prostate Cell Androgen Receptor.
Introduction.
The collective aim of these experiments was to construct an in vitro model 
for the combined effects of heat and antiandrogens on prostate cancer 
cells. The preceding two chapters assessed the effects of the individual 
actions of increased temperature and exogenous ligands on LNCaP and
* A
DU-145 prostate cell growth. The experiments described in this chapter 
were aimed to assess the effects of these two factors on the availability of 
AR.
M ethods.
LNCaP and DU-145 cells were subcultured as described in M e th o d o lo g y
section 2.2. so that 20% confluent monolayers were formed within 75cm2 
plastic tissue culture flasks. Five flasks were used for each cell line: two of 
these flasks were used to investigate the effects of heat shock of which 
one was kept as the control flask and the other was a heat shocked-flask; 
the other three flasks were used to measure the effects of exogenous
ligands and were control, OH-Flut. and 5aD H T respectively. Both cell 
lines were allowed to “plate-down” for 24 hours in 10% FCS RPMI-1640  
culture medium.
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Heat shock (HST 1*+2*) was administered in an analogous manner to the 
experiments described in Part 2. E x p er im en ta l  chapter 2.; however there 
was only one harvesting stage when all flasks were harvested after the 12 
hour recovery period.
The three flasks used to investigate the effects of exogenous ligands were 
washed free of 10% FCS RPMI-1640 medium, this being replaced by 
2.5% HIDCC-dyalised-FCS (M e th o d o lo g y  section 2.2.3.) as described in
the preceding chapter. The ligands (OH-Flut. and 5aD H T) were then 
added to this medium to a final concentration of 1x10'9M, and the cells 
incubated for 48 hours.
After incubation, the cells were harvested by trypsinisation, washed free of
trypsin and 5 a D H T  or OH-Flut. by resuspension in PBS-A and 
centrifugation, and prepared for AR ligand binding assay as described in 
Part 1. Experim ental  chapter 4. DNA was assayed at this point.
R esults.
The results shown are the mean of duplicate experiments each of which 
involved triplicate assay of AR by the “two-point competition” method (see 
M ethodology  section 3.1.5.).
F ig ure  36. shows the effect of heat shock on the AR binding ability of both/
LNCaP and DU-145 human prostate cells. F igure  37. shows the effects of
the androgen 5aDH T and the antiandrogen OH-Flut. on the AR binding 
ability of these cells. Results are expressed in terms of femtomoles of 
androgen receptor per mg of DNA.
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F igure 36. The Effects of Heat Shock on Prostate Cell AR.
LNCaP and DU-145 cells were exposed to double heat 
shock and the effect on cellular AR compared to cells 
maintained at 37°C.
The double heat shock treatment (HST 1*+2*) consisted, 
of 39°C for 2 hours followed by 37°C for 12 hours, prior to 
42°C for 2 hours followed by 37°C for 12 hours.
Controls were maintained at 37°C throughout.
The effects of heat shock was assessed by measuring 
the amounts of AR using triplicate “two-point” competition 
ligand binding assay.
Error bars represent the Standard Deviation of the data.
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Figure 37. The Effects of Androgen Agonist and Antagonist 
on Prostate Cell AR.
LNCaP and DU-145 cells were exposed to 1x10~9M
4-hydroxy-flutamide (OH-Flut) and 1x10-9M 5a-dihydro
testosterone (5aDHT) over 48 hours to assess the effects 
of these ligands on prostate cell AR.
The effects of these exogenous ligands was assessed by 
measuring the amounts of AR in duplicate experiments 
using triplicate “two-point” competition ligand binding 
assay.
Error bars represent the Standard Deviation of the data.
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C onclusions .
F igure  36. demonstrates that heat shock has no effect on the androgen- 
binding capacity of either LNCaP or DU-145 cells. This result is in contrast 
to that of the oestrogen-binding capacity of heat shocked MCF-7 cells 
reported in Part 1. Ex p e r im e n ta l  chapter 4. However this discovery may 
indicate that there is a fundamental difference in the relationships held 
between hsp 90 and these two different steroid receptors.
F igure  37. confirms the earlier results obtained in Part 2. E x p e r im e n t a l  
chapter 4. showing androgen and antiandrogen sensitivity of LNCaP 
cells, yet neither ligand was shown to have any effects on DU-145 growth. 
The LNCaP cell line demonstrates the classic effect of steroid-binding. 
Androgen-binding was shown to down-regulate its own receptor; reflected
in a decrease in available AR levels in response to 5aD H T. OH-Flut., 
however, resulted in an increase in AR. This supports the hypothesis that 
the androgenic action of this “antiandrogen” is not by acting through the 
AR, but instead it acts by relieving some inhibitory function (O lea  et al, 
1990).
The DU-145 cell line failed to demonstrate any down-regulation of AR in
response to either OH-Flut. or 5aDH T. Indeed there was a slight up-
regulation of AR though the significance of this, if any, was not examined./
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C hapter 6 .
The Combined Effects of Heat and “Anti-Androgen” 
on Prostate Cell Growth.
Introduction.
It was hoped that this cumulative investigation into the combined effects of 
hyperthermia and antiandrogens on prostate cells in vitro could be used 
to aid the design of suitable models for prostate cancer therapy. In order 
to simulate the actions of clinical therapeutic methodology the effects of 
heat together with antiandrogen must be observed. This culminating 
investigation was completed in two ways:
Firstly, the response of both LNCaP and DU-145 cells to hydroxy- 
flutamide was measured after growth either at 37°C, or alternatively after 
heat shock. Conversely, these cell lines were grown in either the 
presence or absence of hydroxy-flutamide and then any alteration in their 
ability to survive heat shock was measured.
M ethods.
LNCaP and DU-145 cells were subcultured as described in M e t h o d o lo g y  
section 2.2. so that 20% confluent monolayers were formed within 75cm2
i
plastic tissue culture flasks. Six flasks were used for each cell line: three 
of these flasks were used to investigate the effects of heat shock on the 
response to OH-Flut. The other three flasks were used to measure the 
effects of OH-Flut. on the heat shock response. (See figure legends for the
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details of the experimental treatments used).
Prior to the experiment, both cell lines were allowed to “plate-down” for 24 
hours in 10% FCS RPMI-1640 culture medium; this was then replaced by 
2.5% HIDCC-dyalised-FCS (M eth o do lo g y  section 2.2.3.).
Heat shock (HST 1*+2*) was administered to both LNCaP and DU-145 
cells in an analogous manner to the experiments described in Part 2. 
E x p e r im e n t a l  chapter 2. After the final 12 hour recovery period the cell 
culture medium was brought to a final concentration of 1x10_9M OH-Flut. 
and the cells were incubated for a further 48 hours before harvesting. 
Simultaneously, LNCaP and DU-145 cells were grown in the presence of 
1x10'9M OH-Flut. (the dose giving the plateau response in the growth 
study, see F ig ure  34.) for 48 hours and then subjected to HST 1*+2* heat 
shock; before being harvested after the final 12 hour recovery period.
Cells were harvested using 0.2% SDS in ETN and then assayed for DNA 
in triplicate, (previously described in Part 1. Experim ental  chapter 1).
I *
Results.
F igures 38a. & 38b. show the effect of prior heat shock on the response of 
the prostate cell lines LNCaP and DU-145 to the antiandrogen OH-Flut. 
Correspondingly, F ig u r es  39a. & 39b show the effects of prior OH-Flut. 
exposure on the subsequent response of these cell lines to heat shock. 
These combination experiments were carried out only once, however the 
values represent triplicate DNA-assay of duplicate flasks of cells.
Statistical analysis of variance (ANOVA) was used to compare treatments.
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Figure 38. The Effects of Heat Shock on Antiandrogen 
action in Prostate Cells.
F i g u r e  3 8 a . shows the LNCaP cell response to 
antiandrogen after prior double heat shock treatment, 
assessed in terms of cell growth.
F i g u r e  38b. shows the D U-145 cell response to 
antiandrogen after prior double heat shock treatment, 
assessd in terms of cell growth.
The histogram categories represent the sequence of the 
various types of treatment:
none 37°C/no antiandrogen,
H ST  HST 1*+2*,
OH-Flut 1x10-9M hydroxy-flutamide
The double heat shock treatment (HST 1*+2*) consisted 
of 39°C for 2 hours followed by 37°C for 12 hours; prior to 
42°C for 2 hours followed by 37°C for 12 hours.
Controls were maintained at 37°C throughout.
The cells were exposed to 1x10_9M 4-hydroxy-flutamide 
(OH-Flut.) for 48 hours, after the second heat shock 
recovery period. "
To assess cell growth, triplicate DNA assays were carried 
out on duplicate flasks of cells. Error bars represent the 
Standard Deviation of the data.
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Figure  39. The Effects of Antiandrogen on Prostate Cell 
Thermotolerance.
F i g u r e  39a. shows the LNCaP cell response to heat 
shock after prior exposure to antiandrogen, assessed in 
terms of cell growth.
F ig u r e  39b. shows the DU-145 cell response to heat 
shock after prior exposure to antiandrogen, assessed in 
terms of cell growth.
The histogram categories represent the sequence of the 
various types of treatment:
none 37°C/no antiandrogen,
H ST  HST 1*+2*,
OH-Flut. 1x1CT9M hydroxy-flutamide
The cells were exposed to 1x10~9M 4-hydroxy-flutamide 
(OH-Flut) for 48 hours, prior to commencing heat shock 
treatment.
The double heat shock treatment (HST 1*+2*) consisted 
of 39°C for 2 hours followed by 37°C for 12 hours; prior to 
42°C for 2 hours followed by 37°C for 12 hours.
Controls were mafntained at 37°C throughout.
To assess cell growth, triplicate DNA assays were carried 
out on duplicate flasks of cells. Error bars represent the 
Standard Deviation of the data.
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C onclusions .
These results represented within these figures demonstrate that there 
exists a complex relationship between the actions of heat shock and the 
actions of the antiandrogen 4-hydroxy-flutamide. Double heat shock 
treatment (HST 1*+2*) was shown to induce the thermotolerance 
response in LNCaP cells (Part 2. E xperim ental  chapter 2.); while resulting 
in approximately 5-10% loss of overall growth. It is not so surprising then, 
that cells exposed to a prior heat shock show less growth than cells 
maintained at 37°C when they are both exposed to OH-Flut. (F igure  38a.). 
However, the combination of heat shock followed by antiandrogen 
resulted in an approximate 23% loss of growth when compared to heat 
shock alone (P<0.001); suggesting that heat shock may act to inhibit the 
positive proliferative stimulus of the “antiandrogen” shown for the LNCaP 
cell line both herein (Part 2. Exper im en ta l  chapter 4.) and by others (O lea 
etal, 1990).
The LNCaP cells exposed to antiandrogen prior to HST 1*+2* exhibited 
similar, though smaller (P<0.02), growth inhibition, with a 10% reduction 
of growth when compared to HST 1*+2* alone (F igure  39a.).
As can be seen in F ig u r es  38b. & 39b., neither sequence of HST 1*+2* 
and OH-Flut. had a statistically significant effect on DU-145 cell growth 
compared with HST 1*+2* alone. Tentatively, it might be concluded that 
for heat shock to prime the sensitivity of prostate cells to growth inhibition 
by antiandrogen, the cells must first be growth-regulated by androgen.
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In conclusion, it seems that the combination of heat shock and 
anti-androgen represents a synergistic partnership capable of 
suppressing prostate cell growth, but, this phenomenon is confined to the 
androgen/“antiandrogen”-responsive cell line LNCaP; and is most 
effective if heat shock induction of the thermotolerance reaction precedes 
antiandrogen exposure. Thus clinical application of this sequential 
therapy should be restricted to patients whose tumours are known to be 
growth regulated by androgens.
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DISCUSSION.
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There has been much recent interest in the application of heat during the 
management of cancer patients, the treatment of prostatic cancer in 
particular has greatly benefited from the /instigation of thermal-therapy 
(S e r v a d io  et al, 1987). Treatment involves heating tumour tissue to 
between 41 °C and 45°C; this range includes the temperatures that were 
shown in Part 1 to be capable of inducing both hsp 90 and 
thermotolerance in breast cancer cells. Such development of tumour- 
thermotolerance in vivo has been demonstrated in conjunction with the 
use of fractionated hyperthermia (Ka m u r a  et al, 1982). In addition, this 
stepwise type of heating has been shown to induce the thermal resistance 
of tumours, again in vivo (M ahler  etal, 198jl).
Clearly this is a potentially dangerous situation for the physician using 
hyperthermia, as there exists the possibility of creating a heat-resistant 
tumour clone by using an inappropriate heating regime. 
Thermal-resistance aside, the acquisition of MCF-7 cell thermotolerance 
was accompanied by an unpredicted effect on breast cell ER binding 
capacity (Part 1 ). Although this situation represents an artificial in vitro 
manipulation as regards breast cancer; thermal-manipulation of prostate 
cancer cells is a clinical reality. The implication that there could be an 
interaction between thermal and endocrine effects on prostate cancer 
cells in vivo remains uninvestigated, yet it is of potentially great 
importance due to the combination of antiandrogen and thermal-therapies 
being developed for treatment of prostatic disease.
With these unanswered questions in mind, it was aimed to create an in 
vitro model of prostatic cancer and investigate the effects of heat and
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antiandrogens, individually and in combination.
1. LOCALISATION OF ANDROGEN RECEPTOR IN LNCaP & DU-145 
CELLS.
Thermal killing of cancer cells is highly selective (G e r w e c k , 1985); this 
seems to be attributable to two compounding factors. The less efficient 
blood supply results in poorer clearance of toxins and, more importantly, 
local hypoxia. In addition, the altered glycolytic metabolism within 
neoplastic cells results in both lower energy levels and cellular acidosis. 
The combination of hypoxia and lowered pH is thought to sensitise 
malignant cells to the impact of heat shock.
In the case of neoplastic prostate cells there is one other distinction 
between the tumour cells and the surrounding tissue: this is androgen 
(and presumably also antiandrogen) sensitivity. (Though not all prostate 
cancers are hormone sensitive.) For this reasons two prostate cancer cell 
lines were used that had intrinsically distinct androgen-responsiveness. 
Both the LNCaP cell line (O lea et al, 1990) and the DU-145 cell line 
( S t o n e  et al, 1978) contain AR, though only LNCaP cells are 
androgen-responsive (H o r o szw ic z  etal, 1983; see also F igures  34. & 35.). 
Immunocytochemical staining was used to verify the presence of AR in 
both these cell lines. The DU-145 AR staining is shown (F ig u r es  21. & 22.) 
as this was the least obvious; even so there is a very definite localisation 
of AR within the nuclei and cytoplasm df the DU-145 cells. The AR 
immunocytochemistry results were reflected by the AR ligand-binding
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assay of both cell lines (Part 2. E xp er im en ta l  chapter 5.), as LNCaP cells 
maintained a 2 fold higher level of AR when compared to DU-145 cells.
These results were also confirmed when immunofluorecsent detection of 
AR was used (F igures  24. & 25.). FITC-staining was observed in almost all 
LNCaP cells, predominating in the cell nucleus. Although AR-staining of 
DU-145 cells was also intranuclear, only a proportion of the cell 
population was observed to be AR-positive. This result suggests that the 
lower values of DU-145 cell AR obtained using ligand-binding assay may 
be due to a mixture of AR-positive and AR-negative cells, rather than 
merely lower AR levels throughout the whole DU-145 cell population. The 
reason for this non-homogeneous phenotypic expression of AR is 
unclear. It is possible that in the DU-145 cell line, AR expression is a 
function of either the cell cycle or the degree of cellular maturation. 
Nevertheless, the AR-positive DU-145 component did not show any
growth response to either 5 aD H T  or OH-Flut. (F ig u r e  35.). The true 
interpretation of this anomalous result must await further investigation; 
and work is currently being carried out by a colleague, Dr. G. Carruba, to 
answer some of these questions. The data presented in this thesis have 
only considered sensitivity of cell lines to androgen in terms of growth 
response. DU-145 may well show metabolic responses to androgen.
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PROSTATE CELL RESPONSES TO HEAT SHOCK.
In Part 1, the MCF-7 breast cancer cell line was shown to be sensitive to 
temperatures greater than 42°C, unless first primed by an exposure to a 
lower temperature, in which case this cell line acquired thermotolerance 
up to 44°C. With these results in mind, it was decided to investigate 
whether LNCaP and DU-145 cells displayed similar thermal-sensitivities 
and thermotolerance induction patterns.
The original heat shock treatments used (HST 1, & HST 2) were identical 
to the temperatures effective in evoking both thermal-lethality and thermo­
tolerance in the MCF-7 cell line. As demonstrated by F ig u r e s  26. & 27., 
the first HST of 41 °C, was in fact a lethal temperature for both prostate cell 
lines. This result is surprising, but conclusive; there is absolutely no 
growth of DU-145 cells after exposure to 41 °C. There seems to be a small 
proportion of LNCaP, cells that remain growing after this temperature, 
though the overall growth levels are significantly less than the 37°C  
controls. Acquisition of thermotolerance during heat shock has been 
demonstrated (H erman  et al, 1981) and it is possible that a minority within 
the LNCaP cell population is able to withstand this temperature due to a
spontaneous inducement of thermotolerance.
/
When the heat shock treatments were both decreased by 2°C (HST 1* & 
HST 2*; 39°C & 42°C respectively) similar growth profiles were obtained 
for both prostate cell lines as compared to those previously obtained for 
the MCF-7 cell line (F igures 28. & 29.).
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Combining these results allows assignment of a point of thermal- 
sensitivity for both prostate cell lines. 41 °C is the critical temperature at 
which LNCaP and DU-145 cell growth is inhibited. However, prior 
exposure to 39°C acts to prime the prostate cells, and endows them with 
thermotolerance; presumably through hsp induction. Such expression of 
hsp's, and hsp 90 in particular, has two fold importance:
Firstly, the expression of hsp’s may be one possible mechanism for the 
temperature-mediated suppression of cell growth in the absence of mere 
thermo-killing. Secondly, the accumulation of excess nuclear hsp 90 
could modulate altered androgen and antiandrogen effects and so alter 
the efficacy of endocrine management of prostate cancer. To assess the 
relevance of hsp 90 and thermotolerance expression in heat shocked 
prostate cells immunocytochemistry was used to localise hsp 90 before 
and after thermotolerance induction.
3. HEAT SHOCK MEDIATES NUCLEAR ACCUMULATION OF PROSTATE  
CELL hsp 90.
In Part 1, heat shock was shown to result in an increase in the overall 
level of MCF-7 cell hsp 90, and more importantly a nuclear accumulation 
of hsp 90. When LNCaP and DU-145 cells were subjected to the lesser 
double heat shock treatments (HST 1*+2*) and the levels of hsp 90 
assessed using fluorescent immunocytochemistry, broadly similar results 
were obtained.
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The effect of heat shock is underscored when the immunofluorescent 
observations are compared with the immunocytochemical staining carried 
out on both the LNCaP and DU-145 cells and a benign prostate section 
(Part 2, E xperim ental  chapter 1.). Both the DU-145 cells (F igure  22b.) and 
the tissue section (F ig u r e  23.) show profoundly cytoplasmic hsp 90 
immunocytochemical staining, in broad agreem ent with the cells 
maintained at 37°C  and stained using the fluorescently-labelled  
antiserum. In addition, fluorescent immunocytochemistry shows that heat 
shock results in distinct accumulation of hsp 90 in both the LNCaP and 
DU-145 cell nuclei. Similar cytoplasmic immunohistochemical staining of 
hsp 90 in various steroid receptor containing tissues has been noted 
(P ekki & T u o h im a a , 1990), though nuclear accumulation of hsp 90 has not 
been recorded.
The significance of these observations is two-fold. Firstly,-on a general 
level, this evidence affirms that the results obtained using MCF-7 cells 
were not peculiar to a breast cell line and that the heat shock-induced 
nuclear accumulation of hsp 90 is a more general effect. This result also 
ratifies the validity of the immunocytochemical methodology.
More importantly however, the nuclear accumulation of LNCaP and 
DU-145 cell nuclear hsp 90 has implications for the responses to steroid 
receptor-mediated endocrine control mechanisms.
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4. LNCaP AND DU-145 CELL RESPONSES TO ANDROGENS AND 
“ANTIANDROGENS”.
The overall aim of these experiments was to create an .in vitro model to 
aid understanding of the combined thermal and endocrine therapy of 
prostate cancer. In order to fully appreciate the responses of prostate 
cells to these combined therapies, it was first necessary to identify the 
growth effects of each parameter individually. Having assessed the effects 
of heat and thermotolerance induction in both LNCaP and DU-145 cells, it 
was aimed to characterise their responses to both androgen and 
antiandrogen exposure.
LNCaP cells showed the typical response to the addition of exogenous 
mitogenic ligands: growth was stimulated in a dose dependent manner.
Maximum growth occurred when the androgen 5a-dihydrotestosterone
(5aDHT) was used at a concentration of 1x10-l2 M, although the hormone 
was significantly mitogenic over a range of 10-9 to 10~13M. This value is 
lower than that found by others (W ild in g  et al, 1989; S c h u u r m a n s  et al,
1988) who report optimum concentrations of between 10-9M and 10-loM
for 5aD H T mitogenecity. This difference could simply reflect variations 
between different clones of LNCaP cells, or differences in culture 
conditions.
What was interesting was the demonstration of the in vitro androgenic 
effect of the “antiandrogen” 4-hydroxy-flutamide (OH-Flut.) on LNCaP cell
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growth. 10-8M OH-Flut. was shown to be the optimum concentration for 
stimulating LNCaP cell growth, although at no point over the range of 
concentrations used (10-6M - 10-14M) was OH-Flut. found to be in any 
way inhibitory or antiandrogenic. These data are in entire agreement with 
the work of others (O lea et al, 1990; W ilding  et al, 1989) confirming the 
paradoxical in vitro response of this antiandrogen.
The DU-145 ceils failed to respond to either 5aD H T or OH-Flut. This 
androgen ambivalence was the expected resulted due to the 
characterised non-responsiveness of this cell line to androgen-stimulation 
(Dr. C. Eaton, personal communication ).
The confusing observations regarding OH-Flut. action in vitro have given 
rise to speculation as to its mechanism of action in vivo. T h e s e  
hypotheses are derived from the theory of indirect negative growth 
control (S oto  & S o n n en sc h ein , 1987).
Direct positive growth control is exemplified by the action of oestrogen or 
androgen; where ligand-binding results in the direct stimulation of 
mitogenesis. Indirect positive growth control is illustrated in the case of 
oestrogen-induction of growth factors which are then mitogenic in either a 
paracrine or autocrine manner. Indirect negative growth control can be 
defined as the binding of the primary ligand (eg. oestrogen or androgen) 
to an inhibitory factor, thus relieving its inhibition and allowing 
mitogenesis to occur. Such inhibitory factors have been term ed
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oestrocolyone and androcolyone respectively, and seem to be present as 
trypsin sensitive extracellular steroid-binding moieties (S o n n en sc h ein  et al,
1989).
It is thought that the antiandrogenic action of OH-Flut. is mediated through 
AR binding, and that the androgenic action of OH-Flut. is mediated 
through binding of OH-Flut. to androcolyone, relieving androcolyone- 
inhibition of LNCaP cell proliferation (O lea et al, 1990). This conclusion
was formed on the basis of various competition experiments when 5aD H T  
was given in conjunction with OH-Flut. It was found that the responses of
LNCaP cells to 5aDHT were typical steroid receptor-mediated responses, 
displaying dose dependent proliferation shut-off. However, OH-Flut. failed 
to display this response, and had similar growth induction kinetics as 
oestrogens; even though LNCaP cells contain no ER (O lea et al, 1990).
These workers stress the possible misappropriateness of using putative 
antiandrogens for the treatment of androgen-sensitive prostate cancer.
*As p rev io u s ly  mentioned (P a r t i  D iscussion sec tio n  5 ) ,  tam oxifen has both 
a g o n is tic  and a n ta g o n is tic  e f fe c ts .  This is  thought to  be due to  d i f f e r e n t ia l  
in d u ctio n  o f thej promoters TAF-1 and TAF-2 w ith  respect to  th e ir  in d u c tio n  by 
oestrogen.
The p o s s ib i l i ty  th a t O H -Flut, or o ther antiandrogens may modulate androgen- 
response elements in  a s im ila r  manner remains u n in v es tig a te d , however th is  
type o f dual ac tio n  would re s u lt  in  the paradoxical androgenic a c t iv i t y  
observed when using OH-Flutamide.
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THERMAL AND ENDOCRINE REGULATION OF PROSTATE CELL 
ANDROGEN-BINDING CAPACITY.
In Part 1, heat shock accompanied an abolition of the oestrogen-binding 
capacity of M CF-7 cells. This was hypothesised to be due to an 
accumulation of nuclear hsp 90, which acted as an inhibitor of ER- 
binding ability. It was of interest to investigate whether heat shock had a 
similar effect on prostate cell AR as in breast cell ER. This was not in fact 
the case. Neither LNCaP or DU-145 cell AR levels, as measured by 
ligand-binding, altered significantly as a response to heat shock. This 
disparate result may be attributable to two parameters: either the receptor 
inhibition could be a phenomenon peculiar to breast cells, or alternatively 
the blocking of ligand-binding by hsp 90 could be a phenomenon 
exclusive to ER. In order to answer this question the effect of heat shock 
on breast cell AR was measured. MCF-7 cells were used as these contain 
significant levels of AR (40 fmol/mg protein), whereas LNCaP cells are 
devoid of ER (Olea et al, 1990).
Interestingly, heat shock resulted in a 40%! decrease in the AR-binding of 
heat shocked MCF-7 breast cancer cells (see T able 2.). This suggests that 
the heat shock mediated down-regulation of steroid receptor activity is 
peculiar to the breast cell line, and absent from the prostate cell lines. 
However, there is some specific difference in the receptor down- 
regulation, as the almost total inhibition of ER-binding activity is not 
completely reproduced by AR. The reason for this inconsistent effect is 
unclear, but it serves to underline the dangers of extrapolating the
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qualities of different steroid receptors within the superfamily in the 
absence of scientific evidence.
TABLE 2. THE EFFECT OF HEAT SHOCK ON THE ANDROGEN BINDING 
CAPACITY OF MCF-7 HUMAN BREAST CANCER CELLS.
Treatment ER (fmol/mg protein) Std. Devn. No. of Expts.
HST 0 12.29 2.27 6
HST 1+2 7.32 1.36 6
T a b le  2. shows the effect of heat shock on MCF-7 cell AR as assessed by 
ligand-binding assay. The experimental methodology was exactly as that 
previously described for the effect of heat shock on MCF-7 cell ER in Part 1 
E xp er im en ta l  chapter 4., except that AR-assay, as opposed to ER-assay was 
carried out. *
2 2 5
Part 2 D iscussion
Having shown that heat shock-induced thermotolerance has no effect on 
ligand-binding by prostate cell AR, it was decided to investigate whether this 
ineffectiveness is due to an altered AR response, or an altered hsp 90 
response. To verify AR functionality, the levels of AR within LNCaP and 
DU-145 cells were measured in the presence of different endocrine effecters. 
The results of these experiments showed that LNCaP cell AR is down- 
regulated when the cells are exposed to androgen, and up-regulated when 
the cells are exposed to antiandrogen. This pattern of receptor modulation is 
well documented and is typical of functional steroid receptor.
DU-145 cells, however, failed to show a significant control of AR levels in 
response to either androgen or antiandrogen. These results confirm the 
androgen-insensitivity of this cell line.
Taken together, these experiments illustrate that the LNCaP cells contain 
functional AR, while the DU-145 cells are androgen-insensitive in terms of 
growth. However, since neither cell line shows a down-regulation of AR 
accompanying heat shock-induced thermotolerance, it seems unlikely that 
the functionality of the AR bears any relevance to the heat shock-mediated 
suppression of steroid-binding ability. There have been recent suggestions 
that the AR of LNCaP cells is abnormal with respect to steroid specificity and 
receptor activation (V eldscholte & M u lder , 1990). This is thought to be due to 
point mutations within the steroid-binding domain (B rinkm ann  eta l, 1990), and 
so it may be dangerous to form conclusions based on LNCaP cell AR.
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6. COMBINED HEAT AND ANTIANDROGEN TREATMENTS OF PROSTATE 
CELLS.
The overall aim of these experiments was to create an in vitro model 
representing the clinical treatment of prostate cancer. Having assessed the 
effects of heat, androgen and antiandrogen on prostate cell growth and AR 
expression, the various treatments were combined in order to simulate the 
administration of antiandrogen to patients receiving thermal-therapy.
In practice, administration of antiandrogen in conjunction with thermal- 
therapy results in more effective treatment of prostate cancer compared with 
the individual use of either method (S ervadio  et al, 1987). The suppression of 
growth by these therapies seems to be synergistic, and not merely additive. 
Interestingly, this phenomenon is echoed in the observations in this thesis of 
the LNCaP cell response to combined heat shock and antiandrogen therapy, 
while the DU-145 cells remained ambivalent to the inclusion of antiandrogen 
during heat shock exposure.
DU-145 cell insensitivity to the inclusion of antiandrogen was predicted by the 
results of previous experiments. Antiandrogen failed to be an effecter of 
mitogenisis in this cell line, and did not assert any changes in the regulation 
of AR levels. For these reasons the combination of OH-Flut. with heat was not 
expected to significantly alter the DU-145 cell response to heat shock alone.
The response of the LNCaP cell-line to combined heat and antiandrogen 
exposure was especially surprising in view of the positive growth response
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displayed by LNCaP cells in response to OH-Flut. reported herein and by. 
others (O lea e ta l, 1990; W ilding  etal, 1989). Somehow, heat shock led to an 
alteration in the LNCaP cell response to OH-Flut.: a conversion of OH-Flut. 
activity from that of an androgen to that of an antiandrogen. This effect was 
most obvious when heat was administered prior to OH-Flut. exposure, 
however when OH-Flut. was present prior to commencing heat shock a 
smaller, additive inhibition of LNCaP cell growth was still observed.
The mechanism behind the anomalous “conversion” of OH-Flut. activity must 
be heat-mediated; and may possibly be hsp-mediated. There exists a variety 
of potential mechanisms capable of reversing the androgen-mitogenicity 
manifested by LNCaP cells. These hypotheses can be divided into hsp 
90-mediated effects or receptor-mediated effects:
6.1. Antiandrogen sensitises androaen-responsive cells to heat shock.
The first hypothesis is that the antiandrogen is able to increase cellular 
sensitivity to heat shock. Heat shock has been shown both here, and by 
others (W elch & S u h a n , 1986; Y o s t  & L in d q u is t , 1986) to result in an over­
production of hsp's, including hsp 90 (C a telli et al, 1985). Hsp 90 is also 
though to play a pivotal role in the regulation of normal protein synthesis 
during heat shock (R o s e  et al, 1989); regulating both the translational 
shut-down, and subsequent recommencement of normal protein synthesis. It 
is therefore possible that by reducing the cellular pool of hsp 90, the 
thermotolerant response to heat shock could be debilitated.
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How could this reduction in hsp 90 availability occur? Referring to the model 
of Baulieu discussed in Part 1 D is c u s sio n  section 5., the inhibitory action of 
antisteroids is due to the production of nonactive steroid receptors; created as 
a result of antisteroid-binding producing a heteromeric receptor incapable of 
undergoing activation (B a u l ie u , 1987a & b.). Hence the steroid-binding 
subunits are tightly bound to hsp 90; locked together as a consequence of 
antihormone-binding . It should be reinforced that this model does not entirely 
agree with all the observations concerning antisteroidal activation of steroid 
receptors (R ichard-F o y  et al, 1987). However, it does raise the possibility that 
if the action of antisteroids is to promote the steroid receptor-hsp 90 
association, then the availability of both components is reduced. The 
inference then, is that the pool of hsp 90, and nuclear hsp 90 in particular, 
would be reduced; and as a result, efficient regulation of normal protein 
synthesis during recovery from heat shock would be debilitated. This concept 
would explain why antiandrogen evokes thermal sensitivity, selectively within 
cells that are normally androgen-responsive.
Such a scenario is reflected in the clinical observations of patients 
undergoing combined endocrine and thermal therapies for prostatic disease 
(S.N. Ll o y d , personal communication). Pathalogically AR-positive tumour 
tissue undergoes significant regression while the surrounding normal tissue, 
also in contact with the thermal applicator, remains undisturbed. The 
synergistic action of OH-Flut. may therefore be manifested as a sensitisation 
agent for heat shock, specific to AR positive tissue.
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6.2. Heat shock enhances cellular responses to Antiandrogen.
Heat shock may enhance the putative antiandrogenic qualities demonstrated 
by OH-Flut. in vivo, but not in vitro.
As discussed in Part 1 D is c u s s io n  section 4., it is thought that part of the 
androgenic action of OH-Flut. is mediated through a relief of androcolyone- 
inhibition of LNCaP cell proliferation as a consequence of OH-Flut.-binding to 
androcolyone (O lea  e ta l, 1990). However, this androgenic effect can be
“shutoff” by higher concentrations of either OH-Flut. or 5aD H T, suggesting 
that a proportion of OH-Flut-androgenicity occurs as a result of AR-binding.
Referring again to the modification of Baulieu’s model (Part 1 D is c u s s io n  
section 5., the inhibitory action of antisteroids is thought to be due to 
antisteroid-binding producing heteromeric, nonactive steroid receptors 
(B a u lieu , 1987a & b.). If this supposition was correct, OH-Flut. would promote 
a large population of AR locked together with inactivating hsp 90. This would 
negate one pathway of androgen stimulation of proliferation for both OH-Flut.
and 5aDHT. Consequently, the inclusion of thermal therapy may not only 
promote formation of this nonactive AR by virtue of the excess nuclear hsp 90, 
but may also enhance the “locking” effect of OH-Flut., again by increasing the
available nuclear hsp 90. In this manner heat shock is enhancing the LNCaP
/
susceptibility to AR-inactivation by OH-Flut.
Again, this hypothesis is in broad agreement with the clinical observations 
and the results contained within this thesis. However, much more information
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must be obtained on the actual mechanism of OH-Flut. action both in vivo 
and in vitro, and the relevance of indirect negative growth regulation by 
steroid hormones before these theories can be ratified. .
On a more general level it is hoped that these results may, at the very least, 
open a new avenue of thought on the therapeutic mechanism of thermal- 
therapy. Furthermore, the various observations culled from the use of the cell 
line models may aid in the optimisation of combined thermal and endocrine 
therapies during the treatment of prostatic disease.
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